var title_f25_45_26320="Vertebral compression fx Lat";
var content_f25_45_26320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracolumbar vertebral compression fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 413px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGdAR4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD59kbZGzddoJrPk1TbIV8rODj73/1qvz8wSf7p/lXOzYMrkdM0DZqLqef+WOP+Bf8A1qRtT2jmH/x7/wCtVIIVbDrtI6g8UhAwOD09P0oC5fOpEceTz7Pn+lB1MjrDyP8Aa/8ArVR4B+XPqfrTGJ6DHSgLmj/amOsX/j3/ANam/wBqnPEH/j3/ANas/P4d6NoznHf/ACKAuaiagW/5Y4/4F/8AWqVLzd0j9+tZ8agdQc//AKv6VagTLD39vpQFy/ES5xjH1q7DZGTq+PwqCzXGOoB9B9P8a14CMYBwSM9fY/40BcbbaEZmA+0Yz/sZ/rW9Y+A/tRG7USgP/Tvn/wBmqXSo90obvj69z/jXbaQhGCA3B6igLnOx/CgOoJ1raT2+yf8A2dW1+DgIB/t7HOP+PP8A+2V28Dlj87AAdP8A69aUUrKu9TyOg9ff9aAuedr8FgWx/wAJB/5J/wD2ypE+CO4j/ioOD/05f/bK9LS7jChpGAOOhPPergulC78jaTxzQFzywfA4H/mYv/JL/wC2VXk+C6o2P+EhBP8A154/9qV6/NLstyQeSRz0rLkmYsNzAkDp7cd6AueWv8H1VN39vZB/6c+f/RlVW+FKqTu1vCjv9k/+zr1aadXVUaQBiMYz1rI1CTyoWyC23krn+tAXOCX4Tq6Fl1zIzjP2TH/s9KvwnRlyNdBOcEC0/wDs67O0vm8lirkqSSVPatK2uIJtvmN5ZZdpPHXtzQFzgn+DbhFdNb3KRn/j0wf/AEOoh8IskD+2/wDyU/8As672W9ltpMF2jIODg8Vc0+7WXDht4PUY+lAXPO4/g4JANuvfnZ//AGdTp8FNwP8AxP8A/wAk/wD7ZXrdnsmTgBW9O3apyCjKDx9KAueQD4JZ66+f/AL/AO2Uv/CkTnnxBx/15f8A2yvYDIcE9yeRSIScnP8AnmgLnkX/AAo8Y/5GHn0+xf8A2yq1z8GPIUMdez/254x/5Er2aebZIFPJxzzWfqMwMchBHFAXPHYvhMrsV/tsg5/59Ov/AI/TH+FcSXIhOuNk9/sf/wBsrvZ7mSOUvkgE4x6VGkj3F2jIM4OW9aAucrF8GkcgHX2XPT/Qv/tleQV9b2AZ0QkE8dT2r5IoBDZOY3+hrmiSZDg85610sn+rb6GuZyCx9M0AyVWKgAY4pwZjkEcZ7imjHHof0pxbjqM+vpQIMng4z9aQ88dc0mc/dH05ojG51VTjcfpQA0kjkf8A66nt1OGY+uP51F37c1YhyqgZxmgCZNx6D8quQKd69OD6f/WqGElmywyAPTvjvVy2T+Lj1zx/nvQBeg+XGRz/APq/wrb0m2MpRnB2Dg469qyIF3uqqRyccE+9dZYxgIox93J6GgDodEsw+wRqOgzkfSuxWJLWFIwuWPt0NY/gyLLyF/uhCCSOlbU4PmEHOQfTgdaALEMQ8oOQGBOPpVS6uDEcqdoXoQM4rW2k6USF/eZJwK5m+uFCsF3CTuDwKALcd99pTaobepz16iug0siaFS5OxB3GM1xOlW1xczZgRlKn5z0AHrW7c6pHb2yWsTZ2dWUfePqKAOhnvYkkwxDc9B2GayrnWrcSGPy33f3uw/KsCW7Z58M0axOmVZT86t6EVHY7HWYBt5x94dP8aANj7RG+SxHPRh36VWS7Hmskrc44G3ORVSBdigmRE2nAHXHpT5zFtk8z5SO+DwfagCOe5jWcfKVIGcgYH40rXaKDImA4GdvXFVZ/mgwB5gXq3rxVS1w0z+QckcbW/wA80AbdrOL0mOQgOBg55yK27e2EDjChSc42VzFjIljIWc7wf4D29xXVaZqcIgAILAnIGf0oA0be4zIElU5HO71rXiP7vH3l4rn9M+/KrXss6SuXRZ0UGIHPyKVAyB23ZNbq7QMLwB2/GgBHtm5dTlfT06VNbDggjGOp/wA/WnRsVB5HXtST85KYBJ6D8KAK14PmGOc8n24qnc2pkQsTjJyalnkUnBByMcVDMzPGpB3bR2/CgDmbyKSOR4lCvjkEcY61s+GtPaN/NlByemRyKc9oZZjKpHXPuf8AOa2rM7AB+NAFxIwq8DHFfGFfaecrk4HXj86+LKBobL/q3+hrmR96uml/1T/7prm0UswCgsx6AdaAZJnO3AxgYx607OVHc+5pFzjAyRnNPjGORz6UCCZ9+zEYUgHecnLnJOT6dQOPSoGOSScflU7ZPOfwqPbn6+lABD15/WrcP3hgd+BTUTC4Hfn8KmRTzn3/AK0AWbdB5gK5wp4JHQjHtzV+H3Pb19h71XhRVJ4Bx3zxVuPhwAeh7f8A6/agC7YgGZSf8/5zXW6REJdrNkZ56df85rmLNDlAM9u309vauq08bIY1PYdaAPQvD6WsVpw37xx6dK14kimccqx6ZHX/ADzXGWdyY0WMHtk84NbllcZA2s2SRk+3+NAHRXc0McKxl9oUdqwdTt0nDOm1Uzy+eaLq5QOPNJKgdjyaz76WWKPzLU7U4/djkGgCnLqv2ZzDbr5EIzu7l/rUbYYq7EnOAMcirH2BbiM3Eo2EnlDVIypBJ8zK8eQFKnAFAFCe58u8ZG5JJIIHWnwaiY5CI8hiee3rUWpeXN+8H3weCDgj3rPLCQq0bAuTyR3oA6iG4WZwQoDJwRn2qXzzMrpNnYo645rBt3lZUIJyehH41bmudzKHLA45INAD57h4pigJUdPbtUsJUnCDLqOT61RZiknBJjPOc1a00ZYnPzFuooA0QBcpulGJFOAxHDfWpbQvGxR0Pm9VAPBP1q1a2hkLbjjA4GetXLa2TcFkXcV4+vv+lAC294GfaynzFA3Z7Vs2d9KknzsdvYHtVBrWNRmIHcehP4d6dbqZGEbZBGBn0oA6FdQjJPUHOOOlNuLlHZ9jfOvb86xZR9lV33E4GQM8Z4rn7Sa6e6ILMzOxO0daAOkN75jsMYwfxHNXbR90a4OH/n0qrarEZAZQA54yRWpDEQCF6f8A66AHYGeRg56j8KltycgHpTNp3A5z7Yp7Ar06CgC5v+UEV8YV9gzzbLctngDn9K+PqBobL/qn+hrm0wetdHN/qZP901ziHLgkAmgGWUwRg0vOcjOOufSmLjkjtSqeATxQIccnJ4+Xr/nvRGpyB3FIeCev9KkjKgE/1zQA9MnPHHSrMS5I4HOPSoAefx9P8+lWrfA25HPHX8P8KALkOAg5GMZ/z+dW4Vzz/nv/AI1VRskDd6Z/T3q/ZrvwoXJPt7D2oA0rKPa4JHPPUfX2robbhd3G1ScDPv8A/WrHgR05KHn0/wA+9WvOYDABAxnGfXPvQB0UFxwNx+bt7Vq2WoRx/IwOe2TzXGpdEDcegGRn8aSLUmSYuw8xucD8/wDCgDvI4GuHMx+WInkk5LfQV0enyWdvGfkLug+6w6D1rzm31kcsQAOnXpWtbasTYsGyXk+UY6496AHeIL83Tu1rkR9AMYP1rmWuWRmDgbSc49P84rSR1+c7c7ulY1xcJJIWXCkjaw6Z60APmDRnfH/q89M8Y781XgkIkBc4B4AwfarQIaMAKQTn6Gs66jKOwCYKnGD36+1AG1ZmXKlVZlIPPUe4NW59Vj+zhGsbXK8McEE/r1rLsb97Yhx8i5+YVZuIUvC0sDDB59vyoAt/bLeQZBeP36rWhYxjA8nD5OduOTXLw2zxyD9cc+ldHoUyQyq7kKvTkYFAHWkEwIXGCev+FS5w2GLfl1qsb+KQBHwynjr+ooMMrAGENnPc9qANa2ljjj2sSSRyR6VchWMDc5yp547CsGOPfIu4/OOGHrWlNKETbHtKjr70AWtS8l7WXsuMcD/PpXJi4lhmLWx2uhOG6GtS6vQAFC/eJyBWTPGJA5GCSdwAOKANjT9ReVMuCGU8555rWtb8I6hnZs9j/n3rl9KUi2lVl+f+En1oubiS0t8EMHPWgDtrm8jUFgRjHY/Wq8OrRyOFXOBnOeK4KbVbiO0wDkk7ge9XPDV49xduZiOBj+fagDrtbuNlqvlHhzt6f59K+UK+l9bnO6MJllzzj1r5ooGhk4zDIP8AZP8AKucTI6n8K6OfiGQ/7J/lXNoPwHegGWVHQkdKN3oMD37U1SdnbFLjPPFAgBGQMfrUy9lGOewqJM7xk49KnUdAQMY6fjQBIihj6n1xV6FQAfoR/P3qtEAMdOnr9Kux5I6nB6H/ACfegCeEHee/J/z+ldFY2oiVC456njn/ADxWFYoXmQYPJH9a6qCLzp1iiUEk46/WgDVstNSW3W6+7AOCevPHFQvbxsy8kccZFdUkS22kLCnMZ6YHOR1NZWoW/wBn0s3IAkTd17gf5FAHNXigZRj8gHQd+lZrOQ3bp/j/AI0+7nDtljjkYBA/z2qKwRpriNBg5OMZ+lAGvpqGVcniNRliPxqzcakEcIhBYdMDgDnpTZikdmtpA2T1d+eT7e3NZdyRGG3LhiOD/X9aALtxqrAr8x3DnP8An6VLFPHOnmlQW7kYxnI965m7lzIORkDHHfrWpptwkaMDlgedvPWgDbspVZNssYJPIIPI4FTXcKy27MQpx0GOv+c1WtvJkdRGSH4yrdqluFkiUc5BxkdscUAZIDKzD1Bxn8aetxNbSP5bEDvj6mrTKWbYshIPUH/H8aZ/Z00k+1R8rA8+g/yaALEE32gK8q4I6sowTW7b2z3KqIlV+B904YVktp8sDhQQdwP4DmrEEXkSkl++cg4xQBrQ2dwpdGztA+ZTkEe9atlqps22Bmz0w3IrPttXuUQgsZARj5xnPNSJqMU+Tc26k54dVoA6aO7S6gLy7Vl65Xg//XqrPOY23EBhg8Dpn3rIluowhERzj7ueCtJbXgGPOGU/iYHJoAfdXBl8xlCjacKW6EdxT9KlT7SAx5PX3+tR3UR3qLZfOiY5Mfc/1qv9nZFkd8qAflYHPFAHQ6zf2lmoMWwSYI4Pv6VxN5q7Xcjb5QQODiqWq3+C6s3TliT71w76i/mHys49PyoA7qDUUSVU2M6Hg45wOea7rw/BDcqZbRQHRfmI69a8asbv7Q4O7D9hn6f41618NIp2jmlKkhgBkdDQBr2s0Mly8cjb5Ac47181V9NvYtFcnbGDIDwRXzJQNDLj/USf7p/lXOJjGD9ea6K4/wBRL/un+Vc6oOfegGSpyMkdP0p2emDnNIh5HQe+KeNxAGc0CHqFxzhcnkn8akQYIwpHtmmBTxx+IqeMdOgXHH5UATwdV+vr71bj9MD35+lQxgjPTpnjj/PWrCL1JB/zn2oA0NMwtxEce3+eK7Dw4VW8idowxwTz24FchaqEOeMg+nuK6fRJMTqdyjIxkHpx9fagDvLi7hlt0iKLjGSeBim30Cpo8KqwcNliPUH+dc352Zhgk46enamazfeaUBk2kAbVHGOf060AY2qaWROwUYyMg9O5rJml+yyGOJiGxy2cZ69Ofar93qMzI0ROVI6fgO+aqwwT3Z+aJmjyc5yOOf8AGgB8FyWck/d9AadeSpKibc+b3yOKjuUiijdbfBI5YenBqiJSDycc9Tj1NAESEK+OR0wc/T3960LHYWAwWIHXr61TdnY4IBI54/z7VPZTPbsrInIOCSPce1AGzbf64vICGHzCtCa5Vl/ekAL0OevWst5GaOMeXtyPT27VIjFkwOOOR/n60AWJZERmCZbuuO/SrthdvK6jklQFXAHT0PHqTWL57B2VTjgkjr61r6MI2k3BcOQePXk0AbkU6SEB1wAflbGcfWobkee2VQA/7PQ+9akUMSRqZkPIwCpqIQGH5th8onA3DrQBmlWaLB68jFSxSfLsxjHerUm9mJZVQsMA+v1rOngdZWAOCCec8d6AJpmKtkFRgdM0wTKO5LDHQ8CqTTgLkcOBggd6rLM6yMSSV7j8aANePURl9wYPjarL6cf/AKqdd61vgERf7o546iuburuVSzrt68fpWbcXkzsWYjAPHbHSgB2vTF1bB3ZzwT9feuWYEOc/eGR/P/CunhnS7iZX2qxGMn6Vl3NgqyswO5cnoOvX/GgB+hWctzfRRwKxYkcfl/hX1D4csorXTLaKOIRsqAMB64r5/wDC2mPa363meF5Xnp1r1/w14nW5b7PMR5wOA2ODQB2k8Adflxu/n1r40r7HW5LYHHIJr44oGhk/+ok/3T/KucUY+vHFdHcf6iX/AHT/ACrnlbPUnHv2oBkgIIHXpT0JOSAaYrHgbsZ4xUsfK57jmgQ9c7uR36VZhXoPX0/CoOM8fX+dWosAcHgH1/8Ar0ATxg7OhORz+lWoEzk4HPqevX296rDG9R17Yq3bAcZ9vb0oAvQDrgjJ56/WtvTXCEnPAzjn6+9Y9seBz2wef/r+9XlcLEG9eR/n8aANFrna7Eg4APP+fpWbdXe58tggHg9+vT9KhvrpmLM33344Hbken0rMFwY3Jzk9cHp396AN2zjQSCWdicDIX1Hr19q07vV1k09lhQKeAD69K5Sa4ZoyS+cnr+Jqct/oyR4xjnp/9b2oAYzF3DZ+cj/P86fGQ8ZU9SM5zUEsqJwWIwex5HIqS12SBcNyB6+w96ACSFwSEJI54/OtPTrESRHzEJU/xDr/AJ4qgq/Ngg4z1A/+t710uiypDHtbd8wBwfxoAo31xqeiskEj/u1wV3KG4PvTYNbhmiRblDvJGWUfT/GtzWQLy3Vdvm+Xwq9wK5K5tCgUomefTkf5xQBtW9nb3M/mKwII6k4x7frWoZFsVHlxEsfTGAK5WwMkM4VNykHk/lUmr+MJNMuPsEFml1fmNQGYnCO2MDb/ABcc49SPQigDrdU8aadodgDdkzTFd8VqhIdz0GT0Vfc8+gNQ+D7HWWvbvXtfu3FzeoB9gXhIUBym4H7pH8KjkAnJ5IOH4V8PFbltS1eYXGuO+8hyCISP0LdOnC9uenbQs0ZzOGQMcbxyGNAFu6iLwASqFGc5rNeKQs20b4zwDnoK2SVa1GSpfoQD/n8qqyRMiAADPX3oAwJo2jblMpjr1IrKvXcudq8c89sc9a6VzwAV6jANZl1agoxXCsQTt6Z47UAc9dySFDuOMdST9ayrmYs+OcdTj8P8K1bxCGJJ4PTJ/wDr+9Yjs3mMAPXj8/8A61ADkDbwvbjr27VqWMotZESYBh1459KyJJDGeOv/ANf6Vf0hTPdJvbkc9ev+cUAayag5EjoQFA2jA4/zyK6HwddOl/GzLkN19aw72DykYRgbSc8fUV0vgJIzcIZV2uq8Z454oA9etJNtsjN029/wr5Dr64tGWS3KE5G08j6V8j0DRHcf8e8v+6f5VzanDZGeK6Wc4hkP+yf5VzYwT0wD+lAMmjyffvViJcc4x+FQIcDJx9PXirCc9DjnrQIkiUZ6Dk56VaQcA54+vtUMSn5cGp1yoBx7D9KAHjJcsR39PrV2BRuAUDPb/P4VUhAZT0GR/h7VvaFbGa5ZuSEGeB3OQO/vQBZtbUqp3knBwcdOoqS4h2qAFY468n2rptJ00s6rLkK/AXGTVDWIFtzICMFT0xz1+lAHM3UeQFwFwR1H0rNdeg3dR/nv71o3Lr0Bwcd/8+1Z8kbswxk44x+IoAntVDxl5MlAp4P6fzqKe5G47MDPYj6+3vTpY2htki43PgsM59KoMi7QScn2/CgBz3H7x2AA78VpafcBHXA+bPc1iqe+foM+xq/bHazMOwyR+dAHSq0agGVPlOD/AC9qeJlXY0RBxjdWSJc4D9PQfj/hVxVBUmEkg9R+Xv7UAaUGolsF2IJ7+gxV+LyrggyqSpJ+cDBHWuYKY2khiAef0rQ0q5wwjkYZbpn8Pb3oA2prKMFt6KTghZdmQpxwSOM44OKzbbwloxu2lKSXk5Yuz3TffYnk7VwPw5rchMgjfaCysB8uPrU9uuG+aPGcnpz9KAIJLWWJs7OvQj8KLK5nhdEY5XOSGGQa6SwltztjkQLjpu5wKbLaWbzn9yAO2DwaAI9OuY7px5cHlOoyQOVP4Gor+WRrg5BU/wAIA7Vv2mmRxL+4Cqp5I9KoaubdCAEBI60AczeTvGCJBuT2HNZ13cEhQp2kYPNX9TMahpAyqffvWNJcx3EjKjKsnJ68HrQBR1CUmPay/OWGSOnaslIufmVsjjPJ/wA9a1dQkwApO7k4xx/npTNMhiMrfaDtAORnj09qAMqaLMpyoAx1x7ZqxZyNbzB4TgjJH60tzE/2htpO3IAx9MU1VYHPOQcHPH9fegDq1umu9PHnY84cBgOn+cVd0NmSQpuChuORWFYufKVm4JyefxroNDtHmuC5HGPxoA9M8O3TNAqOQ21cZ/Ovl+vpnQrIrbKc4bByK+ZqBojuf+PaX/cP8q5pTg5ya6S6/wCPab/cP8q5tRyKAZYj7A4GfWrKcjk9u1QRcYGeO9W4TluMEf5/woEToo9f881Ls6ccjvj/AOtTYh0yB9KmUAkk/wCeDQBNbL86447dfp7+1dx4Ltx9luZ3+6rKBnnsDXIW4wePXP8AOu+8PbbfTViPDNh2PWgDodGt3nvYn2kA/liqPiuyfLq4wecMP5e9bGgXEju0ZI4XI4xWT4jllNzIFkfHTrkZoA831JHid94yTnv9feqkbiPdIyg4JOCM56+1dJdS5ybiIc9TyM9P8aw7uKCRf3Xyk87W/GgCsZPMkVnByeRgj1NMdUZVEZUHIzubA7dyake3MCMz5Ruo/Ws+WRhuPIxkde3NADVVQBx/nirFu4RwwGQR0x7VV3ZB4Gc9x9KkjDAjgc8cY9qANqKZNrFiBntnp19/erAnG3co6+n41kWkoMqpKxCnGSPwrQm+xCPassrkjsuB3/xoA1EZXC4TkHg/5FWILIM+9QSMg/Tp1/Ksm2vIUAAIHUk8e9b2l3TnO1l/zmgDasncRBcfMB27VoWtyfM/eovA5PeqdpMse4k89wRxVnzreUtgYZR36kelAFi9nXbJ5eO2Pb6VHbxTtEG3ErnILfrUltBBJ5bNG2T3XpVyWcQWkittOOFB6jjrQBoxX8UNmyo+do27jXJ6nqYinJyG7kEck1najcmEcSHJ6sD061jtJsdsfP6Fh/n0oAh1i9mllxkcnIB7Z/H3rPhdl+Ygjg5PrUlwHlm3t8z5/ibGOn+FPhaKSKMyLtY4J746UAVpXJLlclQTj9far3mWsluHU/Oo+Y5phZXBSLoe5X6f41nyZhBCnLH0P1/xoA0EuoIZSAMg8HJz3+tShoZGDR5x6Y6dKx93mzbcHJzjvnrV+O3kiZhtOVzz37/4UAb8Fsp8sxDABBx3Fdp4Xs1mOUJzXMaSUlCCTKuOcjvXpXhqw8lVYtzjg4oA2NPtjbgAE4r5Rr7Aih6ZPXPI79a+P6Boiuv+PWb/AHD/ACrnUx+NdFd/8ek3+438q52MZ5zg0Ay1EQy4wSevSrcXGMjOT0/Oq0A55xmrKDAHTPoPpQItRjp2Ht+HtViAHAyO3/1vWq65HH9fr71ahzkYOQO+fegC7DkqAB26n/PvXZWr7XVTwAuM4+tcharmROB2HT6e3tXURSYI6BeP6f40Adr4elKSM8hAQD+LHSsLxFqIa8cpGGjyMEdaZFeGO3wGwG7568Vz15Kz3TK7gISTk8jv7UAQXDNezpGiFsnpj6e1aFvp1pZxBrlgZcD5c5qIXqWQfyB8ygkuR356flWOJZZ55ZZH3AHufce9AFbUro3EjKqsI8cKew9uay5YuSwU4H/1/wDEVfmjOFGQVzjn8KhLFsADuOQv09qAKC5BPy/Tj61bRwhAIIGR0HufenqvyDkAEfiOvv708oFVycHvigB9s1tLH5TDZKPuk9O3H6VAw2E/LznHr6e1NwuMqy9D/X2p8acgM64z3PuP8KAIPNLcBTkg9u+K07GZ1IYMwPXg/X396W0jTI3ksqkDnnH+cVrWcMTFSEQrj1x6e1AF+11KVgAw3AdePrWzZXkUQ5j+fvgY4zUFhYRtEnO1sYye9W59NYbvIlikbHTdigDotOuradHXesTFeH4xn3FVtQtCgZ7lg4bo6cjHrWA1tPboRLCysevpSmSWFQqO5HcdhQBXvraNpwVLMuOCeKSWNFhfYmXGcH161GZ5YWaQjeo5ANU4NR3u3m5Hp+n+NAFCawurhHKq2GHcVVuYjCw8wEdMZHv9K6eW+CWg2YHHGB2/KucvZ1vFdTkyDOCPxNAD7S5iMZRWVSP4jz6f4VRckyYbkluPpkVDFZPGC0hGCT0/GnLG3nBcEkHjPpxQArKEkIAwT+hxV+3uHRlyxZs8Y6r1qj5RSc789R1/CtOxt1nUNyDgdD9PegDp9FJluI8ICCQOK9c0dQkCoemOMduOlec+E4BBIh2Fh3J+tem6X5ciAoT9CaANq3+6MA4wf618aV9hxTMrKCBjv+lfHlA0RXf/AB6Tf7jfyrnUrorv/j1m/wBxv5Vz0VAMtwZDYwQM1ajxnG3H5e1V4h34xmrcYHHtQInTnB9RnrVuIHkjpjPT2NVoV+ZfwHP4VdgRce2PT2+nvQBbiwrjA6HnIHqa3raQ4Urzntn6Vk2du08wQZ9Sf8/WuotLcRrwCCB35Pf3oAhkdkRR7cgnNc5eszlj7cDH0ror8KA5IwRx/KuaYfvAo7nHP4f4UANdmktWyMuTgYx7/wCNRh2tQVkyDgkjPrmtbSyoRvMQeWFBLenTHesfUJ/tEjNtAyPlz6Y/+vQBFeTPLgRqMAj+ZqGKGaMgkZXjOMe3+FVpCyK3ygE5P+eKaLqWMHa3+eaALZEqvzkHpnP0oVWMWGB6dSM9hT7a7dhmU7gDxkdP84qyfLk27uD3GPp7UAZzKnJIwev8/wDGoWbawKknqev1q88CNjj0/p/jTGgzjaRnHTP/ANf3oAS0bL5+YYP3efWtmyc7ct0X269P8Kyobds89SD/AJ6VqIm1Nu08Z5H40AbdtdhcYYLj3+lXYLp2HmK7DAx16nFYFvbTSuTEOCef09/at6y0+TygWG1FHA7UAWheSeYBvfPWn3F2dv7sK7kdcCopBEGCMy+o4+lRSOFVsYwBwAMcUAV7p98vyqQw+8PxqvLAqgPIo3Hsenb/AApt3ciCNX2ncc5/U1ialftJlQxGOST+P+FADL25cOy/wk4/l/jVO3lMIL5J7AA+oq2oFx1yp65/L/CpFgCFCyFlyOT+A9aAHxXMzop8shSTxyc/5zT0trhiZETr90nsea0pGspLWLdIom4IA6AcVhXWqSxs6K52HIAH+fegBXYo+J1IZT3wOhroPD371cIuCO/XP+cVyaSS3kuWkKnuT06ZruvDNqqW75kVlUn88mgDuNAaMIcj26dK6WKfynxGcDv6GvPo9ReFVKEqOzAV0WlXG+BHcnJzjmgDs4L35NjD5sf5/lXyZX0rJcKE4POf8a+aqBoiu/8Aj1m/3G/lXPxKdwwOa6C7/wCPWb/cb+VYtvtDA4JAAzigGWIQf0qyre/6/WoI+fY1PHk8j09aBFuDk8D/AD+VaFsMFff/ABFUYUzzzjnPH1rTtgNxGMnPsKAOn8MWRmgll/hyBn2AFdZDZL9haXaSqnH+TVDSYhbaZbwqQXY5NdXpgii06U3IPJ+Vff1oA4LWhJEhVUBByeuMDBrmJlzKBxnPGD7n3rsPEN1GJ3VbcBe4Jrm53ghSRwNr+zA47j+dAEFy22KO3UjC8tg9T/kVneTuIO3jOM49x7VPHl5GZW3Hkc5z3qW5jW3jKPy2dx4xj86AMacgJtzggYH5Cs+TO4kYPOa0JtpYHoCcZyKjEJEKsVbBOOQcZ44/WgCvBKwyW6H/AANXDIfQ8H8OpqmI2IzjAAq5EEZXLvtwOnQn/OaAHhxnaSc9+f8A6/tTkXLD5e+OPwqCSREJ2jI55J+tKl2S23A256f5+lAGnbJhlOcDHT8B7VsQrujGAPU+/wDnNYcMg+QuQu0jsPpWrYTlceS2856ZxnpQBqwSLEcqyglehPU88VWu9Qu5Hmj3N8h6KcDqaijUTAF0cHuevP8Ak1ZVUUlXTcOcMBg560AVYIzCA8jEnOTz34/wq3cTD7OnYd8dxkdahuBGityCOuc/Wqs1wuzMfJx0yf8APagChqExdMqvHTjnt9KxmaR5Sent6/5zWrcTqkZLjuOv5VkmUSMNoGTj+lAF22YqSRgbh0zjPX39qvTXKmFkVxtXnHvmsRZyDjpgY5P+fWoJrnnpzyc5zQBeYM/z4wR26Z/zioiGefDDjcBj8qhgfe5VSM88/nV23VWkwBlz3z/n0oAmtIEHLEAAjofYVt2Fwtshj3ho29uh9+PemS6a1rapI0i5fB7+tZkcqxt87En09OlAHevKTZxjcRgE4IPvzWlo161vblycjd0ribXXJniMPXaAoLHGB/k1o6G93IJNsoIPJGT6UAdodVbnBx7V4dXqj2lzJtHmY7kEdOteV0DRFd/8es3+4f5ViQjkDBrbu/8Aj1m/3G/lWJAcqB6CgGXI+o//AFelWEA2+vHT8qgj9u9WkHzjj9P/AK1Ai3brnbhfTt/9b3rZ0eMSXMa4HXP6GsqAZZRxgkDGfpW5ohAnz1xH60AdnpzmWJdvZiOT0rr4oYfsELyH5Sp5PFcHo0u5SpBAY5rpr+RrjS1gVs7FyOepoA5/WZtPeV1DNkdGx9OvtXLzxfaJxFEGeRxwvtge9W1ieW6kViAuSMk8fzrTlnj0ywdLcIZHwu89R9KAMxtHWxiE1zt3NyAawL+4M0kjEBlI4Hpwfar99LcTQqZnaTJ47+lYrny2XHzDGOT/APXoAax255zzkY+p96VAGGSPr/n8KiZwG5AOR0Pap2fIbqOuP19qAECBWAAzg85H09qS7SLaDGRtPv7DtUbkhyxPGSetV2Yofl65H40ARyD5sZ3Z5qPZzyOMen1q5CPM2+Yg7c/l7UkpjAA2kNjGc/59aAEhcl+uFB4/M1ow3ATmM9Pf/wCv7VnQhAQN65wevHaraR7i3TAzjb/wL2oA6HRr0s4U52qec/hWtearaC3EcsIye68GuZtEZQwiYFjjg8f56VVu1mR23KSQRjnPf6+1AGxcyxvnyJ1ZCM4Y4IP5+9UpnURHBG7Hr14NZYV0yJBtdeCPfimIWfjqBxj/AD9aAC8+Zmzjr6e59qpE+W5POf8AP+FWrmQbSYx14P5VVMUjK2Bxk8evWgCBpN0nOeT9fSmMQx49hVk2jDkqckZ5/wA+1SRwNG2WHHv9aAKyE4GBhvWtSzV1CtkZ+vsahjgTg5z6j/vmtKBMYz1//V/jQBpLdFrV4pTu/u5HTrWOoJmbC8c849M+3tU0qs8eVz/kVJau0RyV69R6dff3oAZBvR8g4Iwev0966zwm3mxs3JIIzj6VnWtiZ/mjXqMn9a11X+zQJYvTlR2P5UAdRBsdlBYFsYPoa8Vr1jRL6F1DuAZO6568V5PQNEd1/wAe03+4f5VhxAFa3Lr/AI9pv9w/yrFgGQBxQDLUffP+eKuQ8OMfnxx1qmg5Ud/pVuEHOT6flQI0YM4HI/OtfTyVmGCckEd/UVlw9T+Oefr71oW+fPB9Ce3/ANagDo7BjvRcEZGOnsK6FJjFb7iTwPWudtCV2kAA4yM1qq7NCFwD360AYWoyvvkEPCNzxnAODVK9D3AVQwzu44+tSuzCVoj0PH0/zmoxbPEkjSDAAyD6/pQAxhHbwlSVbYOOf8+lc/fyHz2IIwD0B+laV9lkKZwvJzn6+9Yt2GEjE46n+v8AhQBFvOe/Tv8AQVPASW6AZ454/wA9arZCN24PP+cVZt14XgZ4/pQAXDDA79Dx9DUbBSSWY4B6YPPJp7qXXt6f5596aEDDBH8Oc4/zigBGIPHA/D/PpUfmKjcdQen4ikuT5bY4Gc/1quxGeuO/NACljwQe/f6CrdmQeGbn0/z9apAjI4z0GKFfpjA59PpQBpm58tmKsORwc/X/ABpEum3M3mEjJ4z7mqkFtJNjsenWr9nYkMN45wRn8KAJSGmT7p47kf59Ks2mmgfNJ8w3dOPUVegtMtjA2E9MfX2ratrZYyCRwf8A69AGGNMQuqrjPGcfQCp20xwOVBA68H/PeuqtbIIzSlRkrtGTxjNRXa7I2I5B7Y+lAHFy223LMoK7fTp1qk4EjjaB3wOPUmuouI2KBUBAPqPpWfJaBSGJHT7vfp9aAM6K2YOcdBnPXnrVhYi0vQ4zwPy/wq9AuEKlMKCc5GfX/GpDAFUuMAdiR9fagDOELCRVAA6dcD0FX4bMFUVsK+QcD8KiClpl2jHPUH3/APrVp2qKspMh3BR1z7CgDSspBasqInsc9vWn36CdDtO1jnqOD+NLZKHiPck9x9Ktz22Ix0bHUHqKAOchWaznGRtOcnn68iuLr1uKGKdBHIp2Y4OOhrySgaIrr/j1m/3D/KsWDtgj+dbd3/x6zf7jfyrEi5B/w60Ay9GCxGc8dqtW6g45Gcev0qtB26dePar9up45OM9v8+1AjRtV9f5f59auxAlwcH8R7H2qrbL90NyeO30ra0K1+0XkSFRt+8enQUAb1hZZTzJQCV+YD15q84ZogisFx3AxW1punG4iy42qQMY70++0xowuwYHcAUAcFNbedeqmMfNkkD6e1JqckVwVthgBeM/lWxPGlsWLoplJOG74/wAisUW4muQyAAs2OD6d/wBKAMmaLy+G29MfX/Oaxb1AWYbsnGensfaum1SSJgqElWTgHB9q5e6GWXgc4Gf8/WgCjJjceN3r+ZrQ0+PdHuIGOvX/AOv7VTKDBOOx4H0ra0YhwYsZOTjGfegCvJGXb5RjaccD3FVpk2FSSdpx0HXge1at0Vi8wMmGHXA6f5xWXOwaTIIUZHUigDNkBGd2D9etQnBB9fb8auTx5A2jd3OPwqOC1LAbgfQ0AVxGzNxkDqKv21mcfMPm/wA/4VZt7QEjC8Y4P4VuWtk/XAwQTx+NAFW2tMcKBuBGR+IrXtNM3xoSSQe35Va0ywldyQOK6zSNKLOAFXJ4AoA56GwMe0LHnPqPpWrZadIXVnXLHt6V1UejYZiqgsOg9TT7a0aHe02FYjGPQUAYbWkvlEHhAMjPc1nvbku277h4roLolyEPCdj1zVUxRKx3kE44470Ac9e2nlqNqgfXr2rLmsvMI2jncM/pXY3MXnINu0DGQT19O1MTS3WFndOOoJoA5iG0MhXOCBgdMelMvrLyY1GCB0A7f55rfeEW+RjjuTxWZIZJXwT8meM/hQBkR27NKpAwecgd+vvW0lmJAQgy30+tLHZtuBQnb069OK3baJY4mZsbl7+9ACwW0EMSpsHmYx071IummSH5iwI5qazYNcoWxkngjmtnYzkKPlI9utAGJb6b5h4fbjsB1rwyvpmK2JQFgEbH518zUDRFdf8AHtN/uH+VY0aj/wDXW1df8e0v+4f5VkQDoeB0oBluE/ez1/8ArVoW/VTzyf8AGqMKk4+laUC55b/P6e9AjRt16ccD2/8Are1dn4It/NvXJ7IeRXIW4XPIHOf6+9eg+AlwbpsDGzv25oA7jSlAfy+AuM5FQ6hc4RlTJ2jkn057UmnSfvFIIG4dqb4nskhDO0myNh6/pQB51rFxPNeNnqw+U49jTHhnsYBcXCHLAkewOa6fTobW333ErLIF+6Cetcb4q1S4vbh0JZYhkBM8fy96AMPUiHdmQ5HPBGcdfb2rMkYOAM7SpIxjtkVNO53MDz14P41VmZdpKqOSTn16+9AESFmcKp56fyFbtraSR2TXKg5GPmHvj/GqGngGUeYvyrz09zVs3TgBdxKkjg9O1AGTf3MzOXYlge/5+1VnlMpLLxzn+db40o3CBol+QnAx+Hv71JBoDx4Eq44xQBk6ereaAVLY4Pf/AD0rdgsLcyliG+993HfI9q04tJReAm0/X6/41owWXlKRtRifXk0AVLHTITsCOuR1V+PStJbI2yPNcnyoI0Mkj4+VFA5OaSZobKF7i7kiggUqGkboCSAM/if84rmzcXHjXWv7Gsp54vDNqwe8mhyBNg8HnqSRhAfTcR1wAdB4Au5dca9upLLydJWbZaylsSPjqpXkHg5JyACcc9vQ9Kt1edTEpAXqKdpVvYJZW1pZWEdraxII4kj/AIVGe55POSSeSSTW9ax2iHaincOMnjpQBHtCStxx1wBjPSs/U41nAUZHHOPWtO6YMRt+UA5z+VVZBk4/P9KAOeeLKHzVPHAI9frUU0W77y4b6da6D7KJYxkDr0Haqkmn4fqcZoAybW2UyoXB29fqa1rqaNYCpAx0FItp+7IUYx3rMvVeSYxZIAPFAGHquXZ2529BVLD4APJ9q6j7CJMo4U5HUetVpbAIGVQpbOOKAMyxQBsDJIIGK3/IQ2rR4+ZupxzTrW3ijUAKpcDk46H3qSBDH+9kORnj2oAhtLVY2DKSWHNb1sEbYSAAehqkMlSyeuOvJrT0jTbiY7iuFz370ASxlfuYz3/DivlmvsrT9IhhAym5sHJPrXxrQNEdz/x7S/7h/lWTB93jt1Nat1/x6zf7h/lWTASQABkenp1oBmhASMep/wDrVetecDjJHqPaqEQAHNaNoQGHP6//AF6BGtaHLL1Of8+vvXa+F5/KikYZwCM+4NcVZZ+X2x3+ldXoZwkqg8soPT0/CgDvdJd45Yx0wfX3pPF87TQFo+eisn8qoWk+63jfByuD/wDrqnrNxJ5mHJCOwoA5PUZpreaKJ2baWJGAcY4rn7iQzTHzDkZP9Pb2ra1xHaWWOXLLgkEjnkH2rnrkmJgjN1Ocjv1/woAqygZwCrdOQfp/jUDKWKkH5SB/KopptpwDk8cg9Onv7U8TKYkAGW6fXkUATu6x5QNlRnn8/ap9OhmvLlYokG0nGSRxjP8AhWdbI802zb1BwfXgV2GjW5gU7W5x/j70AdLplhHb26KhDDtg85qSe3eWQBFwuaqWRmTIY8eua1IWE8j7flwc4oAijsLlFX9zuB7jrU0Fnuf5eHxz2xVuyuZI5yVztAwQea6GzETgPNGoZh6dTQBwnjPwtqviGxtNJ0iJAHkFxc3U77IogAVVc8liSWJCgkYX1rqvA3gU+HdIFgLp7wPIZXLRqihiADsA+bsOWPbgLznqreJARtXaM54rTgk8tF25680AU4tJb5FUYGMemPpUb2U0buinjn5sitDzG8zIJ68D8qiuiVzKGwcZOD16UAVLhDFHjduf0z061XdmJU5UY7GppLhJ0I2gAc1Ci7j7fT60AObcqcj0psXPBGR3H5VPNHuQc4A6ZohjcAZIGTwPw7flQBFewssa+Txnr/n8ayJ4zvJPPvXRTBmCrtwB69O1U5oCzBtpB9MUAYzF1yq++CePzqKK1LISOWJPI7/jWsLLc5LgqDjjPSpjp00gVbdML3PtQBmx2bW8RduWcZ46n2p8Gl3V0wwhWM8/NiunstKAZDKPMIHGa2Y4FQYAH4fjQBk6ToscCjeAz561vQwhQMDH/wCqnRLznmpkA4oAeigYGP8APNfDdfcycY4r4ZoGiO5/49pf9w/yrIgAOeuK17n/AI9pf9w/yrJgHP3uB7UAy7AAcjI556e1adtjOQT+f1rOt26A98ZrRt+QODgj0+n+NAjVtyQOSc47/j7e1b+lSbJ0IIxgqe3eufhwWA4BOf6+3vW7aH5SR254/E0AdjpjkxhT0I4HrVC+lfzTG5YjdwM9DVrTCWA5JBwQNuNoP86dPYo6S3UwRUiYOAx7j6UAc34gVfs4AGZAvzE9cY71x1wjOxJU4xgf5z711ssomuyYyDn72fTjis+7iEG7zPuOpwPyoA4q6Ro5WySev49aZbK0kwJ6A9607iAzucL8vr/n60W1r5UiZwec8/jQBq6RaBGWYkfKMDIx6e9b9kMLkHLngfpTYYN4iKLmMjtzjr71dS2ddoCH8R9KAJbcFokDEgDk5q9bt3TnHeo7eHEeGH59quxQmIcL17+tAF7TTHhSw+c9/Wtq0SPcGfgk+tZdlaMSsg+UdMZ/StmCNREqNjII5oAvvdbCEVmJz1qeKfjqe+M9utZSW7uxPJyTjirDSGJEHqefp/k0AbEZ/cl89cHrVG8vGAPzdOKdDK/2bC9x6/WqVygLgMT1zj15oAZv3yFgx/zirdm4yVYnOM5PSq4CgfKowSc8dBWjHGjwBAwBYDJHXGRmgBUEkixlUb58nbuAJ9MnsKuRxlU+diTk5x+PSow5U8g4PQ47cCrS8pwBknvQBERnOT09aFiDNtVckd/TmrFtZu4BYYGK04YFj6Ad/wCtAFKDT1YAzYOP/rVeS3CjaFAUf/Wq0FHPFKFGTj1oAhWPAGBx/wDWqQLz1OakXgjpilAyOn+eKAGqp56/5zUgXDcdvf3oAH4U8Y7e/SgAXgD6V8M190DqOPX+tfC9A0RXX/HtN/uH+VY8BHHOBWxdf8es3+4f5VjwHkH1FAM0IMHH17n3rRtuSBgf5x7VnREnkg/X860bbO4fKMA9cfX2oEa1mfmTt/kf41u2ZG0DPXjr7fWuetj8ygkcHn9K6bR4GndEXkDrznjigDqdAiaaE/wjG0n8ag8RTCGx+yo5LBfmGO9dLpdmlnZrtHzIN3J71y2rQG+ncbMs5529qAOYthjzXySqep4H6+1ULqY3bmJRy3v0/wA4rV1xnsITbxAAHO4nvweKyrGBSTIc7vQn3NAEENt5YUMMEY4/L2rV0nSvt2BjD4x6f5602eJmwQFVgM9Ov+cVveHiI/LlI+XlcUASjTjYxKJlaRdvVOGXnioraaGSRVJkTB5z+NdgpivXIgUh1Xqf4hWdcaVDOdx2qwOMAc//AF6AI7eWOGAHhwTwD1q9DLBIfQE9Kym06aI4YknP4VctVmicEAMuOD/SgDbijiJOyTAHqKtSQNtCRgNnkle9ZFjLMHAIAAPPBPHetqPhi8i8DkEHpQBIYrmPZ5TJGwkG/wAxC2U7gcjB9/0NMnVjtAUn2NX7e+VpgrrlB2NW2SzkwA2wnnB6f54oAyraRygznAGPoKfIPMkzJwpXORWwLKArhHG7qOevSontERAdwZgePxxQBmRxku4Ujkk9MetXY024IAyKfb28ksmcYzx04rYtbBQAWBY4z1+tAFCKJ5iRsJ/pzWpYad5QzJ8xyD/KrscKrnaq1OowT0+n50AMVAOO3/6qUjP5dzTzj2/zig5oAAOTn+VKDgH/AD60KM5+UZ9PypR3HFACfxcUAHpilx7evf2pSME/59aAADkcUqn/AD+FNJ56ClXqKAJQeRXwtX3Mp+7/AF/CvhmgaI7r/j1m/wBw/wAqx7ccAnPpWvd/8es3+438qxIGPpkfSgGatvnZt7dcfhV+Hhv4Rz/jWdB/CeM/T3q/bHgAnHHr9KBGtbn5xjnH/wBeu88GRGS9GOi5P5Vwdoct1yevr6/416F4Bw14QSASpoA7i1Ekp8kD5SCcjpUS2kNoJJJVXCZOSOT1rT0GIPMygblHc89q4rxRrcImmjjLsiMV4OASKAOM124bUNbcquIQccdM/wCTTVtD5uxUJbBI2jJPrwBVq0shJD5kWSWY5yOc5qb7M6fLIOMfTHAoAgiWORlwc7eh9etblvAihOCUY8gVXiitlhtBAZ/OAf7QZCpQnd8nlgcgbTznv04rQt/llUY+U8YoAs6azxncOOw54raOyZNsuFboDWNclLaUhMlGHHsfSnwTsZUbngfWgDea2CxgMA6Dk5qqIWZ2ChhDn7uM81YjkaSBShznrk1bhk5+VAFzjP40AQ20Dl1IXKsfxrRe3Y7UVCzEDOBTI2KknG3B7jgmntd4lILFcYAwPpQAgtJCc7WGPUVft7UCNWKl/THPrUNvdyIBmQsPetW0+dELDBPp0oAhKvuHkoDnknHSr1vZjYSR83r+NWoIBs6DP0+tWQoGelAFeCHbgADAx347VbiQjA49PpSqtSIvzUAGzjgdqcBz2xmlCjHI44xQD7/Xn6UAIenQdOlDKck4pQcgYHUUp69Ox7UAJtIznmlAOTnpn1+lOP8AEM8f/ro9aAG7Tx/ntTRnd0p5HzYApuO/+e1ACHIB/wA+tKBk0vfvSgcA44/+tQABentXwxX3SoH8+31r4WoGiK7/AOPSb/cb+VYMOOMZreu/+PWb/cb+VYcPy8Y46/pQDNK227cseeOCOetaVqAGAHPbr9PT6Vm2/APX/INatqMEZz+P40CNO1Ul14znvz7f413HgeVYdTgBI+f5TxjqK4i1wAo4x/8Aq9vaui0iUwzQSDqrBvyIoA9g0CXZdvGCcEHGexrifFOkCG6cjhXJYD0z2rsNKcjU0lTGxgGGO+av6zpYvdpAzg7uBQB5nbuNOh6fvRkrk4K4549Of8azX1B57h5HkDMWyc+vc1a8Rgo7+WMsGZA3rjIrmo3dJTuyCD37dfegDo7OVZVCqMMBk8nB6VrwQEhTJjdxjFc3pUu2VQwyM4P+fwrs7eFjKnO7PAyKAES1BVlnIKMM59KPsLwSpxlW5D5wR6fzroLTThLalSMNjqR09KvwaawiCzushH8WMf56UAZVralUBLEY/HNalvFGqn5ic8sO34VJhLcncQwB4756VFHcxGTkA9uPwoAsyW25uGOP7pH1qCexflk5IweMVOl9EX2qo5OOta9lE7xBiuCR0z9aAMyw01t4eXIyeFH1rftoNqrgc8Z/SrEadc/WplUYzjjPNABEoCjJA/Cnrj/P0pwBB4H+eKcq+lAC9SenNOU/MRjHHU/j/hQq+v8AnpSr0HTpQAvGTSr1H1pcHn6UbeTx/nmgBO4P+e1Ieehp2D6CgA5x1/8A10AKDyefwz0pp6HOKcAf8/hRtOD25oAY3JPTvR1HXOKXGc/57UEcHj3oAQEGlUjjvQV4PH+eaUDkZoAEwcdOa+Fq+61XgZ9K+FKBoiu/+PWb/cb+VYsGQQPpW1d/8es3+438qxoQDg/57UAzQg5AGeP06VqQc9Ac5z9f096zIM5HP61oWw6buv0+n+NAjZtwN3px/jW7Yruxg/r7/WsG2I4P19Pf/Gt+xc5B7Z7596APVPCx82wsx1ePKsfp0rrdwW3ccnAPv61yPggFUkbkowzz2IrpYpBn68mgDhfEVgsUajGcHJHoScmuI1uzUyFosKeSeOtek+IFMkzsrcHGV9feuC1FSZcYA7evpQBkWgeBiWBZfp9favV/C6Q3+m2ryOF2ryPUg9K88t7VcqUIJJyVIHtXa+E4pYwwhAVSOTjjNAHTzNKg2wqAuMGs25uZ1BMhKjORg1pmC4CIRKgHQgjArOnguGb95nr1oAaZA9rh3xk8E9RVGNhDPtwSecEfrV7ySECMATjjjNauj6WGdZJ16HKjjigCvo9m0rLLKvQ8A/hXV2yFVVR9KdDarHwowBVtI8AccZoAEXpUqjHTr/8AroRMbcjGKmVBhee/+FAEY5yf896kAxnj8aVV456U5hkNnHQ0AIpx1FPXqPr6/SkIGTn3/rS8AkAmgBecfh/SheuQM80oHahQMgn6fyoATjH4UMeef89aU4pCPQ0AB4zxindz9aQjr1oPQ/59aAE745pOG7dDn+VOI+akx39KADGfWlGf50gHPbP1pyA8f40AKAO3+etfCVfd6jp1xXwhQNEV3/x6zf7jfyrHjbnuRitm5/49pf8AcP8AKseIZXjBC+tAMvQnpyMitG16jnP4VmREAVowHkEkc+/196BGxZH7nbOOPy966DTsNEN5547VzVuenTj/AD/StyxbaVI4/TuPagD1DwzdCO3SMHLsvA6cd66SOUrgY+XIyfTpXmOiXrRXMeGG4e/bivRNIdZUTnAOM/WgCprkBUuzZUMuBzXF3MJLH5cnt/jXoPiyPEXA46ZrjWhJ3KCSpPp3oAzbRSHU4beOSa3dGupYpJF3ZUjHHakWISKUGHKjtxzS2o+ztvGG6jC9CKAOptdT3xBWB2jnnqKv+dG0YOc+m6ubijcpuX72Oc9xWpp1q8zfOM4x+FAG3p9okoDsRxwABW5BCFHHWqlrDsVRxxWhCvTnv/hQA4r2z/nmn9B1689PrQEzj0+lSIpAHToO9ACDhvx4p6nkZzRjng5zmnYIAI9f8aABe3X/ADinAHqc9P6CgLg5Pel2/wCc0AGDSjocnt/jSqD7f5xSgdPWgBMHnk0DOevek7kdwM89Pzp3J/z9aAEP1/X6UuKCv+cUpHPXv/WgBAMk4H+eKXHFLjHFLtzn6/4UARtkdf1pG53DOD04p5Bz0H+RSd+KAExjvSjdnj9eKXt/n3p6r8350ACjAGP1/Cvg+vvMDrj3Br4MoGiO6/49pv8AcP8AKsWHLHnOO/6Vs3X/AB7Tf7h/lWLFgdOTj86AZdjPTB61oQH5OvX6/wCe9Z0fOMD/ADmrlr19f19KBGxCMfr2+talnIAwzwMnuOaxoD90gc9v09vetSzO7PYdTz7fWgDp9JBNwuOSOpr0vwtGGESPkHr14rz7w5GznzFX5c4A65r0rQWWKXcQMjjAoAveLQNka9B1zXHyo4jZegzweufWup8TTNIqEfMSOAayMi2sjLNtVsdT6n/9dAGVChUnPDY/PNIJP4igHOCPQetMkuEYOufm+lRQJvfZ2POc0AdFoym6kEQUquO3cV2NlaCEHH5/5+tYnhuw8lFLZYg9e9dXEMY9CR/SgCRF+X269frVmPvn1/rUcY+UVKoHQAUAPHHepEHA+v8AhTOB/n61Ip5GMn8aAFAOR3pVXpkdT3H+fWjdzjHehc8cdx/SgBRwBz2pw7+1MUmneooAce+P5Uo6/wAv0pG6nj1/rQTyeooAXt1/WkGO9GetNzjGAc+n5UAO7e+KVj6GkHH+fpSE9KAHk9eKXsab6k0djxj/ACaADIDdqUfd/wDr/SkJwSSeOeaPX0oAd3zxTkwf8+1NUjPT9KcvUcUAPHQf5/z1r4Lr7zXGBwK+DKBojuuLWb/cP8qw0GfXn2rcuBm3lGQMqep9qwlJDHj+tAMuxnjOe/1q7bnEg64z6fWs6FgatxMBz1z+nWgRrWxA25bt6/T39q1rIZK+g/8ArVi2zYzg9M9/rWzZsQOCep9c9aAO38Pvi1tgOpYkHHpivQdGDuwJI6g/L2zXm2isFsrR8/dLAivVdIh8q0Vzx5nIwO2CaALM5QXUYYA8jO72rm/Gkq+XHGg4Y5468Yrpox5koz+Fcx4jK3AnjVW3DjOOAaAOKWdhxu+6cf5/Kul8MRpcTAtkkdM1yNyjRXBQYOScYx15rufCVsY4kdupPH50Aei6ZAEjwT0FaSJgj/P+elZmmvyq54K1rxjcMjOf/wBdAD1Xjr3p6j346c/hTSMck/hj605fw6+vv/8AWoAcAM9R/hTwOBz/AJ5pq9ckk04DgUAOIxn9PzpoHenDqPejqO3J6/nQAijnjH+cU9R7/p9Kbj0zTgBz7UAO/HikHTrSg9OmP/1UDGePXH8qAEI5NIOCcdcn+tO7d/8AIo78460AJ+Iowc/l1oHTPqKVs5OaAFAx3/zxS44PPekxy1O9eeM5/lQAwD1z/kU7GetLjnFAHH+fagAxjuf85pRgP1pM9sUoOTx70APXoMHp0r4Lr70QZZfr/jXwXQNEV3/x6zf7h/lXOh/c/SunIBBBAIPUVF9ng/54x/8AfIoG0YkT4wD0q5CxIyTitD7PCP8AljH/AN8ilEMY6RoPoooFYdbuD95sAg/j19/ete1Yckj9PY+1ZKgKQVABHTFODuv3WYfQ0BY9C8PsJYXiOcxvuH0Oa9p06BjptoNgJUYb8q+W4r67hbMN1PGfVZCKup4k12MYj1rU1Hot1IP60BY+mQdhk9FHr0rmNWkE8UkcX3Odzjua8NPiTXSCDrWpkHr/AKVJz+tRHW9VIIOp3xB6j7Q/P60BY9Os7Fp9Q5B+U8H2r0bQtOFvCpx7V81JrWqRnKaleqfadx/Wp08Ta6gwut6mo9ruQf1oCx9aWihGU4/WtOIEqNo64/pXx2PFfiIdNe1Yf9vkn+NKvi3xGv3fEGrj6Xsn/wAVQFj7GwSvPf8A+vThkk8/rXxx/wAJf4lx/wAjDrH/AIGy/wDxVL/wmHib/oYtZ/8AA6X/AOKoCx9kbTz/AF/GpAOnsc18Znxh4m/6GLWf/A6X/wCKo/4TDxN/0MWs/wDgdL/8VQFj7Mx8wwaByB9a+NP+Ew8Tf9DFrP8A4HS//FUn/CY+Jv8AoYtZ/wDA6X/4qgLH2YDwKd1DYx618Y/8Jh4m/wChi1n/AMDpf/iqX/hMfE3/AEMWs/8AgdL/APFUBY+z/XP86XGTkc818X/8Jj4n/wChj1n/AMDpf/iqP+Ex8T/9DHrP/gdL/wDFUBY+0MY+tCHnk/54r4v/AOEx8T/9DHrP/gdL/wDFUf8ACZeJ/wDoY9Z/8Dpf/iqAsfaHagj+VfF//CY+J/8AoY9Z/wDA6X/4qj/hMfE//Qx6z/4HS/8AxVAWPtIjlv8AGms2FZvTJ45r4v8A+Ey8T/8AQx61/wCB0v8A8VR/wmXif/oY9a/8Dpf/AIqgLH2ipzg44PNL0HYGvi3/AITHxP8A9DHrP/gdL/8AFUf8Jj4n/wChj1n/AMDpf/iqAsfafGf/AK9A6DP+eK+LR4y8T/8AQx61/wCB0v8A8VSf8Jl4n/6GPWv/AAOl/wDiqAsfa0Yy6fUfzr4LrfHjLxQOniTWh/2/S/8AxVYFA0j/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiographic features of spinal osteoporosis include wedging of the vertebra anteriorly with vertebral collapse (arrows), vertebral end-plate irregularity, and general demineralization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Toledo Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26320=[""].join("\n");
var outline_f25_45_26320=null;
var title_f25_45_26321="Mahaim fiber tachycardia";
var content_f25_45_26321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Mahaim fiber tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram from a patient with an atrioventricular reentrant tachycardia due to a Mahaim accessory pathway. The QRS complexes are wide with a left bundle branch block morphology and left axis deviation; these changes are characteristic of a Mahaim fiber tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26321=[""].join("\n");
var outline_f25_45_26321=null;
var title_f25_45_26322="Chronic pancreatitis";
var content_f25_45_26322=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic pancreatitis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/45/26322/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26322/contributors\" id=\"au6598\">",
"       Steven D Freedman, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/45/26322/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26322/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/45/26322/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26322/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/45/26322?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PANCREATITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The pancreas is an organ in the abdomen (",
"     <a class=\"graphic graphic_figure graphicRef53979 \" href=\"UTD.htm?12/2/12325\">",
"      figure 1",
"     </a>",
"     ). It is responsible for producing digestive juices and certain hormones, including insulin, which is responsible for regulating your blood sugar.",
"    </p>",
"    <p>",
"     Chronic pancreatitis occurs when the pancreas becomes damaged by long-standing inflammation. Inflammation changes the pancreas' ability to function normally. People with chronic pancreatitis require ongoing medical care to minimize their symptoms, slow the damage to the pancreas, and address any complications that arise. In most cases, treatment controls but does not cure the underlying problem.",
"    </p>",
"    <p>",
"     This article discusses chronic pancreatitis. Acute (sudden onset) pancreatitis is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"      \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PANCREATITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Some of the most common causes of chronic pancreatitis include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Alcohol abuse (the most common cause)",
"      </li>",
"      <li>",
"       Hereditary pancreatitis",
"      </li>",
"      <li>",
"       Blockage of the pancreatic duct (eg, from trauma, stones, tumors)",
"      </li>",
"      <li>",
"       Other diseases, such as lupus",
"      </li>",
"      <li>",
"       Cystic fibrosis or mutations of the cystic fibrosis gene",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PANCREATITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptom of chronic pancreatitis is long-standing pain in the middle of the abdomen. You may also have episodes when the pancreas suddenly becomes inflamed and your pain suddenly worsens (called acute pancreatitis). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"      \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People with chronic pancreatitis can have difficulty digesting fats in foods; this can lead to weight loss and occasionally diarrhea. In severe cases, the pancreas loses its ability to produce enough insulin, leading to diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Abdominal pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Abdominal pain usually occurs in the upper abdomen, often spreads to the back, may be relieved by sitting up or leaning forward, and may be associated with nausea and vomiting. The pain is often worse 15 to 30 minutes after a meal. However, about 20 percent of people with chronic pancreatitis do not have any pain at all.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Poor pancreatic function",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pancreas normally helps to digest foods and control blood sugar levels. In people with chronic pancreatitis, the pancreas may not function normally, leading to difficulty processing fat in the diet. This can cause loose, greasy, foul-smelling stools that are difficult to flush. This can lead to vitamin and nutrient deficiencies, including weight loss. These symptoms do not usually develop until the pancreas loses about 90 percent of its function.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      PANCREATITIS COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Chronic pancreatitis can lead to a variety of complications, including the following (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"      \"Complications of chronic pancreatitis\"",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Blockage of the ducts that drain the pancreas and gallbladder, which can lead to jaundice (yellowing of the skin) and bouts of worsening pancreatitis",
"      </li>",
"      <li>",
"       Blockage of the upper intestine",
"      </li>",
"      <li>",
"       An increased risk of pancreatic cancer",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      PANCREATITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     It can be difficult to diagnose chronic pancreatitis; the signs and symptoms can be similar to those caused by other health problems, such as an ulcer, gallstones, irritable bowel syndrome, or even pancreatic cancer.",
"    </p>",
"    <p>",
"     Tests may be normal, especially during the first two to three years of the condition. It can also be difficult to distinguish chronic pancreatitis from acute pancreatitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests can detect digestive enzymes that leak out of the pancreas into the bloodstream when the pancreas is inflamed. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link\">",
"      \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Stool tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stool tests can detect abnormal levels of fat in a stool sample.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imaging tests such as x-ray, ultrasound, CT scan, or MRI provide information about the structure of the pancreas, the ducts that drain the pancreas and gallbladder, and the tissues surrounding the pancreas.",
"    </p>",
"    <p>",
"     Other tests, such as endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound, are tests that can outline the areas that drain the pancreas and gallbladder. These tests are performed by passing a tube through the mouth into the digestive tract. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=see_link\">",
"      \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=see_link\">",
"      \"Endoscopic ultrasound in chronic pancreatitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Tests for pancreatic cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the tests for chronic pancreatitis can help to determine the likelihood of having pancreatic cancer. These tests may be done because the signs of chronic pancreatitis and pancreatic cancer are similar.",
"    </p>",
"    <p>",
"     Blood levels of two tumor markers, carcinoembryonic antigen (CEA) and CA 19-9, are the most commonly used blood tests.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      PANCREATITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of chronic pancreatitis can help to relieve pain, improve pancreatic function, and manage complications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"      \"Treatment of chronic pancreatitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Pain relief",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of measures can help relieve the pain of chronic pancreatitis. Simple measures may be sufficient early in the course of the condition, whereas more extensive measures may be needed after several years.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoiding alcohol &ndash; Avoiding alcohol is",
"       <strong>",
"        the single MOST important treatment",
"       </strong>",
"       for people with pancreatitis related to alcohol abuse. Avoiding alcohol can improve pain and reduce the risk of acute pancreatitis as well as the risk of dying.",
"      </li>",
"      <li>",
"       Low-fat meals &ndash; The pain of chronic pancreatitis may be reduced by eating small, low-fat meals and drinking enough fluids. Fasting (not eating) for several days may alleviate the pain of chronic pancreatitis; this is usually done in the hospital so that you can be given nutrients in IV fluids.",
"      </li>",
"      <li>",
"       Pain medication &ndash; Early in the course of chronic pancreatitis, nonprescription pain medications usually control pain. These drugs include nonsteroidal antiinflammatory drugs (NSAIDs), such as ibuprofen.",
"      </li>",
"      <li>",
"       Pancreatic enzyme supplements &ndash; Pancreatic enzyme supplements are often recommended to relieve pain caused by pancreatitis. These enzymes replace the enzymes normally produced by the pancreas, allowing the pancreas to \"rest.\" However, these enzymes do not relieve pain in all people.",
"      </li>",
"      <li>",
"       Narcotic pain medicines &ndash; Narcotic pain medicines are powerful pain-relieving drugs that require a prescription. These drugs are often recommended if pancreatic enzymes do not relieve pain.",
"       <br/>",
"       <br/>",
"       However, a major problem with narcotic medicines is that some people become addicted to them and thus crave them even when they do not have pain. Thus, most clinicians use them sparingly.",
"      </li>",
"      <li>",
"       Nerve block &ndash; During a nerve block, an injection is given directly into the nerves that carry pain messages from the pancreas.",
"       <br/>",
"       <br/>",
"       Nerve blocks relieve pain in about 50 percent of people who undergo the procedure. Many people require additional treatments two to six months after the first treatment. The procedure also carries risks that should be discussed with a clinician. For this reason, nerve blocks are usually reserved for people with severe pancreatic pain that does not respond to other types of treatment.",
"      </li>",
"      <li>",
"       Treatments that widen the pancreatic ducts &ndash; Chronic pancreatitis can cause pain if there is narrowing of the pancreatic ducts and the muscle that closes the duct shared by the pancreas and gallbladder. This narrowing can block secretions from the pancreas. The back-up of fluid in the pancreatic ducts leads to pain and inflammation of the pancreas. One way to treat this is to place a tube into the narrowed area (called stenting).",
"       <br/>",
"       <br/>",
"       During stenting, a stiff plastic tube (called a stent) is placed inside the pancreatic duct to hold it open. Stents can relieve pain in people who have narrowing of the pancreatic duct or pancreatic stones lodged in the duct. However, stenting has risks. Thus, it is probably only useful for a small percentage of people with chronic pancreatitis. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"        \"Overview of pancreatic stenting and its complications\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Pancreatic lithotripsy &ndash; Pancreatic lithotripsy refers to a procedure in which shock waves are used to break up stones that have become lodged in the pancreatic duct. This helps to improve the flow of digestive juices. The procedure is available in Europe and in a few centers in the United States.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is usually reserved for people with chronic pancreatitis who have pain that does not respond to other treatments. The best time to have surgery is debated. Some studies suggest that early surgery slows the progression of chronic pancreatitis, while others suggest that the condition worsens even in people who have surgery early. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"      \"Treatment of chronic pancreatitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     At this time, doctors usually recommend surgery for people with chronic pancreatitis who have pain that does not respond to other treatments and who have dilated pancreatic ducts. Three surgical procedures are available; two of these procedures have been used for many years, whereas one procedure (autologous islet transplantation) is considered to be experimental.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Relieve blockage &ndash; A surgical procedure called pancreaticojejunostomy relieves blockage and pressure in the pancreatic ducts. It alleviates pain in about 80 percent of people. For unknown reasons, pain returns within one year in some people who undergo this procedure.",
"      </li>",
"      <li>",
"       Remove part of the pancreas &ndash; Removing part of the pancreas relieves pain in some people with chronic pancreatitis.",
"      </li>",
"      <li>",
"       Remove the pancreas and transplant islet cells &ndash; Simply removing the pancreas is not a feasible treatment because the pancreas performs many important functions. One of the most important functions of the pancreas is producing insulin. An experimental treatment for pancreatitis involves removing the entire pancreas and then replacing the insulin-producing structures (called islets).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Treatment of greasy stools and digestive problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several treatments are available for people who do not absorb enough fat",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     have excessive fat in the stools.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Reducing fat intake &ndash; Reducing the amount of fat in the diet can reduce the amount of fat in the stools, causing them to be less greasy. Restricting fat intake to 20 grams per day or less may be recommended.",
"      </li>",
"      <li>",
"       Lipase supplements &ndash; Dietary supplements that contain the enzyme lipase can reduce greasy stools and help the body to digest fat. These supplements partially replace the lipase normally produced by the pancreas.",
"      </li>",
"      <li>",
"       Medium chain triglycerides (MCTs) &ndash; Medium chain triglycerides, a form of dietary fat, are more easily digested and absorbed than the long chain triglycerides found in most foods. MCTs are available as an oil that can be mixed with fruit juice. MCTs are a good source of calories for people with chronic pancreatitis who have lost weight and who do not respond to dietary changes or pancreatic enzyme supplements.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27016271\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27016278\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/26/42401?source=see_link\">",
"      Patient information: Pancreatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27016322\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/55/31603?source=see_link\">",
"      Patient information: Pancreatic cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/9/30865?source=see_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=see_link\">",
"      Etiology and pathogenesis of chronic pancreatitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=see_link\">",
"      Endoscopic ultrasound in chronic pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000221.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000221.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/pancreatitis/index.htm\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/pancreatitis/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/pancreatitis\">",
"      file://www.gastro.org/patient-center/digestive-conditions/pancreatitis",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Pancreas Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://pancreasfoundation.org/aboutpancreatitis/\">",
"      file://pancreasfoundation.org/aboutpancreatitis/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/45/26322/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/45/26322?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26322/abstract/1\">",
"      Singh VV, Toskes PP. Medical therapy for chronic pancreatitis pain. Curr Gastroenterol Rep 2003; 5:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26322/abstract/2\">",
"      Warshaw AL, Banks PA, Fern&aacute;ndez-Del Castillo C. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology 1998; 115:765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_45_26322=[""].join("\n");
var outline_f25_45_26322=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PANCREATITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PANCREATITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PANCREATITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           PANCREATITIS COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           PANCREATITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           PANCREATITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/2/12325\" title=\"figure 1\">",
"           Pancreas anatomy",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_45_26323="Endoscopic diverticulectomy";
var content_f25_45_26323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic diverticulectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic image of the final stage of endoscopic diverticulectomy using argon plasma coagulation, which has been delivered by the blue catheter. In the upper part of image, the esophageal lumen, with a nasogastric tube, can be observed. In the middle of the image, the remnant of the diverticular bridge with clearly visible muscle fibers can be seen. The Zenker's diverticulum was at the lower part of the image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Chris J J Mulder, MD, and Stijn J B van Weyenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26323=[""].join("\n");
var outline_f25_45_26323=null;
var title_f25_45_26324="Actinic keratosis PI";
var content_f25_45_26324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actinic keratosis causes rough, red, scaly spots on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas and Synopsis of Clinical Dermatology. Common and Serious Diseases. (4th Ed), McGraw-Hill, New York 2001. p.220.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26324=[""].join("\n");
var outline_f25_45_26324=null;
var title_f25_45_26325="Promethazine and codeine: Pediatric drug information";
var content_f25_45_26325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Promethazine and codeine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/10/29862?source=see_link\">",
"    see \"Promethazine and codeine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13989?source=see_link\">",
"    see \"Promethazine and codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cough Preparation",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/10/29862?source=see_link\">",
"      see \"Promethazine and codeine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;6 years: Use of promethazine/codeine combination is contraindicated in children &lt;6 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: 2.5-5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup: Promethazine hydrochloride 6.25 mg and codeine phosphate 10 mg per 5 mL (5 mL, 118 mL, 473 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F214173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or water to decrease GI upset. Administer with accurate measuring device; do not use household teaspoon (overdosage may occur).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14199156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F4431098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to promethazine or other phenothiazines, codeine, or any component; children &lt;6 years of age; lower respiratory tract symptoms, including asthma; coma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease, narrow-angle glaucoma, prostatic hypertrophy, GI or GU obstruction, bone marrow depression, impaired liver function, peptic ulcer, sleep apnea, and hypertensive crisis; avoid in patients with suspected Reye's syndrome; promethazine may lower the seizure threshold; use with caution in patients with seizure disorders or receiving other medications which may also lower the seizure threshold; use with caution in patients with hypersensitivity reactions to morphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone. May cause orthostatic hypotension, use with caution in patients at risk of hypotension or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). May cause drowsiness and impair ability to perform hazardous activities requiring mental alertness. Promethazine has been reported to cause cholestatic jaundice. Use with caution in patients with two or more copies of the variant CYP2D6*2 allele (ie, CYP2D6 \"ultra-rapid metabolizers\"); these patients may have extensive conversion of codeine to morphine with resultant increased opioid-mediated effects.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in children &lt;6 years of age",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , due to the potential for severe and potentially fatal respiratory depression associated with the combination of promethazine and other respiratory depressants (eg, codeine); fatalities associated with promethazine use alone in children &lt;2 years of age have also been reported. Use with caution in atopic children. Dose should not be increased if cough does not respond; re-evaluate within 5 days for possible underlying pathology. Codeine is not recommended for cough control in patients with a productive cough. Neuroleptic malignant syndrome (NMS) has been reported with promethazine when used alone or in combination with antipsychotic drugs. May alter temperature regulation or mask toxicity of other drugs due to antiemetic effects.  May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Nasal): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Epinephrine (Racemic): Promethazine may diminish the vasoconstricting effect of Epinephrine (Racemic).  Management: Monitor for diminished vasoconstrictive effects of racemic epinephrine (e.g., diminished efficacy when used for gingival retraction).  This interaction is likely of less concern in patients receiving epinephrine for other purposes (e.g., bronchodilation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Systemic, Oral Inhalation): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation).  Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Promethazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Promethazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1061446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase fluids, fiber intake, and riboflavin in diet",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13989?source=see_link\">",
"      see \"Promethazine and codeine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may be habit-forming; do not discontinue abruptly. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12736 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26325=[""].join("\n");
var outline_f25_45_26325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854550\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709350\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061439\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061433\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214152\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214141\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214173\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061443\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061442\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14199156\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4431098\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061445\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061432\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061431\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214169\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214146\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061446\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214147\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214158\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061430\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061438\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12736\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12736|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/10/29862?source=related_link\">",
"      Promethazine and codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13989?source=related_link\">",
"      Promethazine and codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_45_26326="Distal type I endoleak";
var content_f25_45_26326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal type I endoleak",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 603px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal type I endoleak noted (arrows) with poor apposition of the iliac limb to the vessel wall at the iliac bifurcation despite balloon angioplasty. Note a widely patent internal iliac artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26326=[""].join("\n");
var outline_f25_45_26326=null;
var title_f25_45_26327="Inguinal hernia reduction 1";
var content_f25_45_26327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Reducing an indirect inguinal hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 588px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJMAdkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD334l+O9M+Hnh1da1qC9ntWnW3C2iKz7mBIOGZRj5T3ryz/hqvwP8A9ArxJ/4Dwf8Ax6rf7ZP/ACSOH/sJw/8AoElezaIAdGsDgZ+zx/8AoIoA8O/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer37A9BRgegoA8B/4ar8D/APQK8Sf+A8H/AMeo/wCGq/A//QK8Sf8AgPB/8er37aPQUbV9BQB4D/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV79tX0H5Um1fQflQB4F/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1e/bF/uj8qNq/3R+VAHgP8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV79tX+6Pyo2r/dH5UAeA/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV79tX0H5UbV/uj8qAPAf8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8er37avoPyo2r/dH5UAeA/wDDVfgf/oFeJP8AwHg/+PUf8NV+B/8AoFeJP/AeD/49Xv21f7o/KjYv90flQB4D/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49Xv2xf7o/KjYv90flQB4D/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV79sX+6PypNi/3V/KgDwL/hqvwP8A9ArxJ/4Dwf8Ax6j/AIar8D/9ArxJ/wCA8H/x6vfdi/3V/KjYn91fyoA8C/4ar8D/APQK8Sf+A8H/AMeo/wCGq/A//QK8Sf8AgPB/8er33Yn91fyrF1HxDpthqx02QNJdrB9qlWNA3lRZI3t7cHpk/KaAPHP+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq98CoQCFUg98UuxP7q/lQB4F/w1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV77sT+6v5UbE/ur+VAHgX/DVfgf/oFeJP8AwHg/+PUf8NV+B/8AoFeJP/AeD/49Xvm1P7q/lS7E/ur+VAHgX/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV77sX+6v5UbE/ur+VAHgX/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV77sX+6v5UbF/ur+VAHgX/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV77sX+6Pyo2L6L+VAHgX/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XvpRf7o/KjYv8AdH5UAeBf8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XvpRf7q/lSbF/ur+VAHgf/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49Xvu1f7o/Kjav8AdH5UAeBf8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9Xvmwf3R+VBVc/dH5UAeB/8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9Xvm1f7q/lQEH90flQB4H/AMNV+B/+gV4k/wDAeD/49R/w1X4H/wCgV4k/8B4P/j1e/iigDwD/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq9/ooA8A/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer3+igDwD/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq9/ooA8A/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer3+igDzj4WfGDQPiVqF9aaFZ6rbyWcSyyG8ijQEE442u3Nej14B8H/wDk474pf8A/9CFe/wBAHhf7ZP8AySOH/sJw/wDoElez6J/yBrD/AK94/wD0EV4x+2T/AMkjh/7CcP8A6BJXs+if8gaw/wCveP8A9BFAF2iiigAooooAKKKKACiijvQAUVTm1OxhuPIlvLdbjBIi8wbyB/s9apS61KL6O2h027l82Fp0cAKuFIBDZ6E5GB374xQBsiisWHV7qPUILfUdOe3jn4juEkDpv6hG6EHGfUcfStqgAorn9R195oHj8Mwxareb/KysoEETdy7jsPRcnPHHUQ2/h6/u5PO1/Wbm4bJIt7TNvAo9MA7mH+8TQBs3+q6dp5xf39pak/8APeZU/madaalY3j7LS8tp327tsUqscevB6ciqFr4V0K1YtDpVort95jGCT9SastommtEI/sNuEBJACAYJ6/yFAGjRWNJZalZGR9LulmjIyLa6JYA/7L9R+OQPSqq+JJmna0/sq6W9Q7WTqmcZ4cDBGPXFAHR0VxGuS+J9QQx2umTRQnrs1AW7H8QjEfgaxbLTNYjuAL2y8TwjP37fXGuR+IcrQB6jRXIxz6zZmG2ttP1K4RyfMuJ7lMxjtgHO79Kgtdb1UTmC8mNrJuIUXOnvyPXcjFf1H0oA7WuYtdKt7/V/FMskZSS5CWLTDhighU/KeuAZG/HNbsbu9sN1xHvI++ox+hqhpk0OnwXi3WpQTRxFpvNZxvCbcsXx6HPPpigDl9MN74ha+1WwnltJLC9ltIkAzvWIKrKR3XesnHv14rs9FvW1DTIbmSPypWyskYO4I6kqwB7gMDzWZ4CsorPw1E8DO6Xs0+obnGGPnyvNz9A4H4U7wddm6tdSRsf6NqV1CMegkJH/AKFQBv0g6YpaTFAC0etFHagBO3FKKKMUABoo70UAFFGc0UAFFFB6UAFIOKWgdTQAYoooxQAUd6KKACiiigAooooAKKKKACiiigAooooAKKKKAPAPg/8A8nHfFL/gH/oQr3+vAPg//wAnHfFL/gH/AKEK9/oA8L/bJ/5JHD/2E4f/AECSvZ9E/wCQNYf9e8f/AKCK8Y/bJ/5JHD/2E4f/AECSvZ9D/wCQLp//AF7x/wDoIoAu0UUUAFFFFABRRRQAVxNj4h/tvVr6yv43t9NE7RWssbHFwFZYzuI6ZkJUDjOOe1dpK6xxs7nCqCSfavJPhppOp2XgLTdRurmW/v8A7IZreKMgI293l3lT1bDoDnptGOuaAPTG0u3hjBsreGKQMrZCgZAYHGfep9Otfsdu0XmNIPMkcFjkgM5bH4Zx+Fc3p/jB5Y4ba60q+XVRbpNPFHHmJMqC2JD8pwTjHXPbvTdJ8Z/2mk6W1puul8xkVnCoFDME3HqCQu7pjmgC38QHS10SDUWZw1he29woUE7v3gRl2j72VdgB6kVQRLjxrGLi4e4svDYbdHAuY5b0DqZO4jJ6KPvAZPBxWpov2nWdMsp9UWFnhnkbMakJLtLKkgB6Aj5vyNb6KqIFQBVUYAHQCgDH8PX+jSpJYaM0EZs8RvaqvltFxxlTg4x36Vs1m6voen6tCY723VjkESL8rqR0IYcgj1qG1tNQ0y32RXLajGgwq3LYkx/v9/xBPvQBsUVzI8UXL3klmnhzWBcKMhpFjWI84zvDnj8M+1aqR6jcWuLiWO0lYHIgG/Z+LDn8qALV7cRWtnNPcP5cUaFmb0AFczptv4insZ7/AO1pZy3B3wWMsQZYEHChyPmLEctg9TgdBT7vwHomoQSR6xFPqTSLtd7uZnP4ZPy/hU39s3puLiw0nTpbwW4SNbyWUCJmwdwZupK4GcA5zjIINAGnoOpf2pp/nPGYp0doZoz/AAOpwfwPBHsRWjWT4e0k6VFdGSUST3c3ny7E2IH2qvyr2GFHXJrQS5ga1+0rMht9pbzN3y4HU59KAJqQgHqARWbda/pFpaLc3ep2VvbsocPNMqAgjIPJFUdK8Xafqto97ZRXsmnAZS7+zsElHqg+8R77cHtmgDoCq4xgYrE1rwpousW11De6fAxuIXgeQKA4VlKnB7cGlh8T6dcj/RBdzsTgKtpIuT9WUD9aS4vNYmBFpa2tmueJLxyx9/kUj/0KgDYgjEMEcQOQihc4xnArk/harHw5eXMn+su9V1C4IznCtdShP/HAtTCLUbd0iPiS0SzCgMWjTzQcYOGzjrzyCar3Vn4ZisraCHVILO4tVAiuYLgCVcdyc/NnuDkHPNAHZUV5Hc+LLXS76ODxPqU9/a3MvlwX+nXJCAnossSkbPTcMqe+2tDwrrfhLxPqS22kQ6pdKpYG4dXMAZRkqXzjNAHpEs0cI3TSIi+rMBWbc+JdDtgTcaxp8ZHY3KZ/LNWmt7EwAMkJiUcZxgVXX+xY8hTp4P1SgDNbxxoGSIruac/9O9rNKPzVSKRfGdk5HlWGryD1Fk6/+hYrYW/0yEYW7s4x7SKP61FL4h0aFd0uq2KL6tOoH86AKY8U2566fqo+tqaX/hKLf/nw1Q/9upofxn4ZjOH8QaUp6c3Sf40sHjDw5cNtt9b0+VvSOdWP6GgBP+Emi7abqh/7d/8A69B8TIP+YVqx+kA/+KrXiuYrhAbeUHPIIFPeeNBlmx+BoA5y58ZW1rzPpWtKvdhaF8fgpJrT0fX9O1df9Cnbf3jmiaF/++XAP6VLPrFlD/rJXH0ic/yFch4htPBetXAuNXsp7twcgGznYZ9cBcUAd/3oryyW10OHTxaeH5PFOnFJDKjWSTLgk5I2v8pHsRio7vxF46tLbGhaXday6kcalaR27MO/zpIAD/wGgD1eiud8HeI5NcS/tr+yOn6xp0wgvLUyCQKWUOjo3G5GUgg4HOR2roqACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwD4P8A/Jx3xS/4B/6EK9/rwD4P/wDJx3xS/wCAf+hCvf6APC/2yf8AkkcP/YTh/wDQJK9n0P8A5Aun/wDXvH/6CK8Y/bJ/5JHD/wBhOH/0CSvZ9D/5Ath/17x/+gigC7RRRQAUUUUAFFFUxqlgZWiW9tmkXqiyqWH4ZoAtSIsiMjgMrDBB6EV5j8MLq7tNPsLC8kja5tIhZStgkRpG2EQDrnDFScY+Q5PSu3n15DP5FhZ3d5Nj+GMpGPq7YH5Zrhtbg8Q+FvEVz4itNLbUdKu2U3NhZSZlt2H3pUB4fcMblGOVB7k0Aeg3lzbpZTPAY5WDhAqOP9ZkYBPbkjNcRqmgJrWj6ncXFiwvr61IV4rcK6hWKqcE53cg89AB71W0jxHotykeo3t7/Z9qJPPkt9Y/0eZ5MYXKPgZUAHIJztHTvmN47Sa4g1ZbfVL2aWaWL7JpH+kRCPIEbyA9GYKox2DE8UAeg2PirTI9B0m91O9tbQ3tsJlBcBeFBfB9ASPzFbdje2uoWyXNhcw3Nu/3ZYXDq30I4rh/hro02n6Tf3/iNI4bi7uXlS3kAEVnCQuIUyT8vGT0ySagvvD3gm51OXUILpobk5LnSLiSMt3+YQn5j9aAOq1Dxdoem3cVtqV+llJKcI1yjRIT6b2AXPtmrVrr+j3bBbTVtPnZhkCK5RiR+BrymPwl4SR7mXTvBGr+IZZiCX1IlkJyecztlfqFrds/D2tQwQW+h+F/C2hW20g+ZuuCmfRUCD9aAPSwQQCDkGub1/xrouinynne8vScLaWS+dKTkdQOF69WIFcXZ/ByG4ne41/WbqZpP9ZbaeotID+C/N+ZrsvDngXw74diCaZp0akHO+QmRv8AvpsmgDltU8Saze3Cm/0nUodNwCLHTVEk8pzn95LkKq442r17sRxWrNrGuz2Kro3hzUbALwkczQR8e5y4H5V3QULwoA+lcT4w8cR6dfrouhwSanr8y5S2gwdg/vOeiKP7x49ieKAPK/iJJrenjd4n1q80w3MkSWlpp+ozXN5cuWxsSNdka59Sp745qzoej+PPDOlRXviPRbfW9CtiZhp63kk15aQYAVEU/JIyDkjqdpwckV3ngv4ePb68PFPi6ePUPEhU+UqZ8iy3feEeeS2MLvPOBgYHFejUAc14futI8VaRbatpVxBdWkygqwiQlTj7rAjhh3HatRtNZgFF5cIgGAsZCD9BXEeJPDOreGtRufEXw+giead/Nv8AR2bZHenuyHokmM89Ceveq6fF1WBiPgzxcL2MDzYvsPyK2OQH3YYA9x1oA706LbOAJZLqQejzsR+WaE0LTEIIsoSw7lcmvOz8W9QcD7N8P/E0jns8SoPzNSRfEnxVMMw/DLWm/wB67iX+dAHpaWVqgwsEQA/2RTzbQHrDF/3wK8xb4g+ORnb8KtTP11OAVPYeOfHF1cLE/wAMru1U/wDLSbVYdo/JSaAPRTaW5BBt4SD1+QV80fCLxjoFrpyeBkvRGY9flhVWyPtUHm/IC3pt6+u0A8GvX/FN58Q5NDn/ALA0zR7e+eNgvmXLSGMlTgj5QCQcdRivn/wB4N0nxjYeChd2sQur+QmW5iUpL5UKMWJZSMMSiqD1PJoEfXiRRogRUUIBgADimG2gJyYY/wDvkVxE/wALtGlAX+0NfVMY2jVZ8Y/76rOk+CHg6Z99zHqs79zJqU5z/wCPUDPSHit0XLJEo9SBWZear4ftci8v9Kh9RLNGv8zXHH4JeBz1024P1vJT/wCzU8fBTwFgBtCjfHd5GY/qaAN9/EngwZ3az4e455uof8agPjLwRC3y61ogI/uSof5Vln4NeBiMDRI1H+y7D+tWYPhL4GiOT4csZf8Arqm/+dAi1L8SfBUA+fxHpi4HaUf0rPufjF4BgB3+JLNiOyKx/pWlF8NfBUP+q8LaOv0tV/wqhMvw60S68gx6BDdqdvkRIjyg+mxct+lIZz918f8AwLC+2KW/uveC13fzIqSD45aBcR77PQfFlyvrBpTN/I10MnivQomEenaJqV63ZbfS2T9ZAo/Wql748uNPuY4ZPDq6akn3Dqd/DbNJ/uou8sfYUCI9P+K0GoHbZ+EfGDN2EmnCIfmziqniz4heKtO0S/vdM8B3qra273DT6hdRIiKoySVViTwCcZFZPiH4w6nZzTWun6BA10IyYhLPIXdgM4WARiVuh52qvH3qi0Hwz48+ITi4+Jd1Hpnh1mEi6FZrtM4B4WZuTs4B2knOR0ximM7X4U21xeaMPFep3YudR8Q29vdPsi8qOGLYWjiVeT8oc5JJJJ+ldxTIYo4IUihRUiRQqKowFAGAAKfQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAfB//AJOO+KX/AAD/ANCFe/14B8H/APk474pf8A/9CFe/0AeF/tk/8kjh/wCwnD/6BJXs+if8gaw/694//QRXjH7ZP/JI4f8AsJw/+gSV7Pon/IGsP+veP/0EUAXaKKytYun+02um2twLe8uleRX27sIm3eR2z8yj8fagCDxN4q0jw0sI1S623E+RBbRI0s0xAJwiKCT0PPT1IrN0rU9a1+e3uDYXmj6Zuz5cyp58o7FsE7B3wOfftSTeFbyO68/S722sbhyPOu/swmuJAPVpCfU9q1n0WSdFS71TUJOOTHJ5Of8AvjFAFnUbCxnjL34UxLyfMfC/jmuYk8ZeBNBdLWHU9NWRjxFZr57Z+kYY1uv4Z0iQItzZJckdGnJkI/E1ft9OsrcKILS3jC8DbGBigDMtPE9nebPsFtqE6t0ItHjH/j4WtRJriRcrbbPaR+f0qzS0AYmraRNqqql0LAorh132/mEMDkEbjjI+lEegkNmTULvH92EiEf8AjgFbMsiRRtJK6pGoyWY4AHua47Xvij4K0FlXU/EdgjtnCxOZj/44Dj8aANf/AIRTRmn864skuZs5D3BMhH4mtaC2hgUCGGOMD+6oFeZQ/GXT9WkMPhLw94g12c58t4rXyoHwM/61zgfiKZc+J/ihdyJ/ZngrTrGN1P8Ax/XvmMje+zAx+dAHq1V769tdPtmuL+5gtrdfvSzSBFH1J4ry2Lwp8SddZpPEXjCLSockra6RFtI7cy8E+uKv6f8ABrw2twtzrkmoa9dqc+ZqNw0g/wC+fu/pQBc1n4w+BNIMwufENtI0XBFurSgn0DKCufxrHtfi9PrcsUfhLwV4g1IPyZbqMWcW3+8HbOR9K9BtfDei2rI1vpVlGUGFKwqMfpWoqqihUUKo6AcCgDzi7i+I3iN1tmOm+GNPcjzpoJDc3RXPKqSAqkjPzYODiuq8J+E9K8LW0iaZAfPmO6e6lYvNO3q7nk9a36KAAUUZHSmySJEpaR1RR1LHAoAdRWTL4l0KFis2taZGw6hrqMEfrVZvGfhdPveJNFH1vov/AIqgDforlLj4i+Dbf/W+JtI/4Dcq38jWbc/Fjwr9md9LubvV5VGRDp1nLMzfQ7dv5mgDve9ISAMngCvJT4v+JmtXDxaF4Ht9Lt2TMdzq12PzKpkj6EVdXwD4i1xP+Ky8V3EkUijzLTTV8iM+o3ZJx2yMUAZHxd+Kk1hb3ujeAlGp67DaTXVzLD8yWUKISXJ6FvQeuPWvCP2f/Gdrp/i3wzb3bEQwzy26L12B4mA47lnKD8PevsDwx4T0PwvZPa6Jp0FrHJ/rSq5aU4xl2PLH3Ncx4r+DngrxGjvLo8NjelzIt5YjyZQ/Zsr1wecHIoA7ywvLfULOG7spkntplDxyIcqwPcVPXjyfDLxjp/7jRPH08FmpLKZbUGVieSXKkBiSTyRmrlt8O/F00bQ6t8Q9SeBs5+zQqj/m27H4UAeq1kap4l0PSXKaprGnWjgZ2T3KI35E5rmrH4Y6THaQQanf6zqqxDAW8vpGQ/VAdv6VuaX4M8N6VMZdO0PT7eUjBdIFyfxoAx734m6FHEj6bDq2rl22hdPsJXH13MFXH41lT+L/AB5qbzW+ieBHsc48q81S+RUI90QMQa9LSNI12xoqKOyjAp1AHj7+FPiLr9lcRa/qWh2pkPCKs1ymPdCyp/47UumfCrVYNMS3u/GNxZFW3Z0eygsxk+4Un9a9bpCAw+YZoA88ufh7YNp6w32o+JdacDGJtUlAb64YLj8Kyrb4SW76hbXCLa6NFBlkNgm+7JOMg3L5YAjI+QKeTzXrPbiigDA8MeEND8Mo39kWEcUz/wCsuG+eWQ5PLOcsTyeprfrxD4meB9K1H40+BGk02eW01U6g2qsksoSQx26+VuIbC4PTGM+9Q3GsfEGLwn441XTL25uJtP1W507T9OFgmY7dbiMCZSELyFY94HDA9SGIoA91pCQoJJAA5JNfPukeI/HF7a6RZW/iGd4r3XFtjfQ2ZllitmgZirNNaxKxDAHcI+MgH0rOu/E3jKbSLfTfEGp6vb6crapayahaaaHmvJIm2wRuBGwUMpJyFG7HXvQB9JI6yIHjYMrDIYHINCSI5YI6sVOGAOcH0NfLsev+OtG8O+FdP065l0Wxh0G1ktZZLaV45p/+WiSBLaZmIAA2AxnkHJrYv9R8VaJB4xutCt7m3F34qQXlxHE26G2Num51/dSEDcAC/lvj09AD6MNNEiGQxh18wDJXPIHrivnrT9c8f6sLOw/4SS4iQaVfXTX1np4PnPHIPKBM0CHODtJVVDYJHrXP6hr3iUap/by3erWPiS78LWDQLZ6d5gvLvzHPlOpjYKCTkgbfrjigD6norwTxF4+8YaZe+IdMmGoQ6oL/AE42CxaZ5kS2ziPz8SCMqRuLjLHOeB04fc674+HgnX9bGrXhZNXlsEhTTI2e0tRchTcKAu5ysecZBGOeSM0Ae8UV5r8FfEV9r6+KUu9Vu9VtLDVDa2dxd26QymIRI3zBY0ycsTkrnmvSqACiiigAooooAKKKKAPAPg//AMnHfFL/AIB/6EK9/rwD4P8A/Jx3xS/4B/6EK9/oA8L/AGyf+SRw/wDYTh/9Akr2fRP+QNYf9e8f/oIrxj9sn/kkcP8A2E4f/QJK9n0T/kDWH/XvH/6CKALtc54oieDVND1hSRb2M0iXRAziGSMqT9A4jJ9gT2ro6r6jbteafdWyTSQNNE0Ylj+8hII3D3Gc0ANj1CykhE0d5btERkOsqlfzzWJqnjvwppasb7xFpURU4K/aUZh/wEEmvJvhn8JfCmseD7YTyX/2y2ke21CFbshkuonZJASpyOQSP9krXc6T8FvAOmtuTw9bXLf3rsmcj8XJoAjf42+ACxjtdd+2zjpDbW0ru30G3moU+MVlcAix8KeL7hjwh/sworHt8zN0967+w0bTNPiSOy0+1t0XhRHEox+lXwABgcCgDx+fxx8TNVMY8P8Aw+jsIznMuq3YYEdsKhBH45rS03w78RNbt5B4s8Uw6TG4I+z6JEocHOR++YE9OOAPrXpzMFUliAB3Pas+TW9KhYrLqdijDqGuEH9aAOWsPhf4fguJLm9N9ql1IMPNfXTzM35nit6z8JeH7MqbbRrCNlAUMIVzjOeuPeo7vxn4ctP9drVkT6RyCQ/kuapn4g+HyhaCW/uMdodOuGz+OzFAHUxRRwrtiREX0UYFPrkbbxr9rciy8OeIZh/fNskY/wDH3B/SpZ9a8SSHGn+GFII4a7vlix+Cq1AHU0Vw3k/EK+ibfd+HtJJPAjgkuHA/3iwH/jtF14N1zUYo11HxxrS45ZbJIrYH8VXd+tAHck4HNYGq+MvDWk+YNR17TIHT70bXKbx/wEHP6ViJ8LPDL3y3mpRXuqXIGC2oXkk4P4MSK6LTfDOh6Yu3T9Jsbdf9iFRQBiRfETTLyZI9H0/WtU3jcHt7B0TH+9LsH5UTa/4ruXkTS/CSxjHyy6hfLFz/ALqK3867FVCrhQAo6ADGKdigDiP7J8ZarEi6vq2lWCEfMlhZl3X6NKWB/wC+a8o+Ofw/0/QfBmlppzzz6nqeu20V1f3UxLuCkmST0ReBwMD2r6OrzT446K3iPTfD2mJNFEW1VJv3qb0cpG+FZcjIywJHfGKAMnwt8KvCF3ZRGDTbWdYHxJcS/vTLIOTgnjbk/jXU3Hww8NXkkj32nwTlsqq+Uqqi9gAB2HGa7CxtYrK0it4VARBjgAZPc8dzVigDw/4/eE9A8PfBrXZdE0aytrgrBCHihAcgyouM9e/869c8M+TLoOm3MMcaia2ikyqgZyoNcx8cbaO8+F2t20x2pKIUJBxjMyVq/DCUz/DTwlK3WTSLRz+MKGgDpqKKKACiiigAooooAKKKKACiiigAooooACcUUUd6ADtQKOc+1A96ACiiigCK7uIrS1mubhtkEKNJI2CcKBknA56Vxtj8VPCF5HcypqkkMEFj/aXm3NpNAsltkDzI96DeMkD5cnJx1rqNetpL3QtRtYMGae2kiTJwNzKQP1NeUeGfgwlx4Tt7TxnqN1d3Z0VdIWGLy1SyTKu2wqvztuVcM2eBjmgDsB8UPCv9k3V/JeXMItp47aS2mspkuRLKMxIISu8lxyuBgj6HGfqnxT06xN9OIpGt7TRptVa1ltrmG8JjlEZUxvEFVcnBYsCOuNuWEF18KIr3T9YGo65cXup6tNBJd3lzZ28iyLChSNPKKbMAMTkDdnnIqDQvgxpOk280C6nqE0E2iXOiSK+3Ijnk8xmTjC46BQMD3oA1NH+J+k6jNbzSTw2enPojaxL9qSeOeJVkCMdrRhCgzjcGyTjapBzUWr+PvAeu+Gr9NcmkbTklt4bi2u7G4SQNIQ8B8spvwxUMrAY461Xi+ElnPCsWtavd6gv9gv4fJ8tIj5JkV1YbRwy7VA4OcZNJ/wAKkt5xLPqWuX19qUl1ZTtdSRxqdlocxxhVAABycnqc0Ab/AMMb7wnd6Fcx+B7eO1sra6eK4gFs9u6TgDdvRwG3EbeT/TA6+uf8L+GIfD+o+ILuG4kmbWL430isABGxRV2j1Hy10FABRRRQAUUUUAFFFFAHgHwf/wCTjvil/wAA/wDQhXv9eAfB/wD5OO+KX/AP/QhXv9AHhf7ZP/JI4f8AsJw/+gSV7NowP9i2IXGfs6Yz/uivGf2yf+SRw/8AYTh/9Akr2jRf+QPY/wDXvH/6CKAGBNTxzPaZ/wCuTf8AxVHl6nn/AF9pj/rk3/xVXsHdnPHpS0AcRqngG2v9Yl1aOVtO1SZdst1p0stu8vQZfa4DHCgc5q5b+GtSgiCL4gvnA7yOzH8ya6ugUAcdceEb2dy0niDVAPRLqVB/46wqKfwKtyCtxf3kqkYIa9uDn/yJXbUUAcFB8NNEhLM+mabcMf4riN5T/wCPNWvp/he307iwstItx/sWuP6101FAGSNPugc/8S/P/Xt/9epFg1FPuz2ij0EJ/wAa0qKAM8xalji5ts/9cj/jSeVqnH+lWv8A35P+NaNFAGeItT73Nt/36P8AjR5WpnP+lW3/AH5P+NaFFAGf5Wpf8/Nv/wB+j/jQItTxzdW+f+uR/wAa0KKAM8Ral/z82/8A36P+NHk6n/z9W/8A36P+NaFFAGd5Op4/4+rf/v0f8a8m+Kega/e/Ejwrcaf4lg0+6kt5ILOKS2Mkfmq3mO+3OMlNv/fNe1VyGqRwX3xQ0SC4iDtY6dc3kLd1dpIo8/8AfJYfjQBgw+GvicrZl8f6e49Bo0Y/rWnbaT4/iP73xRpE4/29MI/9BcV3VFAHlfjPw1421PQdQi1PxXpEWm+Szzoukb/lUbs/M55GMj3FQfA62k0vRbnw9pmqm6ttNjgIaZSSjurFlxk7R8obbnjdXonjCOSbwlrccKNJK9jOqooyWJjbAA9a4X4D2bwWfiyeZU8yfX7zawJLFEkMahs9CNpGB2AoA9BMOo9ruH/v1/8AXoEGpZ5u4f8Av1/9etCigDPMGo8Yu4f+/X/16PI1HveQ/wDfr/69aFFAGd5GpY/4/Is/9cv/AK9KYNR/5/Yv+/VaFFAGd9n1HH/H7H/35FL9n1H/AJ/Y/wDv0K0KKAM8wah/z+x/9+hR9n1D/n+T/v0K0KKAM8W+od75P+/Qo+zah/z/AC/9+hWhRQBnfZtRx/x/r/36FJ9l1H/oIL/35FaVFAGaLXUe+oD/AL8rSi11DPOoD/vytaNFAGd9l1DP/IR4/wCuS/4UfZdQ/wCgj/5CX/CtGigDN+y3/wD0ET/36X/ClFrqGRnUTgHn90vP6Vo0UAFJ0paDSAKKKKYBRRRQAUUUUAFFFFABRRRQB4B8H/8Ak474pf8AAP8A0IV7/XgHwf8A+Tjvil/wD/0IV7/QB4X+2T/ySOH/ALCcP/oEle0aL/yB7H/rhH/6CK8X/bJ/5JHD/wBhOH/0CSvZ9E/5A1h/17x/+gigC7RRRQAUUUUAFFFFABRRRQAdaKKKACiiigAooooARiFGcH8KjaZU6q/4KTUtZV1r9hbatFpszXAupBlQtrKyH/gYUqPxNAGgs6N0D/ipps11FEMvv/BGP8hTpJ1jXJDn6KTVKfVFiDHypyO2ISTQBDd+JNNtR++e5H0tJm/ktc3oMia18T9Q1myuGaxtdLisvLkgeNjI8jOT84HACr+dalx4ojjDGRbiJV7vYTP/AOg5rK8Ia/PrfjK6aGPNj9iy0p06e2YuJMKpMnDcFug70Ad7RRRQAV5t8Hb+xuIvFktmxSIa7ebxI+cSGVi2PQHOcfWvSa8q/Z+t/sfhLXZbklpp9fvnkO3OWEmzj1+7QB6W2oWi5zOn4c1GdXsQMmfj2Rj/AEqx1AKQjn+9xTJI52TEZhjb3XdQBAus2LthZmJ/65t/hVPUfFmi6bLFHf3htzIwVWkhcJn3bbgfUmi60jUbiNlGt3FuT3hgiBH4lTTJ/Da3Xh3UdJvr+6u0vYHt2mlKl0DKVJXjAPNAG/RTY0Ecaov3VAAp1ABRRRQAUGiigAooooAKKKKACiiigAooooAKKKBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4B8H/8Ak474pf8AAP8A0IV7/XgHwf8A+Tjvil/wD/0IV7/QB4X+2T/ySOH/ALCcP/oElez6J/yBbD/r3j/9BFeMftk/8kjh/wCwnD/6BJXs+if8gWw/694//QRQBdooooAKKKKACiiigAooooAKKKKACijHJooAKKK46TVvEt/4i1qx0WLR0ttOlih3XZl3uWiSQn5eMfPj8KAOxoxXB6HrviPXoJ5tF1DwjfxQSmCV7eSZwkgAJU46HkfnXR+DNWl17wppWq3ESRTXdukzpGSVUkcgZ7UAbNFFFABQBRVe5vrW2bbPcQxvjO1nAOPp1oAsUVRTVbRxlXcj1ET4/lTrfU7G4mEMN3C0xyRHvAfj/Z60AXKgsrO3sYPJs4I4YdzPsRcDczFmP1JJP41PRQAUUUUAFFFFABRRRQAUUUUAFFIQS3XiloAKKKKACiiigANFFFABRRzRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAfB//k474pf8A/8AQhXv9eAfB/8A5OO+KX/AP/QhXv8AQB4X+2T/AMkjh/7CcP8A6BJXs+h/8gXT/wDr3j/9BFeMftk/8kjh/wCwnD/6BJXs+h/8gXT/APr3j/8AQRQBdooooAKKKKACiiigAooooAKKKM8470AFFFFABXl/iC+1PTbL4oXOgWdxe6sJIUtYbdC7mRrSFVYAc/KTuPsK9Qrmb7wdb3Or3uowaprFjNeMjTLaXXlozKgQHGDztUCgDyj4CeEfEvw98X3OlappCw6TqWmwyNPaytPEl1CNpLNtGwuCzY55AwTXqfwq/wCSceHP+vKP+VH/AAhv/Ux+Jf8AwO/+xrc0LS7fRNGs9Mst/wBmtIlhj8xtzbQOMnuaAL1MnljgheWZwkaAszHoBT6yGRdYu5ElGbG1lAAzxLKvJz7KeMeoPpQAoS61UB3eW0siDhEO2WQepPVfoOfX0qfT9IsNPB+y20aM33nxlm9yT1q/RQAgAAwAKoapounarEI7+0imA5UleVPqD1BrQooAw0tdQ0n5rSaW/s1X/j3nbMq4/uueT9G/MVpabf2+o2ontXJXOGVhhkburA8gj0qBotSjug0NzDLbEjdHKmGA9mH9QayPFjWOj297rIneyvIoTK0kaZEwQFtrL0buMdeeCKAOoorkdP8AGDG/FrrFktmOENxFN5sUcu0MY3O0bThlIPIIPUV11ABRRRQAUUUUAFFFFABRRRmgAooooAKOtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgHwf/5OO+KX/AP/AEIV7/XgHwf/AOTjvil/wD/0IV7/AEAeF/tk/wDJI4f+wnD/AOgSV7NoP/ID07/r2j/9BFeM/tk/8kjh/wCwnD/6BJXs2g/8gPTv+vaP/wBBFAF6iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAralcfZLGeYfeRDtHq3QD88Uml2a2FhBbIS3lrgserN1LH3JyfxqLVDuksYf+etwM/RQX/9lFX6ACmSypCu6Rgqk4yelPrPhujdajqNhNCPLhWMhuodXB6/iD+lAEOqWVxqOo2UZcx6fbuJ5QrEGZx9xP8AdB+Y+pA961qbGoRFVegGBTqACmSxpKhSVFdTwQwyKfVKK+M2oNbwwO0SKS9xwEDZI2DuTxz2oAy9d8JafqsLhWms5mQKJbZ9hBXG0kdGxgdQeMjoayLHWp/DerR6XrYZbCct9nuj92PGOD6Ic8ZPy9OmMdwfaqerRySWEwghhnl2HbHL91/VT6ZoAuUVjeEYbi30SOC6bLxu6qpYsY03EohJ6lVIGfam6/rMlpPDp2mQrdaxcKWjiY4WJM4Msh7KCenVjwO5ABf1PUrTTIBNfTrEpO1RyWc+iqOWPsBWPJquuXrldI0hIYeMXGoSbc+4jXJI+pH0q5pGhx2kpu72Vr7Un5e5lHT/AGUHRVHoPx5ya2KAMCW18SSKNup6fE3cJasR+rGo2g8VRxnyr/SJn7ebauP5OK6Og/SgDlpLXxhcQlG1PSLRj/HBZuzD6bnI/SqFz4duZZBHd+JddvbwYJW3mFsq59RGFAH611tzMzSi2tyPOYZZv+ea+v19KltbeO2j2Rg+pJOSx9Se9AHKReE9Ttv3lh4q1iFyPuTutymf+2gJ/LFXxqmo6RIRr8cMljgf6fbggIeM+YhzgZ/iHHqAOa6KmuqujI6hkYYII4IoAUMGAKkEHkEd657xj400Lwclk/iG6ntkvJDFA0dpNOGfj5f3aNgnIwDjPOM4NXvDKNFo0MTtu8ppI1P+yrsFH5AVx3xn8O6/4msdBtvD1pYzfY9Th1GZrq6MP+qOVQAI2d2W54xgcHPAB3SanZN5A+1RK8+PLSRtjsSM42nBzg9MZp/221+1NbfaYPtK4zF5g3jPTI6814t4h+E+oaxqHiXV2s9KXWL3VrC+srgvukt44hH5qiTbkfdbp14zjtzOm+H9RT4tWNlDo32qS38T3GqXGs/ZbhJPIZX2pI7xBCo4A2yMDxgd6APoq+1K2tNPmuyxmSOJ5gkPzvIEGSEA+8eOgpItVs3treaSdLfz1RlSdgjguMqpBPB9q8DtvhL40Gg6Pot0dENto+l6xp1vPFcSb5jdxFUZlKYUZIzgnHNXdc+DV/q2na4Lq10me+m0Cw0/T5ZTuMFxCuJGDbcqDxyOSKAPdBqFmb02Yu7c3YGfI8weZjr93Oao+E/ENh4q0G31jSWkaynaRUMibWykjRtx/vKa8fu/hj4puviPp+uXA0lorXWIL0XUcojlNsse1oygi3O+erNIcjAwK9G+EXhy+8JfD/TtF1Qwm8t5LhnMLFlw88ki4JA7OPxoA7GiiigAooooAKKKKACiiigAooooAKKKKAPAPg//AMnHfFL/AIB/6EK9/rwD4P8A/Jx3xS/4B/6EK9/oA8L/AGyf+SRw/wDYTh/9Akr2bQf+QHp3/XtH/wCgivGf2yf+SRw/9hOH/wBAkr2bQeND07/r2j/9BFAF6iikAxQAtFFA6UAGaKKKACiiigAooooAKKKKACiiigAoooNAGFr10bfXfDUeMrc3csJPofs0r/8AshrdrnPGjR2yaNfzMEjs9ShYsTgL5m6DJ/7/AFdHQAUxY0WR3VQGfG445OKxtYuLpdZ0NLeK58trp1mKD5DH5MnLfRgmPetygA7UUUUAQ3sby2sscTbXddu70z1P1rz74zavrWheFFj8IxbtUcbYe4RRgM+O7AEYB6k57V6PUD2yPciZwGITaARkdc5oAz/CCXieFdIGqZ/tE2kTXWepmKAvn/gRNa5oooAzbyykE4vrVsXiJsK5ISVc52kevoe1Q+HI7aW3k1GEmS4vGLSyMuGBBx5Z9NuNuPUGtis7SEhjn1BLfAUz+YQPVlUn9c0AaNR3AZoXCMUbHDAZwfpUlNlkSJC8rqiDqzHAFAHIr43gsrlrXXbK+s2RSTdrbO9s2DjIYAlfXBHHqa6Cz1jT79UbT7yC78z7vkSB/wA8dKgfV0upja6fbvdNghpGUiFfqx6/QZ/CrOm6ZBYmWSNF8+YgyyBQC2On0A9KAJbG1+zLIWdpJZXLu7dz2H0AwB9Ks0UUAB4HrVbUr2HTtPuL26bbBBGZHPsB296s153rXiFta1uKGysbu98NadNvvLm2jDi4uEIKRLkjKIw3Mwz8yqvZqAO00G2a00e1idSsmze4Jzh2+Zv1JrQ71z1r4z0Gc4k1BLR8gbL1Wtjk9h5gGfwzXQAggEEEHoRQB4b4h+IPiTwx428fXKW9vqXh/SbvTI5Ip7lo5IEnijUiFQhBJd8ksR9D21Ivixqtz4yv7Cy8OPPo1jqcmlT3C+Z5kboD+9Y7PLCFsDbu3YOfavSLzw1ol7/aP2vSrOb+0Wie83xA/aDFjyy/rt2jGemBUF14O8NXetjWLnQdLl1UEH7W9shlyBgHdjOQO/WgDzqx+KfiS98O+F9Si8N6ZG/iO6S1skk1F9oykjF5CIsqAUHADZB7dKrWPxSuby+8OT6pbjT5FGtR3qR3Z+yhrNFJZvkLMvcHgrzw1emQ6b4ajutO0WG201bjS0F5aWShd1suSgkVOqjJYA/Wpo/CmgRyxyLo9gHjad1PkKcGf/XH/gePm9e9AHF/Cv4jah4t17UNK1XTYLZorOG/t7iDzVWaGQkA7ZFVh0yDjkHoK9OrC8PeEfDvhuWSXQNF0/TZZE8t3tYFjLrnOCQOeTU/iHXLfRYYt8ctxd3DeXbWkA3STN7DsBkZY8Dv2oA1JHWONnkZURQWZmOAAOpJrmJ/Hnh9bh7e0u5NQnQgMthA9wAfQsoKj8TVP/hErnxDL9o8bTi5iEm+HSoHItYh0AfoZW75bjPQCuvtrWC1jEdtDHEgAAVFAGB9KQGEvi+yVN91aanax4zultHIH125rZ0/ULPUrYXFhcxXEJ43xOGGfQ46H2qweQRjiuX13w7Kty2r+GmistbRQCDxDdKD/q5VHqOA3Vc5HcFXsB1VFZ2g6rFrGmpdRRyQtkpLBKMPC44ZGHqD+fBHBFaNUAUUUUAFFFFABRRRQB4B8H/+Tjvil/wD/wBCFe/14B8H/wDk474pf8A/9CFe/wBAHhf7ZP8AySOH/sJw/wDoElezaHxomn/9e8f/AKCK8Z/bJ/5JHD/2E4f/AECSvZtFz/YtgP8Ap3j5/wCAigC9RRRQAUUUUAFFFFABRRRQAUUUUAFFFBoAKKKKACiiigClrOm22saTd6dfJvtrqJopF74Ixx6H3ri/Dfiy/stNuNJ8T7H8SWCSBXRSqaisYzvQdnK4JTrzkcdPQaydW0O21CeOdlVZ0KndjO7acjPuMkgjkUAacUiTRJJEwaN1DKw6EHoafVS1eK3MdmSFdU+QYxuUen0q3QAUmRnFLWVqVzNp2hXd0iPPcqrMkeOXcnCqPbJAoAtLqNm2omwW4ja8VPMaIHJA46+nUfnVuvIf2fvD2t6MviS517UZNQN9dLIs8mRvlG4SMAeg+4vvsr1ea7hglRJ5FjL/AHSxwGPpn1oAq6vuuAtgLd3S5Rw8oOFiAHBPfOSMY9D6U3VL+LQfD897eyNIlnbl3b+KQqv8zj9ahhglu0s77ez3MJfCuxVCCSCcDjp0J7fWsvVnj1+aNcEaZEVkaVshXVXy5IPG3CbQT13t2GSAdRbO0ttFJIu13QMy+hI5Fcr4dkuLPxd4ugmR2tTLb3FttBOQ8WHX/vtWP/Aqi8P6jft4Ztb3WYL1Zb+5mlSCH53WN5GaJSeMfu9v9avw6jcwTQW1vpkNkszERrPMPMfAycIufxOaANOK8u5HPmWyWsZbahlkyzf8BH+JpYNLQXJubqWS5n/hMh+VB6KvQfzqURLBuubkmSX6dP8AZUVLa+cyl7jCluQg/gHpn1oAmVQowoAHoKWkUgqCOQeRVHVdXs9LWP7XKBLKdsUKjdJKfRVHJ/kO+KAL9c5rnjTRNImktpLv7VqCAn7DZKZ58jsUXO3qOWwPeoU0GfWzJdeIJrqNJhhNOinKxRJ6PtxvY9TnjnA6Vr6LoWlaHB5OkafbWceSSIYwuSeuaAOaez1/xaNurK+haG4YPZxSZurhc4xJIOI1I6quTz97HFdhY2dvYWcNpZQxwW0KBI4o12qijoAKnooAq3+n2moQPDfW0NxE42ssiBgR+Nc3/wAIVHpsbHwrqF1ozbi4hjbzLckjoYmyoHT7uD7111FAHLrrmp6XIkfiHTt0J4+3WCs8ef8Aaj5dB9N34Vv6df2mp2iXOn3MNzbv0kicMPpx39qS5tXnGBcyx/7hArjNa8PPp08mpWVw1pIWDT3tqBG6gDhpY/uSqO4IyBkjmgDP1pm079oTw3cE4TVtEurAe7RSLN+eCf1r02vGvifdXumeJfh5rGsQorWWtraC8tz+6aK5jaNiw6qchfUYzz2r2OORJY1eJldGGQynIP40AZPinXYtA0z7Q0Ml1cyuILW1i+/cTHO1F9OhJPQAEngVV8MaFNaSSaprUkdzr10uJpkB2RJkkRRg9EXP1J5PJqv4egTXNZk8SzlniUNb6ahPypFnDSgf3pCOv90L6muqoAKKKDQAnUUEZpPTFOpAYGpKNH1RNUiB+z3DLBeqOgzwkv1Bwp9jk/drfqC+to7yyntpxmKZGjcexGDWf4UuprnRIRdktd25a2mY/wATxsULfjt3fjS2dhmvRRRVCCiiigAooooA8A+D/wDycd8Uv+Af+hCvf68A+D//ACcd8Uv+Af8AoQr3+gDwv9sn/kkcP/YTh/8AQJK9n0T/AJA1gP8Ap3j/APQRXjH7ZP8AySOH/sJw/wDoElTftDX9vp3wk0uc6lPYaiJLZbYw3kkDOCUEgwrDd8meucdeKAPbqK+fPF/jvxDpUXi648JaxZjQfC9npVxaRSQfaTeRTp0MzPuwQM7uWOeo5Ji1Xxh4p8OeIPil9l1d7+9spoZbPTJoGkMFu5hBnRd2dkauQQBgn5j3FAH0RRXz1oPxD8X6rc6LplnrujTvqGqS2qagkC3IEX2cyAOsbKu8MD90jqMj1t6h448Y2msX9wNWsnsNN8TW2iyWn2AA3EcgjDMX3ZU5YkAD6k0Ae9CivmXV/ihrmoeKNY0ZNQWXSruHWLZrSeFIri18m3ldDtX5l+4ACzEsMnC17j8KWZ/hd4PZ2LM2jWZJJySfISgDqRRRQKACiiigAooooAKKKKACiiigAooFFAENzbRXKBZl3Acg9Cp9Qe1Uni1K2jP2WaK5APCz8Nj03D+ZBrTooAzF1OSKJn1CzmtwvVk/er+nP6VLKlvq1vbyQzrJAsqy5jYEPt7H8cflV6s6XS41n+0WTm1n/iKfdf8A3l6H69aAL8UaRRqkahEUYCgcAUOiuMOoYe4qh9untoyb+2bg4MkALqffHUfTmnwavp8+RHdw7h1Vm2sPwODQA7VZ5Lawla2haacqVijTjLYOOew96w9e0cz+BJdOvbgxj7OouHiO3cFwWXPXbwR9K6H7Xb8ZuIef9sVjazq+m3cM+lJ5t9LcxtC8Vqu/CsCDlvurwe5zQBvgAAADgViXFwttfyXElrNcX+1o4Y44zwmf7x4GcAnmrXh+6a409I5gy3VtiCdWOSHAHOe4IIIPoa0qAMfSPt8kh/tUR+cCzkRfcjBPyoPUgck+pqTXLow6bcyoxVY0K5HVnPyqv5kVHd2+ovbS2dpL5LSs5a8yC0YYk/Kv94A4GeBjvVVAb3wlbmxgMuwxyRxO/MgjlDDLHuQvX3oAbr91P9s0vQNLuHt7m6DSSzIAzQW8Y+ZhnjJYxoP94kdKvaP4fsNKcywRtLdHIa5ncyytnnl2yapeGbbUp9U1LWNZtYbSa4WO3t7dH3tHCm45dsY3MzsSBwAFHOM10f1oAKhuJvKXIwT6E4rP8Q3EkENqiu0MU04iknVc+UCDg+2TgZ7ZqpLY3doH+zsZFPJZ/mY/U9TSbLhFSe5pQalFJcJAyyJK+doIyDj0NXwQelY+lx+VF9quZMs3CoFKhfw9aS51LEhKqxUdAvJouU6d3aJs5oPIxXNxeJofNCONy5wSOCPzroEmR8YPXkZ70Jp7Ezpyh8SHjOORVW+062vVK3CFlYYYAkbh3B9QfSrdFMg8y/aJUx/CbVbuGMtPp0ttew44wY50PB7cZrsjpkU9v9r0e6ls/tKKd0OCrKSGyFPGSMjOM81H4/0xta8C+IdNRA8l3p88KA/3mjIX9cVhfCW+bUPhj4U1O3Bd30+GKdQ33iqhHb/eDKf5UAb/AIEZW8FaCEAAWxhQgdiEAI/Ag1u1i+HQlpJe6crDEUrTwj/plISwx9GLj8BW1QAUnc0tJ2pAZkF+0viO8sFAMcFrDMT6M7SDH5JmtQVyHw9DXbeIdZlIL3+qzomP4Yrdvs6D8fJZvq5rr6EAGub0FjbeKPEFkx4d4r2MZ7Omw/8Aj0TH8a6SsCdFi8cWkmcPcWEqH32SIR/6MP50pdGNG/RRRVCCiiigAooooA8A+D//ACcd8Uv+Af8AoQr3+vAPg/8A8nHfFL/gH/oQr3+gDwv9sn/kkcP/AGE4f/QJK9Ov9dTw/wCGdGuJFhYTvbWoEs3lDMmFyDg5PPA7+teY/tk/8kjh/wCwnD/6BJXofiPwt/wlnhTQrP7Z9k+y3Nnfb/K8zd5RVtmMjGcYz29DQBNF8Q/CUviJdCj12zbVmne1FuCciVCQyE4wGyCME89s0y0+JPhC8luUttetJDbxzTSMN23y4RmR1bGGVcclSRXPv8KUkiSOTVsqPFcniY/6NjIffmD7/H3/AL/t92uF8H/C/wATXF/b6Vrsctn4csNHv9Kt5ZRAJilz8vHlSOGIBJ3MEzgfLnNAHrXiTx5o+kaTc3UN3Z3FxFYx6kkMk/kh7d3CLIXwcKSfSn3PxE8JW2vrok+u2aaq1wLT7OSciU9EJxgE54yee1ef3fwT1DUNMvrXVPFwuZJ9Dh0OKUaYsflRxTiVWwJPm6Yx75z2roL/AOF32v8Atb/ib7Pt/iCDXf8Aj1z5flbP3X3+c7PvcYz0NAGzqPxI8N20mqWsF+k+qWMNzL9kKvGZWgVjIiMy7WI2kHGcYPpW94W1ddf8MaPrKQmBdRs4bsRFtxQSIH2574zjNeWTfBK4n8Rvqt14oNwc34RprEtOVuoZIgrymX5gm/IAVRgYwM5HqXhPSP8AhH/CujaN5/2j+zrKGz87Zs8zy0CbtuTjOM4ycetAFXxx4rsPBegvrGsR3bWMbhJHtoTKY85wzAdFzgZ9SPWmr4z0COytrjUdUtNKa4RZFg1GZLaUBs7coxBGcHHrWZ8YfDWqeMfAd/oGjS2UMt8USWW7LBVjB3ErtBy2VUc8YJrkdf8AhZqXiGTXLrVW0Zr2/wDD0elQ/KzrBOrMfMBZcheV5HORQB6bd+JNDs9TTTrvWdNg1BwpW1lukWVgxwuEJycnpxzU6avpr+Xs1CzbzJjbpidTvlGcxjnlhg8deK+dtW8E+IrXxh/Y+naY99b3Wr6bf3GovasoiEKR7wJidpjG04H3s5G3vXZad8MPEdn4h08tqWkSaHY+IZtbiURyLcsJQ+UJyV4L+nPXI6UAd/Z+N9Bl0S01TUNRs9JiuYzKqX95AjBQ20nKuykZ7hiOfXir1z4p8P2t7a2dzrulQ3l0qvbwSXkayTK33Sik5YHtjrXlXh34N3dlYaDbarLpd4unaHeaYyshdTLNKXV1DL0AJB71kav8FPFF9o1hpp1rTpLe2sLG2QNJNGIZIGBchU4kDYODIDtzwBwQAe0eF/Etn4kfWVsYriM6VqMumT+cqjdLGqklcE5X5xgnB68VuVyfgDwzc+G5fFDXU0Mo1bW59Ti8vPyJIsYCtkfe+Q9OK6z6UAFFFFABRRRQAdRRRRQAUUUUAFUNYns9O0y8v71F+z20TzSkICdqgk49TgVfPIrH8WeS2kCG4G6K4ubeBh6h5kUj9aAKnhPS2OjW93rFtGNUuh9onQgHyWbkRj2QYX3xnvXQRxRxA+Wirn0GKfRQBzHiyebQ57bWrKMzGSaCyubfdtEqySBEYHsys4+oJHoR0NnObm2jlaGWAsOY5QAy+xwSP1rE8dIJdBRSel9YsfbF1Ef6V0NAEF+k8llPHaSiK4ZCqSEZ2E/xY7461keCZAPD9vZMwa407/QZ/wDfjAXP/Ahtb6MK3q5Usuj/ABCUYYQa9b9f4RcwDP8A308RP4QUAdVRRRQBzuoXtzqK3dtZxwraBmt5J5G+YsMBgq/iRknqOlX4NWjaVYZY5ImJwpIyD+NMsIYxPqcGMkXHm7c4++qn+efyqndWIefy7dJosj94WPyIh4JHvjNJmsFGWjNa7tY7gqz7ldejIcVn3mnlkwjBx6MKat9OyzS7yEdiUBXovQf4/jUJ1p4mxJH5sZ4ynXNJtdS4wqL4TOkt555GtTaNFI6kBn5Rvx/xrpL2cWltDBGN0jLtU9gBjJNWI5FaNGZgqsM4fgisXSItTkVY9bgtiqLgzRvuMreoAA2jv360JWFOrztcy0Qy5vLyM7oJU256MMfyqSx16RrhIbuEruIXfngEnAqSfSIi+YZXj9VzkH+tMTRUjvI5biQuiNlFGBuPbPril7xpzUWtTeWRWJXofQ15n+zy7QeBrzR3IL6Nq97p5HpiYuB+Ugrr9TWdL2W4AaJdqqkiDOD33CvNfhpq6aH8Q/iPpcwzE+oQakrr93M8WT+q/nT5jFUW0nHU9au7Y/a4Z4cLKgO0+oPVfoQPzFaA6VXuvmt/MXquHH4UJcoJ/s8rbZf4d3G/6ev0qjIsUdKBR60gOO+HLtbR6/o8wCzadq9yQB/FFO5uY2+m2bb9UNdjXB6ZdXFz47l1m0GNHuCdIfPSZ4tzrOD6BzLF78Hpiu8oQBWNqdt5niLRrhesQmU/RlH9QK1pZY4YnkldY40G5mY4AHqTWJY6gNT8QBrYM1lDbnZNjCyOzDO31ACjnpzSb6DRvUUUVQgooooAKKKKAPAPg/8A8nHfFL/gH/oQr3+vAPg//wAnHfFL/gH/AKEK9/oA8L/bJ/5JHD/2E4f/AECSvaNG/wCQRY/9cE/9BFeL/tk/8kjh/wCwnD/6BJXtGjf8gix/64J/6CKALlBoooA8++I2t69aeL/BuheHb60sW1p7xJZ7i1+0BPKg8xSF3LzkHv8An0rgrTxTr0F7eado9zZWNzfeOLnSpLn7J5g2C3Vt+wsMtkevpXv1UNf1IaPoeoak1vNcrZwPcGGAAySBVLEKCQM8etAHz/8A8LR8UR2djbarrNnpqwy6nDLqrWQIvJrZ9scIU/KjMOTjk4wPf2v4a6xd+IPAHh/V9RKNeXtlFPMUXapZlBOB2qj9h8NfFDw3pWrSrc3WnzRM0Qju5rcFWwHVxG67uVwQ2Rwa6uws7fT7G3srGFILS3jWKKKMYVEUYCgegAoAnrlPij4om8HeCb7WrW2juJ4WijQTMViQvIqb3I5Cjdk/Tt1rq6ZNGk0TxTRrJG4KsjDIYehFAHini/4na74f063hg1TwrqmrySXDD7FC7QtHFFG+G33CrGw385kY4KkKSSBm3fxi8VXGiX+q6Tp2hpb6do1jq9zHc+azP5wO9EKkAYwcE/jmvaP+EZ0H7JFa/wBh6X9micyRw/ZI9iOerBcYB96rND4Xh1P+wmtdJjvbu0B+xGFAZrdDgDbj5lU9u1AHmWsfF7Urb4i2WlWEWn3OkTaraaXMrRFJoWmVMneZQWILH7sRXA5bJrrfgZqF5qXgQ3Go3dxdz/2jep5k8jSNtW4cKMk5wAAAOwFddLoGjzXy3suk6e96pRluGtkMgKY2kNjPGBj0xVyys7axh8myt4beHcX2QoEXJOScDuSSaAJ6xvGl3PYeDtdvLSQxXNvYTyxOACVdY2IPPoQK2apa5LbwaLfzXtv9ptY7eR5YNqt5qBSWXDYByMjB4oA8P+GPjDxQPhvrPiXVL5765t7GG8RNTvLXyZBhmfZ5I3xEgADzO5A9cOvfij4n1qw8Jav4eOlabYaprctgbe7fc+xFbCznB8skqxIXBA2cnJx6LZ6V8P7PT1QaP4Z02LUFheS2ktreIyE/NGHUDBIPTrz0q/quneDZbmbTtWs/Dz3F3Kt1La3MUJaaT7qyMjDLN2DEZ7UAefx/FnWrjxvf6faaHbvpFlqcmlzMzlZkKggTEkhdpbGExkgggmiw+Jni298N+FNSTR9Cjk8S3aW1mjXcpCAxyMzSfJxygwBu4zyK9EvNL8KXGorq9zp2iXGpBjGl20MLTF1ByiuRncACMZqrp954SOhaPcTW2laZaW6i5sre7WGI2nJUMgzhDyRlT3xQB5tefGPW4/DNpJHZ6SviD7RfQT2uJXSQWrYZ4zlQq+pZs+gPbc+E/i+/8WeNdUuriSWKzn0TTbyOyMhaOB5Vcvt+uBz3wK66/wBN8DS3NvpeoWXhp7h5WuYLSeKAs0knLSKhGSzd2Ayaf4GufDt+dUm8OaXb2TafdyaPOyWqQkm3O3aNvVBn5fTPQUAdTRRRQAVz3j9zb+Fbq9EZkFg8V8yr1KwyrI2P+Aoa6GmyIsiMkihkYYIPQigAjdZY1kjYOjAMrKcgg9CKdXI+Gbk6Bfp4X1BlWIA/2TLziaADPlH/AG4xxjuoB7NjrqAPP/Hmh3tuf7WsNWuPLeW3hubG4PmQyoZVA2jqjhmBBH4g16BWF4oRbqXSLEyBTNfRyle7LD+9/mi/nW7QAVyvxKdbPwydY8su+jzxajx1VI2/ekf9sjIPxrqqoa9p0er6HqOmzj91eW0lu/0dSp/nQBdU5J44Hf1p1c98O7uW/wDAHhq7uXL3E+mW0kjHqXMSlv1zXQ0AVTCI9RE68eanlt7kElf5tU0kYdSOxGCOxqQgHrRQBgahY3aBjbxrKOy5xVbR7SUaij3Ni0e3J3BwRnjqM/WuopCoI5GanlNlXko8py+oySmRvkmEmTjAzmrOkQz2CtLezkl1+SEdu/PvW1JArjuPcHmsjUdO2tGUu5keSQIoJBGT9fYGla2paqqS5HoVbnUL4bmiUN345H0xWJPdPqqxwXmm3BZ+XJC7Y/qc/wAu1XNR0Szinha7vNsjHCM7BXZh33f561Pp9kJomtdPkISLIabcXIJ9+5/lUu7Z0xdOMeZffZkPh+8WxvJ7S4uGS08sFBKxOwg4wM9iO3tXKwGwi/aOCQGJodU8PLKSmMNNDPgZ/wCAE13EPh2QSkyS7kP3txJLelcR4/hh0L4ofDLUYhEo+1XOnzbcbmE0XyZ743A1UU1oznrypt80Hqes3BAhI7t8oHqTTbiCG5Xy50Vx1AP8xVODzri+e5uMxWsWUhRuCx7uf5AemfWotVvLVoPntLm8x0EMeT+BJH86s5SPVb640WUXU2ZtJJxO38VqP7/unr3HXtiqviW4utSnj0LR5mie4Tfd3kbc20B/u/7b8hfTluwzP4Utrr+zbs6hHPHFcTu0Ntcv5jwxYChGOSOSGbGTjdjtUfguNIINUtEjCx2l88EbjkugClRn/ZDbP+AUgGa/YNZ6NptjpLQ2cUEsUcG9cohUjy1I6kEgL17ill1LxJHOsSaHbSrj5pRd4GfYbc1d8TQrc6bHA+dsl1bjIOCMSqcg+vFU4NJ1+KNIz4hMyqeXktUDsPcgAZ96lgSWmiz30RfxLJFdyl96wICIYsdAF7kepq+iwprgWMgSC25Qdl3cHH51btI3hto45ZWmkVQGkYAFj68VgRX0P/CZzbXVo5LVIwwHG9WclQe5w2cUOyGtTpaKM5oqxBRRRQAUUUUAeAfB/wD5OO+KX/AP/QhXv9eAfB//AJOO+KX/AAD/ANCFe/0AeF/tk/8AJI4f+wnD/wCgSV7Ro3/IHsf+uEf/AKCK8X/bJ/5JHD/2E4f/AECSvaNF/wCQPYf9cI//AEEUAXKKKKACgjIwelFFAHj/AMH2HhDxt4p+H025LeKX+1dJ3dDbS9UX/db5cezV7BXkPx0il8O6j4a+IWnx7pdFuRbXwUcyWcxCt+TEY9N5NetW80dxBHNC4eKRQ6MOhBGQaAJKKKKACvJPjAw0X4hfDjxIFAVb+TS5nPZZ1BBP0CP+Zr1vvXmH7SOnNe/CfUriMsJdOmhvlK9QEkG8/wDfDPQB6f8ASiqWiXn9o6NYXwx/pNvHNx0+ZQf61dFABWL430qfXvBev6RZvElzqGn3FpE0pIQPJGygsQCcZIzgGtqsfxlq0mgeENc1iGJZpdPsZ7tY2OA5jjZwCfQ4oA8i1n4MX2qabrsdyuiTXl1oNhpllLNuYwTwLh33FMqp4wV5OOQK53xP4T11fiFPp9no76kL3W9Ov5NUaznDQJEse9BMU8sxqAej7s5G2u0k8b66NT8F3er2drbtqlhqF/FBZXsrRmKO1ikTzVKqGfczccheME81j/8AC6te03Sl1PWtD017a70A61Zx2U8hcEOibJCy4x+8BOOgB60AWo/hd4rj1S1g+16G2i2mv3OsRPvlFwyzK/ysNpUEF+x59R0Mem/Bi++w2EGsLol79k8KT6Kgk3SBLxpSySruThQCRu4YZ4Fdt8OPGGqa94i8R6NrKaU0+kRWb/aNNkZ4pDOjsQN2em0Cu/oA+etU+Dfi29GkRPfaLLDY22lxxuZZImie2RFl+7F+93FSVZyCAcYHWvV/hz4avPDMXiNb+W3kOpa5eanD5LMdsUrgqGyBhh3AyPc111FABRUUkypPFE3BkyFPuBnH5Z/KpaACiiigDP1zSLTW9Pa0vkJQncjoxV42HRkYcqw7EViaRq17pWqQ6F4jfzZJiVsNQC4W6AXJR+yygAnsGAyO4HV1S1nS7TWNOmsb+PfBIOxwykchlI5DA8gjkGgCtPF5niqzkZARDaTbWI5BZ48/ota1czpN/c2GoRaX4gcNdHctpe7cLdJxgHsJfUd+o7gdNQAU2WRIonkkYKiAszHoAOpp3auN+KV4zeHRoNpLs1PxA/8AZluByyq/E0uPRIt7Z9Qo7igC38MB/wAW38LHpu0u2bHpmJT/AFrp65iy1620m+g0PVYBppA8qyk/5d50XhVVuivgfcP4Z7dPQAUUZooAKKKa7rGjO7qqKMlicAD1zQA6su/KT6xY22CWhDXZPYYGwD8d5P8AwGrVhfwX8Ze3LFeo3KVyD0Iz2ODUV7HJHcx3lvF5rqpjkQHBZc549wf5mky4PUyLvU9NGuNDciSQwxmGVhCWjjL7SAzdAcAfTIzir1xq+n6c62kQLuE3+VAu7avYnsM9qy31eITLa2Wk6i8s7lpFWAIqkn5mdicflmsHRbPX9SmKKdLgshMTcX1uGYzkH7qKeOOhbkccCo5n0Ov2UWlzuy83+Jua94mAgtrWyYw3t7I8cZbGVVBl2A7nBAHu1eU/FHT57+x01m1UWhtNRgvIkI5coTk8fOznt/SvZb/wppGo6eLO/tVnjAI3ufnBPUhuoPHUVTh+H/huGFI49NTcjbxKWJkzjH3857mlOM3saYWrhad3UTfyW3q3p9x47e32o3s8cFtp8k5+8sdxOTKw9dozt/4Ea7D4fprOhapcXep6ffxWEsGwQJ+83SbhhgucAABhn3r07TNIsNMTbZWsUQPJKryfqav1MKHK+Zs3xWb+1pujTppRfq3+djkrfxZLreneZ4a066leWR4EnuUEcUTK7I5cZ3fKysNuMkjHGc10GkWK6bpsNosjysg+eV/vSOTlnPuSSfxrnfh8xjm8VWgH7q21ucIP+uiRzt/49M1bOqa3Bp8/lPBdzsqiST7PFv8AKU5wzd+cHgZPHStjxhvibcumLMvAt7iGZ/8AcWRSx/75zWuOlccniLWdYg83RPD1vc6dKpCzXl8Ii46H5AjY+hIPqBTLHUPFWmg/btAtptOj4VbW+824VcejKob8xx60rgdZeWxuQqGV0jz8ypxuHpn0qpc6NbXE0JdAIokZUjAwAWwCfrgYo0DXtO161afTLgSBDskjZSkkTf3XQ4Kn6itSiyY7tHLXV1N4Tj865klutFB/eSN8z2o9T3ZPXuPpXSwTR3EKSwurxuAyspyCD3FOljWWNkkUMjDBBHBrkLCKXwhqItcM/h+5k/dMTk2jsfuf9cyTx/dzjp0WsfQNzsaKKKsQUUUUAeAfB/8A5OO+KX/AP/QhXv8AXgHwf/5OO+KX/AP/AEIV7/QB4X+2T/ySOH/sJw/+gSV7Ro3/ACB7H/rhH/6CK8X/AGyf+SRw/wDYTh/9Akr2jRv+QRY/9cI//QRQBcooooAKKKKAM7xFpFrr+g6hpF+u60vYHt5AOoVhjI9x1HvXn/7P2rXUvhS68N6zIG1nw3ctp047lFJ8tvoQOPYCvUTXjninb4G+OWj+IMFNJ8URDS71hwqXK4MbntyoA+iNQB7HRRRQAmMnmszxTpS654Y1bSZMbb60ltjn/bQr/WtSigDzb9nfV31j4SaI07ZubVWtZh/dZGOB+Cla9JryX4I40rxF8QvDATy/sGstdxqe8dwN6/ku2vWqACoru2gvLSa1vIYp7aZGjlilQMkiMMFWB4IIJBBqWigDHFjoF1eQ2v2XS5rrToTFFD5cbPaxOoUqq9UVlCjAwCAO1Rah4U0a7017OKwtbP8A0N7CKa2t4leCFhykeVIC8D5cFeOQa89+Ga/2h8afiTqmOIZ4rIH6RRKf/RX/AOqvXx70Acf8Pfh9o3gQagdIM8k9+yGeWURpkICEUJGiIoG5uijqc5rsKKKACgHOcUVHABsLD+Ji1AFDxHY3F/pUqWEwgvoyJbaQ9FkXld3qp6EehNReFdetvEmjRX9sGjbc0U8D/ft5lOHjcdmUgj34I4IrYrzzxU0ngfxI3iqDzn0C+ZItbgjTcIGACpegDn5QAj4zldp/hoA9DopEZXVWRgysMgg5BFLQAUUUUAVdSsLXU7KS0v4Unt5BhkcZFZMGmavprhbDUxdWYXCwXyl3X6SAhj/wLNdBRQBg3U/iRlCWljp0bk482WdmVffaACfpkUukeH0tdRbVdRmN9rDxCE3DjAjTqUjXoik9ccnAyTit2igCtqFja6laSWt/bxXFvIMNHIoZSPpXPDQdV0eONfDep5t4wQLLUAZo8dgr53rjsMkD0rqqKAOYuvEl/puP7V8P3vlgAtNYstwi/UfK35A02Lx94ZZts2qx2hHBF7G9tg/9tAtdTUM1rBP/AK6GKT/fQH+dAGPH4v8ADspIt9f0eY+iX0RP86i36XeXKzw+VM552/aVMZPrgEj9Kku/Bvhu8YtdaHp0rHqWgXn9KpN8N/BpOT4a0vP/AF7rQB0VjCyB5ZXV5X6lRhVUZwo9hmrVcTP8LPBkwwdDtk/655X+RqrfeAPCOhaVeahJZzx21nC1xJtuH+6gLHjPoKANHXr2XXtbk8L6a0kcMSLJqt0nHlxsPlgU9pHHJP8ACnPVlNdVa28NpbRW9tEkUEShERBgKB0AFc38NLK7tfCdrc6suNX1ItqF7lcFZZTu2f8AAFKxj2QV1NABRRUdzPDa28k9zLHDBEpZ5JGCqqjqSTwBQBJTJZEhieSVlSNAWZmOAAOpNcgvjqHULnyPDelajq/yhvtKR+Vbcn/no+Mj3UNUuraX4i16IW9xf22k2TEGSO1TzpWH93e424/4DQBX8F3Ulv4ebUri2aK71vUZrmGGU7Dtdm8nd6HyUQkdc8V0Wk2c8D3V1eyK91cspYJnYgUYCrn8Tn1JrOXwdprQyi7a6vJ5Iwn2i4mZ3THQpn7pzzxitDw/dyXNiYbxg19at5Fxxjcw/ix6MMMPrSAzWQaN4vthbqEstYDpIgHAuUTcrD/ejVwf9xa6XArA8YrJFpcOowIZJNMuEvCoGSUGVkx7+Wz4963IJUmiSSJg8bqGVh0IPQikBheINKmWeLVtFSNNUgZS4CgfaYc/NEx9wSQezAds1oaJrFlrNp59jMHCnbJGw2vE3dXU8qfY/wAq0a5bxDoSx3w1vTN0F8o23BhHM8fuOhK9Rn3Heh6aoa1OprC8dSRx+ENXebG0Wz/iccAe+aS31a8WGBms2voZVBS4tCMMPUqxGPzNN1bTrrXZbKO4At9NjlE80LDLzMpyinHAAYAnrnA96G7rQDW0nzf7LtPtJzP5KeYfVsDNWqAMDA6CiqEFFFFAHgHwf/5OO+KX/AP/AEIV7/XgHwf/AOTjvil/wD/0IV7/AEAeF/tk/wDJI4f+wnD/AOgSV7Ro3/IHsf8ArhH/AOgivF/2yf8AkkcP/YTh/wDQJK9o0X/kD2H/AFwj/wDQRQBcoooNABmisq+lIZsHHvmudv53DOVmmR2AyUcg8e9S5WN6dBz6nb8d64v4weF28X+ANT0+2UHUI1F1Yt/duI/mTH1wV+jGshfE+r6UzEMupwgj9zJhZAO4VxwT9fzFdz4f1iz13S4r/TpC8EmRhl2sjA4ZWHYg5GKUZpuxdbCVKMedq8e5h/CfxSPGPgDSNYbi5li8u4XjIlX5Wz6ZIzj3rrq8d8E/8UT8aPEXheRtml68P7Y01D0Ehz5yLjpyGP0C17Eas5Qooqhq2rWOkW/najdRwIfu7uS30Ucn8BRew4xcnaKuzzKJDo37TU2Cwh17Q1cjsZYm2k/UKi/99V64TXg/xY8WWNt4x8A+JbZLuKCw1F7S5mktnQeTMo3HkZONh/Ova9L1Oz1S3M+n3Mc8YO0lDyp9COoPsaSknsXOjUh8UWi7RRTJ5VhgklkzsRSxx6AZpmZ5N8ApRe3HjfUk5S61u5IPsJpcD/vkrXrleQ/suwFPhgLtgM31290SO5ZEDf8AjwavXhQAUUVHcSGKF3UbmA4Hqe1AEN27O6W0YOZOXI/hTv8An0q0AAABwBWfDZXKfM985kblvkXH0HHSrUKzLgSyK49duDQBNUV1bw3drNbXUSSwTIY5I3GVdSMEEdwRUct9bxQNM8mI1JDEKTjHXOKktp4bqBJraWOWFxlXjYMrfQigDz3Rb1/hzdJoWuTyHwwzBdK1Kdy32cEgC2mY9AM4RzxjAJyBn0eq+oWVtqNlPZ38EVzaToY5YZVDK6kYIIPWuFbw34k8Jl5PBd9Hf6XkH+xtTckRj5QRBN95OA2FbcuW6CgD0KiuK8P/ABD02+1CDSdat7nQNelAC2OoAL5jYXIikHyScsBwc57V2tABRRVbUr+10yxmvNQuI7e1hXdJLI2FUUAWaRWDFgrAkHBwehrl4p9U8SMTAJtK0fIKykbbm5XHOAeY19/vf7tdHZ2sNnAIrdAiDnA7n1PqaAJqKKKACik9aUdKACiiigAzzXG/FpWufBcunJI0Z1S7tNOJXrsmuI0k/wDHGeuyrkPiKvHhhyMxprlqX/Hcq/8AjxWgDrxRRRQA1mCoWY4UDJNck/h6XxLew3/iUsbBBm30jP7oHORJL/ffGMA8L2GeT1+Mj2ooAaiLGgVFCoOAFGAKdRQO9AAaydV3WNxHqUWPKXEd0MdY88N9VJz9C1avOPes/WdSt9Pt1Ew82W4byYLcfemcg/KB9MknsASaQF7gjsQf1rj/AAvqlpo0114fvb0ZtLtobR3DbTEwDpEXI27lD7AuckKvrWta2WpXWmx219KLMKio32WQlzgc4fAI/Dn3q5HounpprWH2SFrRs742XIYnqTnqT60twNGg8iuUlg1LwvAH05bjVtMV/ntXfdPAh6mNj98D+6x6dCMAVuaVq1jq1gt5YXCy25yC2CCpHUMDypHcHkU7gVdEiWx1DUdPiz5IZbqMHogkLZUe25WP/Aq2axNGuGv9X1C7jQCzCpBFKDnzSu4sw9gWx+BrboWw2FFFFMQUUUUAeAfB/wD5OO+KX/AP/QhXv9eAfB//AJOO+KX/AAD/ANCFe/0AeF/tk/8AJI4f+wnD/wCgSV7Pov8AyB7H/rhH/wCgivGP2yf+SRw/9hOH/wBAkr2fROdGsP8Ar3j/APQRQBdqOZxFEzuwAA6mpKbIiyIyOoZWGCD0IoA52/fBIIxn1rnb6bOcVNrqjSPEVjp9jM7wXUM0s1u7bvIVQNrr3UFjtx0OeOhrJFrdeINUk03T5WtoYcG+vF6xAjiNP9sjkn+EEdyKwk+h7eHpJRU29LXv5Xt+f36GHf36G+FnapNeXvA8i1Te689W7KPqRXR+CofFOiWWoRpotov2q8Nyv2i927QURSCFU8kqT1712Wj6TYaJZJZ6XapBCgxxyzH1ZupPuank70RpO929QrZhGcXShC8fO9/wat+PqeNfG2511bLR/Ez+HzDe+G7pb0XNrciVWhJAlRhhWAwFbuPl5r1/wr4p0jxTpcN9ot5FPHIgcpnEkeezL1HOR+FUrg2+oNqWnToJYlURTIx4YSJnB9ipxXkHwj0y1SXXPBetR51Hw3c5sbqNvLmNq53IQy4PGVJ/38dqu7W2pwuFKUveXL6a/g319T3S81QIdkA3H+8elc5Jbx/aTcMu+diSZH+Y/QE9BWdLZ67p7btO1FNTt+jW2oAB8Z6rKoznHqDUUfiOzMn2fUkl0m7HHl3g2ox/2ZB8rD8R9Klz76HVTwrir0ve9N/mt/08zlfjvp7ah8M9VLAs1psvFx1HluCx/wC+dw/Gt+yuZrvTdN8R6NiO/ktY7nC8C5VkDNE4757HqDg1Brk9r4i36JZTpcxTRTC7eJt8aI0TIFLDgks4OPY1g/Am8nuvhlpEdzn7TZSS2b56gq5OPw3Y/CldSRpyypSXMt1t/n6nuel30Op6ba31sSYbmJZU3cHDDPPvWN8SLz+z/h54nvMgGDTLmQZx1ETED86d4BGPC1ptzs3zbc/3fNfb+GMVzn7QF0IPhJ4hiDFZLqJLVcdvNlSPP0+atou6ueRWgoVJQXRsPg1AdF+F3hzTY0zcmJyFPYGRjkn6V6IOnrXM/DqAp4L0OaVSJpbGF2H90sgJ/nXTDpTMwqCOTzp5FUHZGcZPdvb6VPSAAdOKAIn85GLJ+8Un7p4I+hpYJ451JjbJU7WHdT6GpaYsaK7OqgM3UgdaAFCL83yj5jk8dawb/Qp7eaW88OXCWV24+eGRS1vMfVkBGD/tKQa6CigDmbLxQ0E0Np4ksn0q8k+VZN3mW0jeiy4GCfRgPQZrpqjuIIrmF4riNJYnGGVxkEVwzakPA/iWx0u7lkPhzUYpPsbsN32OaMbzET1KMm4qOSChA4IAAOq1/QtM8QWD2Ws2UF3bt/DIucHqCD1BBAOR6VxWlXd98PtZtdE1q5kvfC16/labqVw+ZLOTBItp2P3lODsfr/Cexrdk8XGVC1hps7r2adhECPUDk4+oFYHi+O88YeGtQ0TU7ewjtLyIoxG53jPVXU9NysAw46igDW1D4gWL3TWPhi1n8Q6iDtKWX+ojPH+snPyL16DcfapNF8NXt3cwar4yuYr7U1RfLtIQRaWjdTsU8s3be2TxxgcVVsrrXLa0SKK40wMiqryfZiDIwGCxAYDJ61ahudXcEz6ovI6Q26qP1zQB2FFcus2pceVqRP8A11hU/wAgKkTUdaRxmCwuY/VZGib9Q1AHSGjvWMur3II83S5/rFIr/wAyKbL4msbdsXkd5bj+89uxX81BFAG33o+lQWd3b3sIltJ4p4zxujYMPpxU/egAoFFAoAKxvFtg1/oUyR/66CSO7i4/jikWRfzKAfjWyKKAI4JUnhjliYNHIodWHcHkGpK5jR7l9G1eTQ7xClnIxl064LZV1PLQn0ZSTgd1xjoa6egAooo70AFJmqOp6xY6apN3cKr4yIlBeRvogyT+VZgl1nWDGYIzpNgwyzy4a4f2C8qn1yT9KANDU9WS0kW2t4zdX7glLdDz06sf4V9z+ANVNH0eSK8bVNWlW51WRQoIH7u3X+5EOw9T1PfoMaGl6bbaZB5VqhBJLM7sWdyepZjyTVzHpSAAaUHNIB60tAAayL7w5pV7cCe4somkzuYgY3H3x1rXooauAyKNIY1jiRURRgKowAKfRRTAKKKKACiiigDwD4P/APJx3xS/4B/6EK9/rwD4P/8AJx3xS/4B/wChCvf6APC/2yf+SRw/9hOH/wBAkr2fRP8AkDWB/wCneP8A9BFeMftk/wDJI4f+wnD/AOgSV7PonOi2H/XvH/6CKALtYvinWxo1jH5KCfULp/ItLfP+skI7+igAlj2ANbR6V56sx1TxNrGqvJuhs3Ol2a84Xbgzv9S/y59I6ibtoup1YWkpycpbL8ey/rpczpYk0HT9S1G9mN7qDRtc3t0RgzFFJCqP4UAGAo6fXNdd4J0xtM8MWMU6hbyZPtN0e7TyfM5P4kgewFefeOtRiSwubBo5ppLy3kQJboXZcqQGYDopPGa9bt5kurWC4j+5NGrr9CM1nTtzO3Q78c5qhFy+0/yVl+b08kRvWRrX9rSbItHezt8gmS5uVMm30CoCMn3J/Ctlxz0qvMODj6Vq1dHnU5crTscE0useHvEUuoa+1tc6XdQR2093ZxlPLdWOySRCThcMVJHbGelcp8TwfCPxC8MeN4iI7KRv7K1Rh90xPko5x1x83Prsr125hinimguYllglUxyRsMh1IwQfbFcC/hmbxT8O9d8JSsss1jLLp0cszYbC4kt5OPQNH/3zWcfddujO6rJV6ftNFKNr22a2T8rbP1R2b4BIBGMdR3qrcxxzQlJUWSNhhldQR+RrhfhD4kvNY8FWkF5p1y+o6YzaddqsiFw8fAyrEHoMe5U12QvVbcZILuEr1Eluwx+IBFNigm9UMWGG3jENvFHDEOQkahR+leYfDR57Txd478LW2ftDaiLu0UD7izjc7+yqCn6DvW7f/E/wpBeCyh1i1mumOMgOyL/3wpJPsPzrK0e/GjfFG58TaJZ6pr9je6R5F9cW1k8bQSLJkFUkChgQI1Cgk8EnpyJX2HWqqlaUt+3+Z7taxwaVY2un2i7vJjWKNM8hQMAn0HHWvLf2k3ki+HNumd091qlsmfXaxk4HpiM+taayfEPWo2+wQaX4UhnTcst2De3e4H+JRhAMY9cVk+LfBviHXJ9Btr/xRHqqadeJfX6zW8cEce2Nl+UooxkSE4YnitTym3J3e569awpZWMMKkLHDGqA9AABj+lc5rPjO1tJPJ06CTUZsjPlsFjUe7nj8s1zOv6w/iS7byHlXRYWKRqDgXb93Pqg6Ad+T6Vm3kkVtbme5mht7deDJK4RF/E8VjKp2PXw+XRVpVt+3+f8AWhs3PivWZySj29qpBAWJN5HuS3X8qzpvEXiLI8jVwoXA/eW0bA+/TNec+Ifip4a0tWitZ31O5XJCWowgPu5/pmt3wxqFzrWkRX17Fa2zz/PFBDMJGRCONxz174HSs5OW530YYdy5IxTa8kzsYfiHqumIx1jT4r+BcZms8o6+7Ic57dPyqVfiVdSqk1tpdvLbONykXRyR9dtcxIrBhkEY5rDm0+e2lkl0mZIldiz20qlo2b+8McqT3xWbqzWzOuGXYSp8UEn87fht+X5nqel/E3TJZPL1e1udMc9HYebGen8S8jr3Aro7fxZ4fuMCPWtPz6NcKp/ImvAZLzUIgBdaWZFxkyW0ob/x081HBNYaifKKKZcbjFPHtcD6H+lCxMthVOH6MvejdLyaa/4HzZ9G3+s6dp8CTXl7bwxP9ws4+f6ev4V5vfeIrLUNfubm5nZ0jcx2imByEQAAsPl6scnPpgVh+DtLt7fTIrjyl8+5/en0RSflUegxj8a6iIEHB5NdsW2tT5GrGMZuMHdJlX+27EZYPOw77baQ8/lU0Wv2GCRHenPpaSf4VaUEHOatRsSeeO3FMgonWlKnytN1OU52jEAXP/fRFSHV5YvvaLqoUjJKojfyatFG7nJ5qxGxUYGcUCM2y8R6XKoV7lrWQ4Gy8jMJz/wLj9a34cYD5BDcgg5B+hqs0aXKFJ40lXoQ6hhVeDR7aFSNPaaxbOf3DYXPuh4/SgaNpSc8VKrEgjPBrLhbUbdR56xXozy0X7t8f7p4J/Krlte207iPfslbkRSrsb8j1/CgZHLo0DTSXlg5sb5xgzQjAf03r0b8aSPXJbCZYNeg8gY+W9jBMD/Xuh+vHvWrHuHBHOaeVV0KOAyEYIYZBoESoyyIHRgyMMhgcginVHbxJBEkUKKkSDCqowFHpUlABRRRQBBeWkF7btBdRJLE3VWGRWRNoNwkSppus39mFGBkrN/6MBre7UHmgDnotH1kE+Z4mu2HtawD/wBkqc6G8sZS71TUZgRztl8r/wBAxW1nmigDP03RtP0wH7Faxxs3LPjLMfUnqa0KKO9ABSClopAFFFFMAooooAKKKKACiiigAooooA8A+D//ACcd8Uv+Af8AoQr3+vAPg/8A8nHfFL/gH/oQr3+gDwv9sn/kkcP/AGE4f/QJK9n0T/kC2H/XvH/6CK8Y/bJ/5JHD/wBhOH/0CSvZ9E/5Ath/17x/+gigC6eleX+GnKaC8Mh/0iO+vUn/AOun2mQn9CD+NeoGuB8V6Le6bqVzrGjwSXdtdlWvrND8wZQF86IHjO0AMvfA71lUurSPQwMou9KTtezXqr6fi/mjFuXCFyqgMxyzdz9TW94O8S23lQaVeSLFOv7u3ZuA47L7HsPWuAvvEWluWj+2eXKG2NA8bLKD/dK4zmsTUbqG5LWyw3FxL08qO3kLH8Mda5/aqOqPf/s514clRNedtj6Ik6+9V5ORXEeFY/HdjokDXUVpfKWO23vJClxHHj5cyDIJz2IP1qc+NJbS9lt/EOgXulpGnmG4VhPGFzgtwAcDvgHHcY5roVRWu1Y8KWBmpONNqduzX5b/AHI6eUnHHoK5HXvDhm1O41SyRJZ7hUW7tJWKpchBhSGHKMBxnkHuK60OsyLLC6SwuMrJGwZWHqCOtQPxkfr60SipbioVZUnePzPBNPtdG0T41DT5NLSLTfEcHFrcJhrS7UYI9w2ByCQTIfSvQLmHSNH12z0O/mI8PapbyST2U8zGNZInRlZM8/MSVKDg46UnxW8IDxbolssM62eqWV1FPa3m3LRHcAwyOcYJ49QPSrXhWBr3RrXV9UWOfVL5Bcu5XKxZ5VI8/dUDH6mpceq3OmFa94Tu4u+l/Lf5PX/MZdSySWUll4Z0y00DSkGyOUQKLhyeBsXGEBz1OT34qCXQoLqWVbqe9uIYlWIebcuSzjDbuvGOAPxremQl4cZJ3729+DVXzI7czLLPEhMhYh3C9cetJruaU3yWVNW9P89zEkR9ItdVvLXUdURLKCQxwfbHKMRHnnJ9T+lXoI5zpUFlfTyXLbA1wWPE8hHzMw78+tNea1aS6hMtrNDdAIUWQEtuXawIB7jFJpunatDZeW9nPc28ChI514kZR0DKepHqOtJbWRbdpc9T72PkOCqqMKMDA4xXKeNvBejeL0RtYS5EqJ5cckMzLtHJ+70P4iuld+80c0JPUSxsmPzFQyyxvkiRTxgYalqjdKFRWeqPBtY+CWoWMcknh7UIr1Bk+TcL5b49AehP5V1nhfwZoVxo6ST6dqVhfx/JcRyzuCrgclSDgqeoIr0V3Xcf3i7cdc1Se/hnuFtLPzL67JwsFqPMbk4GT0UZPUkUpVHYdHAUoycox/y/4BkW/h77IALPU79AB915Nw/WrsCzQoPNmExHBdlwTW9H4V8XTIsq6Zp8SMATHNdnePY4XGaxdXg1HSUL67pVzZRbiPPXEsIA7ll5A+oqJSa1a/A66VOjKXLTkr9lL9E9RHRHUlJgr/3XGM/jVKWLDqZFzIuSrYBxxjg1YZlkhWSJg8bD5WU5Bqu/3QpJAGTnNZt3O6lFx6nS+GpS2kWqgBTGgiIB6FeP5YP41twyYAI545rgdJvjpl28uDJbzYEqDsR/EPfHHuK7TS76zv1JsrqKRh1QHDL9VPIrupTUonxmY4SeFrNNaPZmqmDlgPl/pU8XzD0PU1WTIz8rACraLkDaDnNaHATRgZBParEeB71BEhYZwQfQVYHUZBGaAJkAA65qxHgMOc9qhRQMZ444NToB/XNAyZBz7U6WGG6TZPFHIh7MM0iAcCpQOcd6AKgsrm1YSabcs0Y6207FkP0bqp/T2rQsrpLlG2gpKhxJG33kPof8e9Ojxn5eM1FcWfmTpcwuYrlONw6Ov91h3H8qBF5egpe9Rwlyg8xdr9Djp+FSUABGRik749qWk70ALRmk/i/ClHpQAZooxRQAUd6KKACiiigAooooAKKKKACiiigAooooAKKKKAPAPg//AMnHfFL/AIB/6EK9/rwD4P8A/Jx3xS/4B/6EK9/oA8L/AGyf+SRw/wDYTh/9Akr1jR9WtI9IsVnZ4GEEeRIhA+6O/T9a8n/bJ/5JHD/2E4f/AECSvZtGVW0aw3KCPs8fUf7IoAsRXNvN/qponz/dYGpT0qpPpllOSZbaJj6leah/sSwwB5HH93ccUAOaTTTc4ZrQznnnbuzVn/R0fd+5VvXgGiO0t44vKSCNY8Y2hRio7KCMWsQZFJCgZIoHdkhuYFODKmfY5qtfW9jqlq1teQC4gkBVldDgj8asTTW8H+sZAQPugZP5Dmqxurudf9Dtgg7POccf7o5/lQCbTujCl8B6ZG7nSJ7/AEgPjclhcNEhwMfdHA/KoYPBd3BJ5kHivXG/2ZpFlX8mU10y2LyKPttw8x7qvyL+Q6/jVyNFRAiKFUcADtUezj0R1fXq/WV/Wz/M4G703xVCJIZIdO1SEgFJ0Y28gYHI3Lgqeg6YqtpUF1pFoNNurVzHAxW2lQ5V48khSf4WXO0564BFek4ppUHjAxQoWFLFyk07L+v66WOEtfDmo61IzapOLLTc4FtaufMlH+3JgEDrwuPqa3bbwb4dt4gkej2eAMZMYJP1NdAKKFBIU8XVlonZdlp/XzMy00LSrN91rp1rEw7pGBWhGgRAq9AMDmn0d/arSsYSlKTvJ3GMisPnRW+ozVaTT7OTPmWsLfVBVs/rRjrQTexnSaJpkgxJp9sw9DGKsWlja2abbS2ihX/pmoWrJFKKVkU5yas3oJikdFkQq6hlPUEZBp1A6UyTz7xJ8NbO7llu9AnOl3j8sirugkOerJ2PXkY615zq2ka3oxC6tpFxzgedZKZ4ycZPT5gPqK+h6QjNYSw8XqtD2MLnVeiuWp7689/v/wA7nzC15G80EcUF8zzyeXGPszAFuuMnFdB4f8MXiawdR1L7EiIjRxW5j8w/NgFmPQnHAHIGa7bxTKZvGM6E4Wyt41ijHGDIWLNj32qM/wCyahQEsAckHpmiFBR1erHjM6q4iLhBcsWterfzt+RmP4fV3Z4dU1G2LY+W3k2L7YHSrKaXfW5Be6u9QgHVftTQy/gRwfoQPrWkh7DoCOtW1yVx09jWx4xb0LS9D1eBpIHv2kjJSSG4ncSRn3BP6jg1bj8LfZN39n6leRjGFSZ/OUf99ZP61j3Vs8lxFdWcv2bUYQRFMBkMO6uP4lPp9CK6HSfEcF1cCzvY2s78AfI/3JD/ALD9G+nB9qYFNrfVbTP2i2iuowPv2zbWP/AG/wAadpt7bXjGOFiJ15eGQFJE+qnn8eldPWdqukWmqKhnQrPGd0U8Z2yRn1DDmgCJOMe1SjIPX8ax4Lu50+4istcKmSQkQXiLiOUdg/ZX/Q9vStK1uYrma5jhYsbd/Ldh93fjJUeuOM0DLydfpUi1Gh4qRelAiQdBS0i9KU0AFIaWigBMUtFFABRR7UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgHwf8A+Tjvil/wD/0IV7/XgHwf/wCTjvil/wAA/wDQhXv9AHhf7ZP/ACSOH/sJw/8AoElexaLOBpNgrI6/6PHzjI+6PSvHf2yf+SRw/wDYTh/9Akr2bRP+QNp//XvH/wCgigCwbmEHDSKv+9xTHv7RG2meMt6Kcn9KsFVPUA/hTQiZ4VQfpQBVaWW6ykCskecNI4xkdwo/rVgxFgAWKqOipxUtFAEUNvFDny0AJ6nualAoozQAUVU1LUrHS7f7Rqd5bWcGdvmXEqxrn0ySBXIy/ErS7tdvhiy1LxDM29V+w25EW5exlfamM8ZBNAHc1S1PVbHS0RtQuooPMO2NWb5nPoq9WPsK5f7N4z1xU+13Vp4dtGzvhs/9IuCCOnmsAq/gufQ1JqVr4b8CaVe+JNWEjC2RTPfT7ribBIUcnLdSOBQBpw6jqWrB/wCzrRrK36Lc3a/M3usfX6FiPpWvZW5todrzSzOTlnkOST/IfQVjeGfF2l+IrYTWRuoA0nlIl7bPbPIdob5FkALDB6jNXLjxFolsIDc6xp0InJEXmXSL5hBwQuTzzxxQBqGiqN3q+m2d5DZ3eoWcF3N/qoJZlV5P91Scn8KeupWLJGwvLYrIhkQiVcMg6sOeQO5oAt0Vzmp+N/DOm6FPrNzrdi2mQSJFJPBJ54V3YKq4TJySR26c9ATWm+taXHcWkD6lZLNdjNvGZ0DTD1QZ+b8KANA0VV1HULPTLU3OpXdvaW4ODLcSrGoPYZJAqI6zpguLWA6lZCe7Xfbxmdd0y+qDOWHuKAL4oqh/bOlm9WzGpWX2tiwEHnrvJX7w25zx39KztH8Z+HdY0ebVbDWLNtOhkaKWeR/KVGDFSDvxjkHBPB7ZoA6Cis2417R7aBJ7jVbCKF0EiyPcoqshOAwJPIzxmq8firQ5PEk2gJqUH9rwwLcvbnIIjbJBBxg8AnAOcc4xQBm+MPDs19cRarphA1CGMxvE33bmLk7D6EE5B7ZPrXM2UouF3KHR0OHicYeNvRh2r0XTNW07VVkbS7+0vUjO12tplkCn0O0nBrkfi15Gi+FdR8TxIVvNNi84hTgTqD/q39Qc8HqDQBVj47H6GrIJzk4INZ1hefaA8c0LWt7EF8+2kPzRkjI5HUHsa0IsDp60gLSEg8g/5FSNFFNEYZow8bdQe309KjXjGMkCrMZ79PSgBLS81HS4iHkOo2kfOGB88L356Pj8z610tpcw3ltFcWsiywSqGR1OQwNYUWQ24darwRXWlXEs2lBJrSUl3sS23Dk5LRntnJyvQn05pgdPcQRXELxTxrJEwwysMgiuZ8ORrpSf2LMrRSxSSNC7nIuEZi2VPqM4IPPHpWjH4htBEXu4rqzIOCJoTx+K5H61YkGm65a7fMhuYlYMGRwSjDoQRyDQBYXn0qRegrl4de+zGWzlc30qDMc9oBIZVzjBA4V+cHOB39q6HT3uZow91CkBIz5YfcR9TQBbXoB3paO9HegAooooAKKKKAACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A+D//ACcd8Uv+Af8AoQr3+vAPg/8A8nHfFL/gH/oQr3+gDwv9sn/kkcP/AGE4f/QJK7KxtfHtpoNs2mapoeokwoY0vbR42xtHBaNgP/Ha439sn/kkcP8A2E4f/QJK9m0P/kCaf/17x/8AoIoA4eDWviXaRbtR8LaHeH+7Y6g6H/x9DVeTx143R8H4YXzD1j1SE/zAr03vSigDzBvH3jTA2/C7VCfQ6lAKmtfF/jy9BSP4efYpD0e71RNo+u1Sa9J71xmnePrfUdPtb6x0HxFPaXMSzQypY8OjAFWHzdCCDQBnWUnxSu5pUvIvCemwn7kkfnXDj8CVFZmueDPiBe6WrN45kmvYpRIILaEWUUy/3C6fOM+uT9K6h/HFvA9sLzRtetIp7iG2E09ntRXlkWNMnPALOo/GuuBoA8l8A6H4N1a+uLfUtAlg8U22y5ubPWZTdTx5+7IjsSHTIxuXoeDg16vFEkKBIY0jQfwqMCuW8eaDc6hDa6xoWyPxHpJM1mxHE64+e3c/3JBx7Hae1bPhrWrXxDoVlqtiJFguU3BJF2vGwOGRh2ZWBUj1BoA1K5D4teGbzxh8O9a0DTJbeK8vY0SN7hmWMESK3JUE9FPY11/ejNAHijfDDxD/AMIBFY2H9kaV4j07U49S06eK/urqLeFVH3vKpdQy7htUFenqazvGHwY1u88O6RoWh3OknTbTRjYMty7wsLosWafckbM6sSTsJAB55zivZfF2sjw74V1fWTbvcjT7SW68lDgvsUtjPbp17V4b4y+J/imfwP4ggtn0y21KC0068W/02V2WOG6lCbMkHEgyOe6kkYIFAHV2fw31mx8SXV35Ph3U7bUfsPnz34ka4s/IjVG8n5SG+6WUkpg4zmsTQvhZ41tLfSLa5v8Aw6iaRpF9pdrNEskpczAbHkR02kccryP97OK7Pxte3vhXwP4cSea5nvDqNjaTyJeSbmZ5AGzIfmdck8HqOtYCfFLxAuvRtLpOmHQT4nn8NExyyG6Z137ZAuNuMLyMnJ9KAObh+CHiCbQfFdtey6It3qsFj5B8+WZBPbybmZiYl2hhlRtHAYjGOul4g+D+san4mn1RYtF8i9is99ol1LAthJAoAEJWIl0yMgfuzkn1q/YfFbVZ/Bcnii6k8NWlldW5ksrXzpZbiN/PSILIqj5vvc7duGKgnByKmifF7xLqklnpseiaWNZm1ifSiJp3ii+SAShjtDlTzgj5unX0AO3+JHhHUNf1nw1q2lrpl3Lo8k7HT9TLC3uBKgXcSqthlxkHaep6VxOq/CPW7/ULplPh62g1L+znmlgSRZNLa1IJSzG3G1tvGSuMng1uW/xE1mbU9edrfRINP0K5azubaW4cXdy6xB2aEYAwScICMtg9Olcra/G7xCfDF/rVxoFg1v8AYoLy0ZJmVcvcxQtE+SSxAlB3AAZBBFAGxH8IrpdSi1HZo328eMpdde5APmNYuXPk7tmS2WHy/d461kn4L61H4eh0+2bQo3sNYk1C3MbOgvI3MmFmIjOxkDgKQHA5rS+I/wAVPEfgzEMljolxqNrafbr+0geaRUjMzKmJWCAZUL/CTuz8oGCa1/8AFDxFoWs/Ei8vUsb3StESzezsg2yRPPjjK8hclfn3OSTjBC8UAN074KXK7kvrXQ2tk8P3mm29u8r3At7qWcyI6s8YwAGPzAAgk4XFTQ/CPVILmF2t/D16s3heHRLtp3lR1njhaMvGypkqwIUtlWC9jjBli+K3iMWENvdaRpsGqXeq2+n2t3LIyWpSVGfzGXJcY2MoGfmJBBrp/gZquo6x4T1G41e9N5cpq95EJN5dQqykBUJ/hHb2oAZ8GfBOseDLbVY9ZurOSK4aIW0MBErQoikENN5UbPkngFflA6nJo/aKjmn+DuvW1qMz3LW1sg9TJcxJj/x6vSK88+MD3MzeCtNs8M174kszKh7wwlp3P4eUKAOj8T6ANS8u8sikOqQDEchHyyL3jf1U/oeRXN2F0twHGxoZom8uaFx80T+h9vQ9DXolYmveH4tSlW7t3+y6lGpWO4UZyP7rj+Jfb8sUAYysd3yjIAqyoB/i6d6z4ZZorsWmoQi2vSPlUHKSgd0Pf6dR+taCcE/Kc5xSAmQk4C9hzViMgn3x2qBMbcd+KniPGCPpTGidScDv7VXudJsLt989qm88Fl+UsPQkdQfSrKH5vb1qzDGW57etABZwRQxhLaFIkXgBFAGKtqMChFCjApT0oEFBrH028afxFrNsXJS2EAC54UspJ/pWxQAUUd6KACjtzRSc8UAKaKMUUAFFFFABRQM4ooAKKKKACiiigAooooAKKKKACiiigDwD4P8A/Jx3xS/4B/6EK9/rwD4P/wDJx3xS/wCAf+hCvf6APC/2yf8AkkcP/YTh/wDQJK9n0P8A5Ath/wBe8f8A6CK8Y/bJ/wCSRw/9hOH/ANAkr2fRP+QNYf8AXvH/AOgigC7RRRQAV8y+Nr25t/BPwSt4Z5Vt7nTkWeEaq2nJMBaREB5l+6AeR+XevpqvM9N8IeIYPDOi6LqNl4Q1SHSrSK1he8t5JDhEVN2CCASFGcUAcV8OdVuNS+EjwXt9dX1xYeLbG1aSa4FyigajalUjnyfNQKR8x9TxjFfQOK4C48O+JLuwsNMaPw3Y6XBfWl20dlHIpCw3Mc+1V+6MmPH4139ADQfrXN+GrCXSvEfiK2VSNPuZY9RgOOEeQFZUH/Ao9/1kNdIKMflQAopQc0CigCvqM6Wthc3E0bSRxRNIyKASwAJIGcD865Wxh8ERaFHbnT9A06x1IQ3D2E0UEQd2w8e9B8pfIBHXkcGt7xVp8ureGdY022ZFnvLOa3jaQkKGdCoJIBOMn0NeL3fwT1C80DVbW8Ghz303h3TtKs5pNzeRPAm2RwxjyqkgYI5OOQKAPZdXuNAuLmHTtYm0uW4DpPFa3TRswYN8jqjc5B6EDr0qBrPw0kSutnpDAXzXaBY4sm8Gd0g/6bfey33uvNeDeJ/Ceur8Qp9Ps9HfUhe63p1/JqjWc4aBIlj3oJinlmNQD0fdnI2100fwu8Vx6pawfa9DbRbTX7nWIn3yi4ZZlf5WG0qCC/Y8+o6EA7q1h8Cz6dJql5pOgWH9qwb7kXsFvHJNGWHEvUMNwHUkZx3q7a2HgnSNSs7K1tfDdjf+Z59tBHHBFLvZdu9FAByVGMjqOOleaab8GL77DYQawuiXn2TwpPoqCTdIEu2lLJKu5OFAJG7hhngVn6r8G/Ft6NIie+0SWKxttLjjcyyRNE9siLL92L97uKkqzkEA4wOtAHqujXHhfxHfanr0Gj2r6lo17Pp8l7NZx+eskPytsflsdgciqHg2P4feKdM+3aNoug51KBbi4t2s4FnZN4ZTKgBP3lVhnPIB61a8D+FL7QdN8V295LbO+raxfahAYmYhY5myobIGGHfGR7mvPdM+CN5a6VolpFNpVhcRaDe6VqF1ZqweWWYAI4+QbwOc7iDzxQB6fqFp4K8TN9r1G38O6u0J+zedOkFx5ZJ/1e45xk/w0+5XwdHfm9uV8Pre3EItDPIIRJJE3Ai3HkqcYC9DivH7P4I6x/Z6213Hoakz2HnlbqWRLmK3kyQYzEAp25AX5uuC2K3PGXwbXWbjxe2n2Wgww6hpltZaUjRbfsbxlixACHywcj7uenIoA7GOy8DWtnrOm3WhaFpulW9xGtytza28VtNIV3K2OhIz/EAfSun0C00i001B4et7CDT5CZUFiiLE5PVhs4OfWvJta+GPia4k1ySyvNJZdQ1S1vDFLI6mSKO38p18zy2MbluQygnHcZNdr8HfCl94L8C22ianJbSXEU88mbZ2eMK8rOACwB4DelAHa1wOs28er/Gnw5GRJ/xIdLur9iD8u+4ZYYwf+ApcV31ch4IsTLrXibxDI259TuxBBzkLb24MagfV/Of/AIHQB19FBooArahY2+oWzQ3cQkQ/gVPqD2PvXM3FtPpDEXchmsyQEuSfmX2k/wDivz9a6+myIssbJIoZGGCCMgigDnY8HBGSKvQW8jjAXC+p4q9aWcFpEsVvEqIvAA7CrFAFaK1VMFvmP6VZxQORzRQACiiigDkPB7Gbxf45lzlU1CC3B/3bOBj+shrr64T4RJ5mneJNS85Zl1LxBfzoynI2JL5C/wDjsK13dABQRmijvQACiijHNABR3oPAooAKKKTmgBaQ+3WkHTpSikAjMFUliAAMknsKI3WRFdCGVhkEdCK5rW7v+19cXw5a5aFYxPqUitjy4z9yL/ecjkf3QfUV0yqFAAAAAwAKEAtFFFMAooooAKKKKACiiigDwD4P/wDJx3xS/wCAf+hCvf68A+D/APycd8Uv+Af+hCvf6APC/wBsn/kkcP8A2E4f/QJK9o0X/kDWH/XvH/6CK8X/AGyf+SRw/wDYTh/9Akr2jRf+QPYf9cI//QRQBcooooAKKKKACiiigA7UhGTS0UAJ0FLRRQAUUUUAFFFFABRRRQAfSiiigAooooAKKKKAGSqzxOqMVYggMOx9ajsrWKys4bW2QJDCgRFHYCp6KACiiigAooooAKKKKACiiigAzXO/EHxCnhTwPrmuM0YaytXliEn3WlxiNT9XKj8a6KvMfip5niHxf4O8GQENb3F1/a+qLwwFrbEMqOp6rJKUX6rQA34TWD+CU0zwpqDLE13pkN5AjNnddKuLtFPf5ij4/wBtj2NeoVgeNPDw8RaP5MM/2TUrdxcWF4E3NbTr91wO46gjupI71X8E+JZNagnstWgSy8RWGEv7RSSoJziSMn70bYJU/geQaAOnoo4oHegAooooAQe9L3oooAMigmikoAK57xx4lTwzo4nit2vNTuZFtrCyjPz3M7fdUegHVm6BQTWnreqWOh6Tdanq11Ha2NqhkmmkOAoH8z2AHJJwOa4vwPpl94h1o+NfEsEsErI0ejafMNpsLdursvaWQYLE8gYXjkUgOj8FaC+haSVvZ/tWrXchutQusY86dgNxHooACqOyqBXQU1etOpgFFFFABRRRQAUUUUAFFFFAHgHwf/5OO+KX/AP/AEIV7/XgHwf/AOTjvil/wD/0IV7/AEAeF/tk/wDJI4f+wnD/AOgSV7Rov/IHsP8Ar3j/APQRXi/7ZP8AySOH/sJw/wDoElez6J/yBrD/AK94/wD0EUAXaKKKACiiigAooooAKKKKACiiigAzRQaKACg80UUAFFFMmfZGSMZ7UAPorIuNQmjPGz8RWfN4huIPvW8cmOwbaTS5kjaNCctjp6KxtF8RWWqzS28TNFeRDL28ow2P7w7MPcfjitnvQnfYznCUHyyVmFFFFMkK5f4oSyQ/DzxDJBJJFKtnIVeNyrKcdQRyD7iuorlPir/yTfxHwf8AjykPH0oA4TxXbWNr4wt/CnhXQ73Vdaa0N/cNc6/d28FtDu2glg7EsW42ge9auk6W2m614LupLG90i/u7m5iu7N9VmvEAWCYgZZirDKqwOAelZXiu/wBBuvGNv4r8K+PNI0rWVszYXC3KC4guId28BlDKQwbkMD7dK09M1yz1HXfA9kviS18Qapb3NzJc3ECLHkG3m52KSFA3BRz6UAep0UUUAFFAooAD+lFFAoAazBEZnYKoGSScACvOfhXEfEGs6949n3FdWkFppYcH93YQkqrAEAr5j75COmCprQ+IMk+vzR+DdLm8uS/Tfqc6gk29jnDgHtJJ9xfbe38NdlZ20FlaQWtpEkNvCgjijQYVFAwAB2AFAE1cx4v8KJrbQ3+n3T6Zr9oP9F1CJQSv+w69HjPdT+h5rpvpS0AcHp3jxtOvU0vx5aJol+7bIbvdmyujtzlJD9w8N8j4PHBNd31FVtSsLTVLKW01G2huraUFXilQMrA8dD7VwMngvXPCwkm+HmqhYCxf+xtTYy2pyWJCN9+Lls8HHGMUAekdBRn0riPD/wAQ7O81VdF8QWdx4e11uEtb0jZOcj/Uyj5ZOq8cH5gMV22aAFooBzRQAVW1G9t9Osbi9vp0gtLdDJLK5wqKBkk1Br+tad4f0m41LWbuKzsoFLPLKcDgZwPU+gHJrzGx0zVfipqUOq+JraXTvBdvIJrDSJRtmvWHSW5HZe4j9xnvkAvaFbz/ABK1e18RatC8XhWyl83R7GUFTdOOl1Kp6gHOwdgc+lenHkUihUUKigKBgADAA9KjuriK0tZrm4bZBAjSSNgnCgZJwOelICcUVx3h74leFPEcnlaNqTzztbtcxRPazQNPGvVoxIq7/wDgOa37XW7GaxsrqaYWgvEDxRXREUhz22k9famBpUVj6f4n0XUF1FrTUrZ00+4a1umZtgilXGVJbH94c9OaZd+KNLttY0LTTP5s+tGZbNoRvR/KQu+WHA4BoA26KwrnxVpNr4ofQLq5EF+tkt+TLhY/KaQxj5jxncDxWo9/ZperZvd263bDKwGQByPZc5oAs0VXW9tWuFt1uYDOwJEYkG4gdeOvFZUvivSU8U2fh4XIk1O6jlkVI8MFEeNwYj7p+YcGgDdooooA8A+D/wDycd8Uv+Af+hCvf68A+D//ACcd8Uv+Af8AoQr3+gDwv9sn/kkcP/YTh/8AQJK9o0bjR7H/AK4R/wDoIrxf9sn/AJJHD/2E4f8A0CSvaNHH/Eosf+uCf+gigC5RRRQAUUUUAHQUd6DR3oAKM0dKKADPNFFFABRR3ooAKO/SiigAqvdn5cVY71FPCs0ex8jnIIOCD7Gga0Zz973Hr1rCvMheatS3V1beIptH1Ab/ADIWu7O6AA81FIDow/vqWU5HUH1FVrsEnjk9PrWLdz1qUHG1+upyficywWbahZP5eoafm6t5V7FBkqfVWAII6c16/omoJquj2OoxKUju7eO4VW6gOoYA/nXkF1a3/ipLvTfD0StC6GKfUZDiCME7WVD/AMtGxuHHAx1rrNP8FSJY29trGvaldxRQJALe3k+zQKqjAwqYPTHUms6cpczcVodePp0ZUYRqytJN6buzt+vRtde56Dmqd3qNta8zOwA6lVLY/KuOi8F6ZZow0651aykIIEsV9JkfgSQfxqvJf63oDH+2Im1nTd2Be2keLiMEnHmRDhh0+ZfckVs5tfEjzI4SFR2pyv5PRv03XyvfsmdBdeMtOiIW2g1C9c/w29q/82AH61Ufxheqwb/hGNU8nPLeZFuA/wB3d/WobPX9J1JQbDVbKXPRPNCP+Ktg/pSTalZC7S1juYZ7lz/qopA7KO7HHQfWlzX1uaqhGD5XTd/O/wCljd8PeJNO11XFm8kdzH/rbWdDHNF/vKe3I5GR71tV53rllNPsv9KCJrdmC9rK3Rj3jb1Vhkc9M57V2nh/U4dZ0Wy1K2BWO5iEm0nJQnqp9wcg+4pwk3oznxNCMUqlPZ9Oz/yfT59rvQoopCQASSABySa0OMSR1jRndgqqMkntTYJPNiV9pUNyA3XFUWH9ozqCP9GQ5IYff9K0qADvVa9nkjTZaxiS4bhQfuj3b2qz3pB14oAz9F0tNNjlYuZru4fzbi4f70r4x+AAAAHQAYrRoooAp6hYRX6Klw0hiHWNXKhvrjrWdL4V0lxmCB7WQdJLaRonH4qc1u0nA5oA5sWHiDTblXsdRTUrPgNbXqhZFH+zKoz/AN9Bvwq7p2v2l1drZXAey1E5xa3GFd8DJKHo4xzx0HXFbFZHiXQLHxDYrbX6NujcTQTxnbJBIv3XRhyGFADvEnh/TPEulzadrVnHdWsgxhhyp7Mp6qQcEEcgiuMs7rU/h7fpY61cy6j4SnkCWuozNmXTyekc7fxR56SH7vRuOa6LwZq97dSalpGteW+raTIkU08Q2pcK6BklA/hJGQV7EHHGK37u1gvbOa1vIUnt5kMckci5V1IwQR3BoAlZgiksQFHJJ6CuJ1j4i6fHOLHwzby+JdWY4EGnENEnBOZJvuJwDxkn25rifCXgPQ9W1/XdA8SJqV5deHrpDbCW9mMMlnKC1v8AKWwdqhozxj93717DpOl2OkWcdnpdnBaWsYCpFCgRQPoKAOF0fwJf61q9rr/xHuYNQ1G2ffZ6bb5FlZHqCFP+sfPO9vRcYxXo2MYxRnFLj3oAQD86o67aSX2iajaQbRLPbyRJuOBllIGfbmvIrb4zXp12aA6XZ3OlTW2oz2N5bvKokNopZgS6AMDjBK5AOeuKiu/jVqmnaPdXuoaFYFj4ftvEFrHb3jMBHLJHH5cpKDa37wMMAjAxz1oAg8P/AAw8Uzaf4UtNdXSrOHwxYXdvbm2uXmku5poymWyiiNADkgbicfln6j8HvEs1v4XFmmkLfWGl22nzXVzMs8KeW2XBt5IG3j+6VeM5PPrWx4k+IOvPrsOiTRwadfaf4o0m0uJLC4MsU9vc7mMZLKpyAuG4HbpVuT4sXl9qGt6Cmk+TqelQalJqRjuCpt4oEHkyISvJkLrj05POMUAZ158LNdtbfxda6PpvhwJqmsrqMVwwQSyWxZC1thoWEe0qWVvmALEhQeam+H/wu17QNa8MXN2LCO10zV9UvXhhuDII4biDZGqHYucNnPC+uO1QSfF3XbLw61zp2i2l5b6XoWnareS3t+wmkSeMEqMR4Z+vzHA6nHatfU/izqMOs3gstIs20i01Wz0h2nuWW4aWfad6oFI2gN3PODQBN8SvhlL4u8V65qU1ppt1DN4XfTLE3Q3NDe+ZIySDKnbjePmHPWuU1P4T+Lb3X9Gu5v7IkFjLpkqXKzCOVBAkayqcQ7pGJU4YyAYwMc8ejfFjxtqfg6HTTpeki9S581ri5cSOlokag7mSJWcg7sbgMLjnqK88h+Imo3Wpa7dm9lmsn1LQI7aOzuSscQuYEaQIzJkoWJJBUE/7NAGlpXwjvrLUtK1OOHTYdVh8R3eo3F7EcTNaSiTam7bkkbl+U8daX4Z/DHXfDXinw5d39losUGk2t3bT3trOzT37ysGWWQGMYP1Zu/0rUsfinqV34ktYV0myXR7vX5dBidrlvtKvErF5GTbtAJXgZzyK4vwf8UPGVv4D0Mahb2V1caro+o3dlqMl0zSmW2BZjKnl7QMEAAZzgZI5wAfR9FeFaD418X3Oo+Gbm5FvdXV14Sm1QWNvMRHdSjymQt8g2OwYggAhS3BIrtvhX8Qx8QhqF3YWSxaVbR26LcbyS9w8QkljxgY8vcqk9yaAPP8A4P8A/Jx3xS/4B/6EK9/rwD4P/wDJx3xS/wCAf+hCvf6APC/2yf8AkkcP/YTh/wDQJK9p0f8A5BFj/wBcE/8AQRXi37ZP/JI4f+wnD/6BJXtGjf8AIHsf+uEf/oIoAuUmKWigBAOaWiigBMUtFFAARmkHfmlNJnjpQAtFIeKWgAxzmiiigAooBooADUdxNHbwSTTOscUal3dzhVA6kn0qQ9K4zV2PiLxRLpLjdpGlpHNeKc4nncZjiPqqrhyO5K1MpWNaNL2jd9EtX6f8PojOae48ReI7fWvs7W2lWEU0VkZAVkumk2hpCv8ACmFwueT19KqX9rJrmtx+H7SRo4TF9o1GVSQUgJwIgR0aTn6KCa6u7yz4PQnArM+G8fnJ4g1V1Tzr3UpYwwHPlQ4iRfw2sf8AgRrFx15e+/8AX4HqxrctN1UrcqSivNvT/wBul6+Wh09vaW9jZRWtlEkFvEoRI0GAoHtSMCTirEnIqrPGsilXGRyMVvY8pNt3ZjT6g6+L7fSgP3cmnS3bH/aWWNRj8GbP4VcJ2nIJ4rmtQ8E2aagmq+HpW0nV4shZFy8Tqequh4IPtg8Cn2fiq2SVLLxGsejatzmOZv3MuP4opOhU9cHBGcGseZpvn0PSlQjUjF4f3rLVW1vrrbXTzXzsW9S0PSdQlWW/0uzuJRwHeFSw/Gks9Ps7CIpY2dvaqeoijC5+uKvxulwge2kjmUjrG4cH8RUbgk4II9sVVluiVUm1yNu3a5Dn5sg4x0pvwsn36frtqv8AqbPWruCIDoFLByPzdqq6zqUWkWonnVnkc7be3X/WXEnQIo784ye1bfgjS38P+GLaC/ZTfzO1xdMB9+eRi7AeuCcfRaS1mh1mo4aXN1at8r3fy2+Z0bEKCWIAHJJqmXN4SqfLHjIyPve+PT+dHltcndc/LGP+WQPH/Av8KmaWG2iaSR1RepZuK2PJJIUEUaoCTjuepp9QrOhiMnKRgZLPwMevNee694/mvZpLDwdHHcMjGOfUpR+4hPT5P+ejDnpxwOoNROahudOGwtTEytTWi3fRer/pvoegXt5bWMBmvLiG3iBwXmcIo/E1kJ4x8OPMYl1zTt465nUD884ryXULCwUPeeJb86hM4+aa/f5RznCJ0A54AFU5NR8OTxlTHDLH0A+yMR/6DWDrtdke1SyWnKN7yl5paf19x7vDq+mSxh4dQs3Q9GWdSD+Oangu7e4JEE8Up/2HDfyr5zH9gPJtt9JllGOPLsyqj88UlxBo6xFn066t1H8aRMpHvlTUrEvsvv8A+AW8ghe3NJf9ur/5I+kyRiobhZjhoJVU+jrkGvANM1/UYQzaD4rmwQFENywnVR7K/IrbHxG8SW6rGZtBuJDwDLujJ/ANVrFR6o56nD9dO0JJ+t0/xX6np8+q6lZy7bnRpp4ucS2civ8Amrbcfmagk1nWJ7YSad4fk3sMhb24WHH12h64G2+J/iCDJv8ARLG5Ufw2k7If/Hga63w98RNE1e5jtJnk06/chVguxtDnHRW6H068+lXGvCWlzjr5Ri6K5nG68mn+WpqeEtFudNF9e6rNDcaxqMvm3UsKbUAHyxxqP7qrgc9Tk966Dtiko+lbHmnnN0GtP2hNPlEjCPUPDcsLRg8FobhWViPUCVx+Nej153Kst5+0BbgRFrbTfDbu0g6LJPcgKp9ysLmvRKADvQKKZMhkhdFcoWUgMvVfcUAcZP4K8E3Dar9i07R7TUbiK4hnurWONZ4zIhWQkjocE5zWVdfDLwdafDe78NQm10y0u7eC1utRiWKKacx7SrO2MFjjPP8AeJ71414P8Haxqdz/AGLZaJFBJaaBqunz6qba4gF3POCqNKZYUO7J6Avxk5xgV3fiX4N3Emh+EotEtNN/4lsEg1GwMiwpdTSRRo8wdopBv+TqyZI6EHqAemweHvB2kxWmmwabolkn2pL63tkjjjzOp+WVV4yw7EVk+GtL8LTeKfHOpwX6ajfX0iWuqxzBQkCxxBfKxgfLtPJ5z3PFeXeNPg74r1bR7PT7OPSGittLgs7ZpLv97avHIzYMpg3yjDYXBjA5OPXY134Qardv43g0630S2TV76PULa8B2u6ho2a2lXyzhCysxOWGcEqeaAPU4fD/hSawkSHT9Kks7y2js2CKhSaGIYSP0KqOg7VzPiD4V+H9W8Z23iXUrxl8qaCaK3WC2jUvEF2Ay+X5pX5c7d/6cVyOk/B+8eTRI9U03T10yLV59QvbF7wXKsr24j4AhjXlgDtC4x3PSuk+OmkT3eleCrTS9Hi1JIPEVqTZyKRD5axTDEhCttTkAkqQM0Adpr+ieGPFMFnJrthpOqwx7pLd7mNJQo43FSc8cDOOOBnpSf2B4Xlvp7cafpTXbPBPLCqJvzCAIWKjkbAAFPYYxXlui/By5bUfDDeIbXSLnS7a71W8u9OUl4LcXXlmKGIFRuVSmeQMHoKq6Z8INbsfFl3ezLZXga4vp4tQN+YXdbhHXZIiwbyfmAJ83AAyBkAUAdbb/AA78Lv48m8YSatHcXFpcvdFES1jSGQgj95IkYdsZON7HtnNdfYaF4XW204WNhpRt7GGVbQRqhWGKTiTZ2Ct0PY14lp/wY8Qw+GtQ06a10s2rSWptrVbxFnHkliS1ytqA4yRhJI3HXJB5N6z+F/jfTYoZrZ/DlxdXOiXuj3UfNskKzSmRXXy4grt2J2pk/nQB6/o3hrwzo8sL6JpumWU0UbRwtbRIpRZCGIGOzEA++Kr/AA48PaR4T8Pf2Jot4LwW80j3ErOjSNK7FmL7cAHtjA4ArgvCnwmuLe9e41tbL7RH4esNMs7qMl5LW5igaOSRMgYwSMHqfan/AAX+GuqeC9b+1anb2SGPTfsDXFreBluSHVlbyhAmDgNlmd25xz2AMP4P/wDJx3xS/wCAf+hCvf68A+D/APycd8Uv+Af+hCvf6APC/wBsn/kkcP8A2E4f/QJK9o0X/kD2P/XCP/0EV4v+2T/ySOH/ALCcP/oEle0aN/yCLH/rhH/6CKALgooooAKKM0gFAB9aD1paKADvQTRRQAUUUd6ACiiigAFFFFAAa4vwUWc+KJZW3PJrc/4BVRFH5KK7Q9K5DSStj4s8R6WwCtcvHqkI/vKyLE+Po8eT/violujqw+tOol2X5r/h/kO1OK+kuFNtdRW8SjJ/dB2Y/jwBVb4by+VH4g0uRkE1lqczhAefKm/eoxHvvI/4Ca0rzgkHkGuT1CSfRNci8Q2EMk4WL7Pf2yH5poASQ6ju6HOB3BIrOXutSO2jH21OVHq9vVba+auvVo9Hl5wKrvwCRUem6laavp0N9pk63FpKMq6/yPofY1l+I9fttH8qExSXV9MCYbaLqQP4mPRV9z+Ga1vfVHnWcHaSs0aDtwenHUmuP8Ra/aSxta22nxavJnGJAPIQ+7Hr9BVG+ub/AFMH+05U2btwt4MrGo7ZPVj9fyquUAAAADUrX3D2zj8JmyWj3dosU9ho0RJzi2hePaPZgwP41JHLOmn3lsPEmq6bJEqtskCz5DcAQsRvPI6ZyP1q4dkETyyMFjRCWJ9BVXTraSeVNRvE2yFSsETDmCM/+zHqfyqXTi+htTzCvDeV152a/G5V8OWGp2Fw99NPGL5jxeSqZ7gr/wADJVM9wv510j6zr8J3WtzHeSEj5bpAoC5wdrKODjPY1HEmAQeQOR61Io54OQaqMVFWRjWxFTET9pVd2O0jxdq1xZQRRaBZtuZg8a3xBVlbBDZTru/OqUOqeI9aka9udQtLBYZJIYobaASruVsF8yZycggcDge9UP7SttF8Uz/bbiG3s7i0SfdI2P3ivtbHrkBelUrXxNY6fBcK0GpzaesryxXkdm5i2OSxDMcdCSPpisZy5dHI9nC0faxVSnSWvk3+d0XvEcfiDUliS/1EarYxgM9lgWwlI5yWUfNyBweKrQPq8sMcNvY2mjWqLgZYSuo7bVACj8c1bsPEmh6km601ezfB6NJsI/76xV1QJFZomV4z3Rg2fxFZpJu6Z6PPOnFQnBK3lb8NF+Bl2ulW1tK0rKbm6Y5ae4O9yfbsB7Cp345GAAelS3ciQLunkjiVe7uFH61hXHiHTvNaCz8/UbgdYrKJpSPxHFKTjFGkIVKzuk3/AF+BoueCCSoHTmoSDuO3nBGM96kt/D/jPWFBtNNtNItyRmS+k3yY9Qo4/A4qCDw1czO7X3iCa5gbAj+yxiBWGeWOOee3tz34cVKT0RnXxNDDxvKab7LV/hp+JQu7C1uW33NpE79maME1UGkRTTyRWOl20rxgb2cBFXPI5xnOOeK6geGNOAYIs6P13rO2765zVPTbW58OI8EwkvdNklMv2nJaaMnA+cfxAccjp6VSoK92cVTPpeycaV1Lp2/r5GXJpmrxRkzWcTxjnNtLkgf7pAzTY9DuNXsSXW1aF+QC5LKfy+Vh+ldug3KrxsGRuVZTkEVTvdOaWf7VYuLa+C434ykg/uuvce/UVo6MH0OBZzjIpWlqutkbfw316bTdGh0fxPN5dzbyGG3uGyVli42bm6BuSOcdBXoE08UFu9zNLHHBGhkeRmAVVAyWJ6AY5zXk1neC4l+zXkP2a9Ay0THKv7o38Q9uoqHxDplzqehPo8d3cR6RPMhvbWI4aeEHLxI38G7jOO2RxnNaxXKrHn1qrrTdSW7100Og+EMMmptr/jS5RkfxJdCS1VgVK2MQ8u3yCTgsu5+P79eiA5rltL8WaFDp8Ymmg0i1hQIiXTrCEAGNoBIwR6flXB+Kv2hvBujySQ6U1zrV0o6Wq7Y8+hdv6A1VzO57MeRVCbWNNh1KLTptQtI7+X/V2zTKJG4zwuc9K+R/E3x38Y+IBLDYvDo1o4IAthmTH++eQfpiuw/Zu+HR1C7t/HOtTeeEZxZRs5ZvMBKNIxPp82B759KVxXufSF2ZxazGzWN7kI3lLKxVC+OAxAJAzjJAP0r578NeO/Hus2fwwulk02a+1iTUcxNO0UV0scLbTNtjOwqQxAUHO0cjJx9F1gab4O8N6Xdw3Gm6Hp1pPDNJcRvBbqhSSRdjsMDgleD7UxnlN78bNSPg7SdX07SbGS/msbq/u7BpJnaOO3laJ3VkQqqEo3zORyQOeasa98ZNXtLfWtQ03w/ZTaXo1pp19dme9ZZmju0DBUUIQWGTySBx0OcV6Nd+AfCN5aWtrd+G9Jmt7USCCOS1RhEHYs+3I4yST9TmrcnhLw9Ja3ts+jWDQXsUMFzGYRtmjiGI1Ydwo6DtQBmfEHxTe+HJ/D1rpdjbXd1rF+LFPtEzRJGSjNuJVWJ+70xXGaH8WNa1u60PT9N8P2M2pXxvY5S18yQK1tIqMyPsJZSDkce3vXdeOPBWl+M/7ITW08620+7+1C3ZVaOY7GXa4IORhs/hWnZeHdGsZLB7LS7K3awiaG1MUKr5CNjcqY6A4GcdaAPO9E+KOo6p4isLVdKso9P1W9vtOsW+0MZ0ltgxLTJtwFbaehJXIzmuev8A4w3eteAvF+oW2nGy/sKGOK5a21BfNa5M2xhEwVh5WBkSEc5wBwTXr6eE/D0eq3mpx6Jp0eo3iNHcXSW6rLIrfeBYDPPf1qF/BPhh7Y27aDpvkG1WyMYgUKYFbcsZGOVDc49eaAOB8XfFTWtH8W6vpun6FYXVlpmoWNhJLNetHJI11GrJtURkAAnBJPQdDnirP8W9YGihI9M00eI01O+017MSTypKbXBd4tsedoDAkvtAH1xXqVz4a0S6ubm4uNLs5Z7maK4mkaIEySRDEbk9yoAwe1Vb7wT4X1CIxX/h/S7mM3T3pWW2RwZ3+/JyPvNxk96AOE+Hvji+8W/EPTpsyW2mXvhOHUfsO/ckc5unRmBwMnC4z6V65WVpfhzRtJnhm0zTLS1lhthZxvFEFKQhiwjGP4dxJx6mtWgDwD4P/wDJx3xS/wCAf+hCvf68A+D/APycd8Uv+Af+hCvf6APC/wBsn/kkcP8A2E4f/QJK9o0Y40ix/wCuEf8A6CK8X/bJ/wCSRw/9hOH/ANAkr2jRv+QRY5/54J/6CKALlFFHWgAo70UUAFFA4ooAKxvFfibSfCelf2lr101tZ+YsO9YXlJdjhQFRSxyfatmuA+NnhPUfGXgtNM0dYGuVvYLgrNM0IZUbJG9QSp9xQBsaT440TWbGC80aW4voJb/+zXMdtIrQTAZIlRwGQDjORxketbj6nYRlw97aqUQyOGmUbVzjceeBnjNeMaF8LvENnZaYkjWMEMPi2PXvsS3Tz/Z4Ajhx5zqGlkJYHLfnWdZ/BC48zSpL7T9FmdDq5vmYBjOZzm1zlfm2Hnn7p5FAHvM+o2VvLDHcXltE83+qV5VUyf7oJ5/CnSXtrHOkMlzAkztsVGkAZmxnAHc+1fPXi74QeLtY8MaNpQXRrj7JoUNhvklEbw3EZJLb/JZ3THAUMgB5+uzrfwi1DUbvxDqJt9MfV7rVNPvLG8dv3sUcIjEo37cqTtbgdeM0Ae3i4hOMTRnLFB8w5b0+tY+u+LNG0bRNS1W5vYpbXTkMlyLdhI6DOOVB65ryyw+HPi6113ToidGOj2PiS41qO4WaTznSUPgGPbgEF/73P6nlk+C3i+WPVmnTRYbq80efT3kt5wiTSNKjq2xIUCJhenzHPOeaAPpWGVZ4I5UyUkUMufQjNYPi7Rrm/W1v9Ikih1rT2L2zyjKSAjDxP32sPToQD2rasYmgsreF/vxxKhx0yBipzjPSlKKkrM0pVZUpqcf68vRnD6frdtqx8lkey1JOJrC4IWWNhnOP765Bwy8GorvIOApGPauo1vQdM1yIR6pZxT7fusRhk9w3UV5veaZZXt0kWhXupJpkEh8yb7W8gueCCiZJ+XPVu+OPWsnGR3wxFBK6uvLf8b/mvmzK1KVNP1Ce50W4u7bUNyrL9if5HbPAcH5SST0xmtqzhuFVp9Qm+06nNtNzOAF3MBgAAcBR0xVSxt4Zr0LbwCLT9Oby4VHAebHzN77R8oPqWrYYcqMcE8nuacYKOxzYnFzxNubp9/37lVkJyMfjS+Xnpy30qfaxB7nA7VDfziytQ6p5twzCOGPvI56D6cZPsDVnKZ86fb9QFplvs9sVmnI6M/VE/kx/CtIjdkkDmjTNP+w2aReb50pJeWU/8tHJyzfn+lWvJ4J4APbHWgCsUO7kcjjPtTkXnGMn19qnKE53KaoavfR6bFH+7ee7mby7e1Q/PK3U/QAck9qANbwZarfeJtTuZoY5IbS3jtVLKD+8Yl3H4Ax/nXdJEqo0ZVTH/d28YryzTtP1GOEibU7m2d5DM0Vi3loGY5OT1b05Pauw8J6rcvcvpWqSme5WMzQ3BUKZUBwQQONykj6gj3poLsn1bwT4a1V2k1DRbGaVhjzDEA351zzfB/wjg7LW7jzz8l5IAPw3V6Hj3pamVKEviSZ1UcdiaCtSqSivJtHC2Hws8JWk4l/s03B/u3MrSr+TEiuvsdPtNPhSKztYYI1G1VjQKAPSrX1paI04x+FWJrYuviP403L1bZT1XcdLvAn3vJfH12mvPkhVESNFwiqB06Af/qrtdV1i1inexw8spXEojx+6Ujgknv6DrXJQoSp3YcxttYj9Cfr1qznISoH3RyOtKFXA2554zVjywMZHNJsAGBkL0qQMp7CWLMunOsbM2Xgb/Vv/APEn3H41JZ3iXMnksj290oO6CXhj7g9GHuK0gpyPyqK/sob6Ixz5BHKSJwyEdCp7GgCC5s4rqLyrhVdAQVJ4KsOhB7GsXxXa+K28KX8fhK7tP7ZjZXhknADSR87lGflD9MH+XWtnTpJt32TUChvYhnzAuFnX++o9fUdjV/YedoAOOPagD4j8Z6B41t9SluvGdjqpkbBkuJwZE9vnGV/Ws+whBUbcY9q+43juLOOQ2hMkJBL2j8o/+7nof0rh/EHwx8L+JITeWdqNPupMnzrUbPmzyGXpnPXiglq584WkWRluQK9G+GkfjVxOngyXUI7cvmTy2xDv988ZpmufDTV/D5G2SO6hY4UqNrMeuMeuK3/hX8QL3wLNJZXds8+jyuXkhA2vE5xllPfgdKQlod9bR/F5IQskqMRxk+Vn8eKmSy+KcxG98H/avAg/Ra9jtJ0u7aG4hJMUyLIhIwcEZHBqcU7Fnj/9l/FEEGObTMekt9Kf5KKsxad8VPMGbvQI1PdnmfH6ivV6MUcoHnA0b4jyoQfEui2zeqWDv/6FJXT+EdN1zT7aX/hJNaXVrl2+Vo7ZYEQegA/qa6CihRHcKKKKoQUUUUAFFFFAHgHwf/5OO+KX/AP/AEIV7/XgHwf/AOTjvil/wD/0IV7/AEAeF/tk/wDJI4f+wnD/AOgSV7Ro3/IIsf8Argn/AKCK8X/bJ/5JHD/2E4f/AECSvaNH/wCQRY/9cE/9BFAFyiiigAHSiijvQAUGik74oAWuN+Iniy+8My6Bb6XpkOo3erX32JI5rgwKpMbMCWCt/dx0rqLi+htWAum8lScB2+7+fb8aZeadY6jJZz3ltBcvay+fbO6hvKfBG5T2OCefegDyz/hauuP4zl0eDwyJrawvLex1F4mldomkVS0its2BFLYG4gsBnisNfibr+reKfCepwxW9n4euptXEdpHOWluFtoJMeeNuF+dMgAnGa9f1Hwj4c1LWYdX1DQtMudUhKtHdy2yNKpX7p3EZ47enamWvgvwza642sWugaZDqpd5Ddx2yLKWcFWJYDOSGbPrk+tAHm158cY7PRdP1FtKjnFx4ffWZIoLnLRyB0QRHjpl+WPTB4NSeK/GXjzTr7wrbxQ+Gkm1HUVgkWG+d0dHiZlRiYiUHyt8wznC4zk49C03wL4U0yWSTTvDmkWryxvDIYbRF3o+NynA5BwMg+lRD4feEBpcmmjwxow095hcNbi0TYZAMB8Y6gEjPoSKAOD0/4iakLybStLtVuNUvvE2paZbyandnyIktxvJyqZAIGFTB69TVWP4yazqun2s3h/w/YtK+g3Gtzi8vWUIsE7RSIm1DvyVypO3II6V6jeeD/Dt9YXFje6Hp1xaXFy17LDLbqyvO33pCCPvH161MPDWiKwZNJsUIszpw2QqoFsTkwgAcJx93pQA/wrq41/wxo+sLEYF1GzhuxETuKeYgfbnvjOK0z696hsrS3sLK3s7OFILW3jWKKKNcKiKMKoHYAACsHxPrM0dwulaW2L+RPMlmK5W2iORuPbcSCFH1PQcgEHiq9a9LaVaSMkXS7lQ4IH/PMH1Pc9h9eOb1WV7Kxit9PQLc3B+zWqquAmf4seijLfh71qwwR20KxRcIMnJOSW7knuTWfYo1zf3l4cFYHNrCM8ADBc/Utx9FpCFtLGOwsobWHJjhUKpY8t6kn1JyT9an28nJHHTFSlDwO38qd5eByvOaQyNYst0Aqlp8a3sw1JgTHgrbKeyE8v8AVsflirOsGRNMlS3wtxPi3jb0Zztz+AJP4VeigSNI0jXCIAoA6YHA/lTQEHl4HTjpmlEeCDjOOM+lWtpIzjBPagoCT2HahCKyREkKO54zWHpEIvtQuNamTDSFre0B/ggUkbh7uwJ+mK1PEVwdP8P6ldo2Hit3Kf7xGF/UirFnZ/ZbS1tlHywRrFz7AD+lIBuzOOuMc1DLMbPV9Eu14C3iwP8A7soKY/76KH8K0NnHy4x3rM8RgpodxPzm3aO4Ht5civ8AyU0xnoo69aMUDB5HINL3pgFBNFFAHn9soL3kpGWmvJ3Ynq2HKj8lUD8Kbc2pdN9vM1tcrwsgGQR/dYfxL7Gm+G5mudDguc5+0PLMP91pXI/QitAKdpU5PNJAZ0c8yHytRhSFi21JY2zG2enXlTnsfzq6yEHByOelPngjuYXt50EkMilXB7g1U0pZo1exumZ7i2wqyscmaL+F/r2PuPekBOIzg+ucZpAhwM4yByashCF6ZH8qGjJPpn0pgUL6yW8jVNxjnjO+GZRzE2Ovv7juKbYTtP5kF1Gsd5CAZY16EHo6/wCyf06VoKmOQDmqmo2LXEMc9udmoW4LQsxwG9Ub1U//AF6QErJ0IH/1qz54lsrhrtci3kwLhB0B7SD+R9ue1aFjcLe2qzopRuUkiPWJx95T7g/41OFGCpAIPBGOtAGfqFjHeWz202cHDK69UYchh7g1zreHtM1hJo9QsrZdWtmCylBgbuqvjurAZx9RXS2YME5spS3CmSFm/iTPK59V4/Aiq+sxtatHqkQ+a24uBjloCfm/FfvD6Ed6AOz8O6mNU01ZWjENxGTFPCDny3HUfToR7EVp1xdjJ/Z2qR3kRDQThYrkg8Ff4JPwzj6H2rtM00wCiiimAUUUUAFFFFABRRRQAUUUUAeAfB//AJOO+KX/AAD/ANCFe/14B8H/APk474pf8A/9CFe/0AeF/tk/8kjh/wCwnD/6BJXtGj/8gix/64J/6CK8X/bJ/wCSRw/9hOH/ANAkr2jR+NJsv+uCf+gigC5RQKKAE7c0tFBoAbnrSg0me9KOpoAa6K67XUMp4IPNc7e+FIzdfatH1C+0i4LbnFs4MTn/AGo2BU/XGa6TBxzRwKAOFJ+IWlzxBRoevWg3Fy2+znx2GRuUn/gIqOX4gajp1m8+veCfEFuUbB+xiO7U+42sGP8A3zXf0UAcHF8WfCAe3j1DUZtLnm+7DqNpLbsPqWXH6102n+JdC1KQR6frWmXUh6JBdRufyBrQntYJyDPBFIR/fQH+dc3qnw88I6nPLPe+HtOe4kGGmEID/wDfQ5oA6qivObT4RaDpqS/2Ffa7pMkmcva6lMP0LEUHwnrPh/TppYfH2vSKvIF3HDcknso3Jkkngc0Adb4m8QWmgWbT3JLMEZxGvXaOp/kB6kgVz2lQ3K2rzX5Bv7o+fOB/Cx/gHsowv4VlWenalLe2llrd9/ad0m29v7gxLGpZeIIQq8ABgXP0966hlLO5I5xzQIpTOtvDLNKBsiQyN+Ayay/DlvLbaBYLcA+fKn2iX2kkYu35FsVf1+IzaTJbJw9262w+jH5v/Hd1aDoC7beB0A9KQFJVyVO3qBgU9VO89fWrCxZIGMAVIkewHHUcUAZk48zV7KED5YEe5cfhsT9WY/hV7aAxxUdkFfUdRlPVGS2Uj/ZXcf1c1eZMjjp60ICuUOM54pGUDpVgpxnt70bc9aYHN+MIhNo6WzHm4vLaEY7gzISPyBrckUNIxGOT61n6vtl17QbHkv5kt5gdNscZH/oUi1qhRnpz1pARBNnPvmory0F7Z3Vqek8LxH/gSkf1q15bH8alQYdSB0PSgZZ8I3TX3hbSLhzmR7WMv/vBQG/UGtisDwPGINB+zjpBc3EY+gmfH6YrfNMAqlrd2LDRr67JwIIHk/JSau1heMsS6OLQ/wDL3cRW+PVS43f+OhqAMXSbH+z9HsLMdbe3jj/EKAateWcghuOvvVt0JfPGc0zYwyfakBXWPjHUDvWX4mElrpkmq20fmXmnK0yqD/rIx/rE/FQce4FbgXnHeo5o/Ntpo3XKSRupB9CCDSAgsriK9tLe7tG3286h0Psex9x0qbAOQKpW2mz6bYWuoWCtPZS28cl1aqMsG2KPMj98Dle/Xr1vwMk0CTQuHilAdHHRlI4NMBpHI5pVGM5PSpSuWB/pSFThSR16ikBlzxm11eGaMfuLzMMwH/PQDKN+OCp/4DV4pzTdQtmubOSANtkPzI391gcqfwIFOtpfPtknKgb1BKjse4/PimBT1SzluLZXtiBdQMJoCem4fwn2YZB+tTWksV7ZxXCLmKZd2xvQ9VPv1Bq6q8r71St42tr+eAACGfNxGQOjZG9fzIb8TSAz9KhFmraNIGZIY827Oc+bD0wfdchfpg10uiXrqwsLkguFzBJ/z0QY4P8AtDP49fWsvULN7lYnhIW6t28yBjwM4wVPsw4P/wBalYNeWyvbnybhG8yPeP8AVyDoD7dj6g0r2GdfRVXTLsX1jDcBdpcfMufusOGX8DkVaqxBRRRQAUUUUAFFFFABRRRQB4B8H/8Ak474pf8AAP8A0IV7/XgHwf8A+Tjvil/wD/0IV7/QB4X+2T/ySOH/ALCcP/oEle0aR/yCbL/rgn/oIrxf9sn/AJJHD/2E4f8A0CSvadI/5BNl/wBcE/8AQRQBboxz1oNFAAKKKD7UAJ7igHnmjHPtR6cUAJ3NHal6igCgBaKBxxRQAd6KKKACuU1eRNQ8RRhpcWOjqZpv7pnZflz/ALibjj/bX0roNUvBYafPclS5jX5UHV2PCqPckgfjXLXtubewsNLmxLc6lc/6SycbuskrfTC7foRQBNo1sRbzXMgP2i9c3L56qCAEX8FCj860PK45zyKnK5Y5AGTTguTgZ5oAyZIxNq8MOP8Aj2iM7ezN8q/pvq6YRwM8HiodLHmi7vcc3ExKn1RPkX+RP41eVccAUgIRHgAdeO9PEYyo561KVwOByOaDhA0hPCgt+A5pgZGhR7tOaQ5zNcTTc+hkYD9AK0Cmecc9Dim6VFs0uzXp+5Un2JGf61ZKtt4HNAELJnJppiAwBnPfmrGzv2oKHtQBzM8bN44trplPkQ2z2W/srOBJ+u0D8q39nJ4+lVXt5JpZIekbzuZTj7wCLgfmR+VXo4WSNEJ3FRjJ70WAjEeOOcCnBcVKF56UbcDOKBjfDkfl295jobyZh+Lmtasbw3IWXUoz1hvpVP0OGH6MK2aBAOnNYfi8eXpkV3z/AKJcxTn/AHdwDf8AjrNW5VfULZL2wuLWT7k0bRn6EYoAzHi2yMPfFHl855qHR7hr3SbS5kGJXjCyj0dflcf99A1c249aBkO05B/CqurSm00i8uCCWjhdlUDlmwQAPcnAq/tGSMkA9exrAbw7cOUI1u9XyzujAVcFgcgvx8+D60rAdTpFu9rpNlbyffigSNvqFArnPDDCTw1pbDGPsyfgQMEfmDWz4f1OS/t5Y72H7Pf2z+VcR5yM9nU/3WHI/LtWVosAsp9U0zORBctPEP8AplMS4/AN5g/ChiNDHHA/CkZRgHHIqbb1xSlOOetIZXaPPOOlUrSMQ3t3bZO1iLmMf7LcMPwYZ/4FWrs5yaoaqVtms75gQIZRFIR/zzkIUk+wbYfwoAsKoI71T1aGVrUzQAm4tyJowOrYHzL+K5H41pbCpKkUYwQaAKsTx3EEc0DBo3UOh9jTinBI796ljgWNSI1wCS2B0GetLs3HpwPWpY0Q6RItrq9xanhLpftMfpuGA4/9BP4mt6udvwYViukXdJauJPcrjDAf8BJroI2DAFTlSMg04sTHUUUVYgooooAKKKKACiiigDwD4P8A/Jx3xS/4B/6EK9/rwD4P/wDJx3xS/wCAf+hCvf6APC/2yf8AkkcP/YTh/wDQJK9p0j/kE2Wf+eKf+givFv2yf+SRw/8AYTh/9Akr2nSP+QVZf9cU/wDQRQBbNBpDS0AFAozSd6AF7c0nPeg0Z9qAFopBS5oAKM0e9FABSUtFAGLqn+laxZW2SUtwbt19W+7GPzLH6qKikt/N120uHHFvbShf952QZ/JT+dT2ERe/1K6f/lpKIk/3EGP/AEIvV7YNwbHOMUAQBTgEik2k9eDVkL2xQU60AVY4gkSxphUQBQPSnheemRU+wcUu3FAEO3JAqprBY2EsUZ/eXBFuv1Y4J/AZP4VpBc4rKhA1DWDOr7rax3Rpj7rzH7x/4COPqWoAv7QMKo4HAHoKNuBzjNS4xRtHpQBDtOcHrigLwKmIBoC0AUBIkmptAv3oYxK5Hq5IA/JTVrbz+NNitlS+ubgD5pljUn/d3f41YxxigCELnpRtOevsKmC446UYHpQBR0yD7PquokfcufLnx/tbdjfoi1q1DGmJQ2OxFTZoAKKKOKAOf09Rb6lqtkqkBZRdIPVZRk/+Pq/51obDnnpVfUI1i8QafcdDPHJan348xf8A0Bvzq+Vz9KAIMdqNvGM1MVGaNmKQzHaSTTNbmunhMlhdxxrJIgy0LpkDI7qQRyOhHvw+6ntZda025tZI5TcJLbl42DBgo39R6FT+ZrV2nP4YrnTZRR+N7FbZBHGlnPcyqowu9mRFP1ID/lQI2wCOe9O28ZqXZS7ePrQBAw7YqK8tVvLSe1lGUmjaNvbIq4V60mKAK8IZoYjITv2Dd7nHNSbTngcUkFu0LznzGdJH3qp/gyBkD2zz+NT4x0oGQ454HSmleuR15qfb7U0rjNICsVPGQMelT6Srx2gikOfLJRTnkr2/Tj8KCuT/AFp9qdrsuPepWjG9i1RRRWhIUUUUAFFFFABRRRQB4B8H/wDk474pf8A/9CFe/wBeAfB//k474pf8A/8AQhXv9AHlH7S/hLW/Gfw6j0vw1Zfbb4X0Uxi81I/kCuCcuwHcd65O38RftCQW8UKeBfDhWNQgJnTOAMf8/VfQdFAHgH/CUftDf9CJ4b/7/p/8lUf8JR+0N/0Inhv/AL/p/wDJVe/0UAeAf8JR+0N/0Inhv/v+n/yVSf8ACT/tDf8AQieG/wDv+n/yVX0BRQB4B/wlH7Q3/QieG/8Av+n/AMlUn/CT/tDf9CJ4a/7/AKf/ACVX0BRQB8//APCT/tDf9CJ4a/7/AKf/ACVR/wAJP+0N/wBCJ4a/7/p/8lV9AUUAeAf8JR+0N/0Inhv/AL/p/wDJVH/CUftDf9CJ4a/7/p/8lV7/AEUAeAf8JR+0N/0Inhv/AL/p/wDJVH/CUftDf9CJ4b/7/p/8lV7/AEUAfPcPiH9oKGMIngPw3tBJ5nTqTk/8vXqak/4Sb9oX/oQ/DX/f9P8A5Kr6AooA+fv+Em/aF/6EPw1/3/T/AOSqB4m/aFH/ADInhr/v+n/yVX0DRQB8/f8ACTftC/8AQh+Gv+/6f/JVH/CTftC/9CH4a/7/AKf/ACVX0DRQB8+S+I/2hZInT/hBvDiblK7lnQEZHUf6VUVlrn7QFlapbw+A/DexSTzOmSSck/8AH16k19EUUAfP/wDwk37Qv/QieG/+/wCn/wAlUn/CS/tC/wDQh+G/+/6f/JVfQNFAHz//AMJN+0L/ANCJ4a/7/p/8lUn/AAk37Qv/AEIfhv8A7/p/8lV9A0UAfP8A/wAJN+0L/wBCH4a/7/p/8lUf8JN+0L/0Ifhr/v8Ap/8AJVfQFFAHz/8A8JN+0L/0Inhr/v8Ap/8AJVH/AAk37Qv/AEIfhr/v+n/yVX0BRQB8/jxN+0KOngTw3/3/AE/+SqX/AISj9ob/AKETw3/3/T/5Kr3+igDwD/hKP2hv+hE8N/8Af9P/AJKo/wCEo/aG/wChE8N/9/0/+Sq9/ooA+ebnX/2grnyfM8CeHMxSCVSLhOCP+3r0JH41L/wk37Qv/Qh+Gv8Av+n/AMlV9A0UAfP3/CTftC/9CH4a/wC/6f8AyVR/wkv7Qn/Qh+G/+/6f/JVfQNFAHz9/wkv7Qn/Qh+Gv+/6f/JVQrr37QK3klz/wgnhvzXjWI/v06KWI/wCXr/aNfQ9FAHz8PE37Qv8A0Ifhr/v+n/yVS/8ACTftC/8AQh+Gv+/6f/JVfQFFAHz9/wAJN+0L/wBCH4b/AO/6f/JVH/CTftC/9CJ4b/7/AKf/ACVX0DRQB8/f8JN+0L/0Inhv/v8Ap/8AJVH/AAkv7Qv/AEIfhr/v+n/yVX0DRQB8/f8ACTftC/8AQh+G/wDv+n/yVR/wkv7Qn/Qh+Gv+/wCn/wAlV9A0UAfPx8S/tCH/AJkPw1/3/T/5KpB4k/aEByPAnhvP/XdP/kqvoKilZAeAf8JR+0N/0Inhv/v+n/yVR/wlH7Q3/QieG/8Av+n/AMlV7/RTA8A/4Sj9ob/oRPDf/f8AT/5Ko/4Sj9ob/oRPDf8A3/T/AOSq9/ooA8A/4Sj9ob/oRPDf/f8AT/5Ko/4Sj9ob/oRPDf8A3/T/AOSq9/ooA8A/4Sj9ob/oRPDf/f8AT/5Ko/4Sj9ob/oRPDf8A3/T/AOSq9/ooA8I+BHhbxtYfEXxb4l8daNBpkurxIQIJ43QuG5ChZHIGPU17vRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Anatomy of an indirect inguinal hernia. B) Gas and stool are first \"milked out\" of the bowel to reduce its size. C) Constant pressure is applied for up to 5 minutes (distal to proximal) to reduce the hernia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King C, Henretig FM. Inguinal hernia reduction. In: Textbook of pediatric emergency medicine procedures, 2nd ed, Lippincott Williams &amp; Wilkins&nbsp;2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26327=[""].join("\n");
var outline_f25_45_26327=null;
var title_f25_45_26328="Clonazepam: Drug information";
var content_f25_45_26328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clonazepam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22197?source=see_link\">",
"    see \"Clonazepam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"    see \"Clonazepam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F153382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      KlonoPIN&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Clonazepam&reg;;",
"     </li>",
"     <li>",
"      Clonapam;",
"     </li>",
"     <li>",
"      Clonazepam-R;",
"     </li>",
"     <li>",
"      CO Clonazepam;",
"     </li>",
"     <li>",
"      Dom-Clonazepam;",
"     </li>",
"     <li>",
"      Dom-Clonazepam-R;",
"     </li>",
"     <li>",
"      Mylan-Clonazepam;",
"     </li>",
"     <li>",
"      Novo-Clonazepam;",
"     </li>",
"     <li>",
"      PHL-Clonazepam;",
"     </li>",
"     <li>",
"      PHL-Clonazepam-R;",
"     </li>",
"     <li>",
"      PMS-Clonazepam;",
"     </li>",
"     <li>",
"      PRO-Clonazepam;",
"     </li>",
"     <li>",
"      ratio-Clonazepam;",
"     </li>",
"     <li>",
"      Riva-Clonazepam;",
"     </li>",
"     <li>",
"      Rivotril&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Clonazepam;",
"     </li>",
"     <li>",
"      ZYM-Clonazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F153387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Panic disorder:",
"     </b>",
"     Oral: 0.25 mg twice daily; increase in increments of 0.125-0.25 mg twice daily every 3 days; target dose: 1 mg daily (maximum: 4 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seizure disorders:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial daily dose not to exceed 1.5 mg given in 3 divided doses; may increase by 0.5-1 mg every third day until seizures are controlled or adverse effects seen (maximum: 20 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Usual maintenance dose: 2-8 mg daily in 1-2 divided doses (Brodie, 1997); do not exceed 20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Discontinuation of treatment:",
"     </i>",
"     To discontinue, treatment should be withdrawn gradually. Decrease dose by 0.125 mg twice daily every 3 days until medication is completely withdrawn.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Burning mouth syndrome (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 0.25 at bedtime for 1 week; increase dose by &le;0.25 mg every week; maximum dose: 3 mg daily in 3 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Use should be limited (Buchanan, 2008; Grushka, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical: May administer topically with 1 mg 3 times daily (after each meal).",
"     <b>",
"      Note:",
"     </b>",
"     Patient should be instructed to suck on the tablet, retain saliva in mouth near the pain sites without swallowing for 3 minutes, and then expectorate saliva (Gremeau-Richard, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Essential tremor (unlabeled use):",
"     </b>",
"     Oral: Initial: 0.5 mg at bedtime; increase dose by 0.5 mg every 3-4 days; maximum dose: 6 mg daily (Biary, 1987; Thompson, 1984; Zesiewicz, 2005; Zesiewicz, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      REM sleep behavior disorder (unlabeled use):",
"     </b>",
"     0.25-2 mg 30 minutes prior to bedtime (maximum: 4 mg 30 minutes prior to bedtime).",
"     <b>",
"      Note:",
"     </b>",
"     Use with caution in patients with dementia, gait disorders, or obstructive sleep apnea (Aurora, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F153404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"      see \"Clonazepam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seizure disorders:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &lt;10 years or &lt;30 kg:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial daily dose: 0.01-0.03 mg/kg/day (maximum: 0.05 mg/kg/day) given in 2-3 divided doses; increase by no more than 0.25-0.5 mg every third day until seizures are controlled or adverse effects seen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Usual maintenance dose: 0.1-0.2 mg/kg/day divided 3 times daily; not to exceed 0.2 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &gt;10 years or &ge;30 kg and Adolescents:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F153388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Initiate with low doses and observe closely.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F153389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.  Clonazepam metabolites may accumulate in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F153353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     KlonoPIN&reg;: 0.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     KlonoPIN&reg;: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F153338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F153428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10815684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225680.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225680.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F153358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally-disintegrating tablet: Open pouch and peel back foil on the blister; do not push tablet through foil. Use dry hands to remove tablet and place in mouth. May be swallowed with or without water. Use immediately after removing from package.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Swallow whole with water.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F153357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alone or as an adjunct in the treatment of petit mal variant (Lennox-Gastaut), akinetic, and myoclonic seizures; petit mal (absence) seizures unresponsive to succimides; panic disorder with or without agoraphobia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F153423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Restless legs syndrome; neuralgia; multifocal tic disorder; parkinsonian dysarthria; bipolar disorder; adjunct therapy for schizophrenia; burning mouth syndrome; essential tremor",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F153435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ClonazePAM may be confused with cloBAZam, cloNIDine, clorazepate, cloZAPine, LORazepam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       KlonoPIN&reg; may be confused with cloNIDine, clorazepate, cloZAPine, LORazepam",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions reported in patients with seizure and/or panic disorder. Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema (ankle or facial), palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, ataxia (seizure disorder ~30%; panic disorder 5%), behavior problems (seizure disorder ~25%), coma, confusion, coordination impaired, depression, dizziness, drowsiness (seizure disorder ~50%), emotional lability, fatigue, fever, hallucinations, headache, hysteria, insomnia, intellectual ability reduced, memory disturbance, nervousness; paradoxical reactions (including aggressive behavior, agitation, anxiety, excitability, hostility, irritability, nervousness, nightmares, sleep disturbance, vivid dreams); psychosis, slurred speech, somnolence (panic disorder 37%), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hair loss, hirsutism, skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, libido increased/decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased/decreased, coated tongue, constipation, dehydration, diarrhea, encopresis, gastritis, gum soreness, nausea, weight changes (loss/gain), xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Colpitis, dysuria, ejaculation delayed, enuresis, impotence, micturition frequency, nocturia, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, eosinophilia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (transient), hepatomegaly, transaminases increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Choreiform movements, coordination abnormal, dysarthria, hypotonia, muscle pain, muscle weakness, myalgia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, eye movements abnormal, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, chest congestion, cough, hypersecretions, pharyngitis, respiratory depression, respiratory tract infection, rhinitis, rhinorrhea, shortness of breath, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, aphonia, dysdiadochokinesis, &ldquo;glassy-eyed&rdquo; appearance, hemiparesis, flu-like syndrome,  lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Apathy, burning skin, chest pain, depersonalization, dyspnea, excessive dreaming, hyperactivity, hypoesthesia, hypotension postural, infection, migraine, organic disinhibition, pain, paresthesia, paresis, periorbital edema, polyuria, suicidal attempt, suicide ideation, thick tongue, twitching, visual disturbance, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F153362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clonazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); significant liver disease; acute narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F153342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; accumulation likely to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valproic acid: Concurrent use with valproic acid may result in absence status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group and slower metabolism of long-acting agents (such as clonazepam), avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Worsening of seizures may occur when added to patients with multiple seizure types. Monitoring of CBC and liver function tests has been recommended during prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F153421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of ClonazePAM.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of ClonazePAM.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F153378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Clonazepam serum concentration is unlikely to be increased by grapefruit juice because of clonazepam's high oral bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease clonazepam levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F153348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F153366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clonazepam was shown to be teratogenic in some animal studies. Clonazepam crosses the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. Epilepsy itself, the number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines, including clonazepam.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to clonazepam during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F153367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clonazepam enters breast milk. Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F153365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (ClonazePAM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125 mg (60): $77.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (60): $77.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (60): $77.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (60): $88.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $123.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ClonazePAM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $74.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $85.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $118.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (KlonoPIN Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $225.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $256.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $355.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F153350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver and renal function tests; observe patient for excess sedation, respiratory depression; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F153354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relationship between serum concentration and seizure control is not well established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Peak serum levels occur 1-3 hours after oral ingestion; the half-life is 20-40 hours; therefore, steady-state occurs in 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic levels: 20-80 ng/mL; Toxic concentration: &gt;80 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F153368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amotril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Antelepsin (HU);",
"     </li>",
"     <li>",
"      Anzatax (PE);",
"     </li>",
"     <li>",
"      Clonapilep (MX);",
"     </li>",
"     <li>",
"      Clonaril (TH);",
"     </li>",
"     <li>",
"      Clonatryl (CO);",
"     </li>",
"     <li>",
"      Clonazepamum (HU);",
"     </li>",
"     <li>",
"      Clonex (IL);",
"     </li>",
"     <li>",
"      Clonopam (TW);",
"     </li>",
"     <li>",
"      Clonotril (PH, SG);",
"     </li>",
"     <li>",
"      Clozer (MX);",
"     </li>",
"     <li>",
"      Convolsil (TH);",
"     </li>",
"     <li>",
"      Coquan (CO);",
"     </li>",
"     <li>",
"      Iktorivil (SE);",
"     </li>",
"     <li>",
"      Kenoket (MX);",
"     </li>",
"     <li>",
"      Kriadex (MX);",
"     </li>",
"     <li>",
"      Lonazep (IN);",
"     </li>",
"     <li>",
"      Neuryl (EC);",
"     </li>",
"     <li>",
"      Paxam (AU, NZ);",
"     </li>",
"     <li>",
"      Povanil (TH);",
"     </li>",
"     <li>",
"      Ravotril (CN);",
"     </li>",
"     <li>",
"      Riklona (ID);",
"     </li>",
"     <li>",
"      Rivatril (FI);",
"     </li>",
"     <li>",
"      Rivopam (SG);",
"     </li>",
"     <li>",
"      Rivotril (AE, AR, AT, AU, BD, BE, BG, BH, BO, BR, CH, CL, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FR, GB, GH, GR, GT, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LU, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, SA, SG, SV, SY, TH, TR, TW, TZ, UG, UY, VE, YE, ZM);",
"     </li>",
"     <li>",
"      Zepanc (TW);",
"     </li>",
"     <li>",
"      Zymanta (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F153341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism is unknown, but believed to be related to its ability to enhance the activity of GABA; suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F153361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~20-40 minutes (Hanson, 1972)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Infants and young children: 6-8 hours (Hanson, 1972); Adults: &le;12 hours (Hanson, 1972)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapidly and completely absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Children: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.5-3 L/kg (Walson, 1996); Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.5-64.4 L/kg (Walson, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via glucuronide and sulfate conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children: 22-33 hours (Walson, 1996); Adults: 17-60 hours (Walson, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;2% as unchanged drug); metabolites excreted as glucuronide or sulfate conjugates",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aurora RN, Zak RS, Maganti RK, et al, &ldquo;Best Practice Guide for the Treatment of REM Sleep Behavior Disorder (RBD),&rdquo;",
"      <i>",
"       J Clin Sleep Med",
"      </i>",
"      , 2010, 6(1):85-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/20191945/pubmed\" id=\"20191945\" target=\"_blank\">",
"        20191945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barnett AM, &ldquo;Treatment of Epilepsy With Clonazepam,&rdquo;",
"      <i>",
"       S Afr Med J",
"      </i>",
"      , 1973, 47(37):1683-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/4202487/pubmed\" id=\"4202487\" target=\"_blank\">",
"        4202487",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berlin A and Dahlstrm, &ldquo;Pharmacokinetics of the Anticonvulsant Drug Clonazepam Evaluated From Single Oral and Intravenous Doses and by Repeated Oral Administration,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1975, 9(2-3):155-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/1233263/pubmed\" id=\"1233263\" target=\"_blank\">",
"        1233263",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biary N and Koller W., \"Kinetic Predominant Essential Tremor: Successful Treatment With Clonazepam,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1987, 37(3):471-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/3822141/pubmed\" id=\"3822141\" target=\"_blank\">",
"        3822141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Birnbaum CS, Cohen LS, Bailey JW, et al, \"Serum Concentrations of Antidepressants and Benzodiazepines in Nursing Infants: A Case Series,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 104(1):e11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/10390297/pubmed\" id=\"10390297\" target=\"_blank\">",
"        10390297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bladin PF, &ldquo;The Use of Clonazepam as an Anticonvulsant - Clinical Evaluation,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 1973, 1(14):683-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/4633863/pubmed\" id=\"4633863\" target=\"_blank\">",
"        4633863",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodie MJ and Dichter MA, &ldquo;Established Antiepileptic Drugs,&rdquo;",
"      <i>",
"       Seizure",
"      </i>",
"      , 1997, 6(3):159-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/9203243/pubmed\" id=\"9203243\" target=\"_blank\">",
"        9203243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN and Goa KL, &ldquo;Flumazenil. A Preliminary Review of Its Benzodiazepine Antagonist Properties, Intrinsic Activity, and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1988, 35(4):448-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/2839329/pubmed\" id=\"2839329\" target=\"_blank\">",
"        2839329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buchanan J and Zakrzewska J, &ldquo;Burning Mouth Syndrome,&rdquo;",
"      <i>",
"       Clin Evid (online)",
"      </i>",
"      , March 14, 2008. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/19450321/pubmed\" id=\"19450321\" target=\"_blank\">",
"        19450321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brodie MJ and Dichter MA, &ldquo;Established Antiepileptic Drugs,&rdquo;",
"      <i>",
"       Seizure",
"      </i>",
"      , 1997, 6(3):159-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/9203243/pubmed\" id=\"9203243\" target=\"_blank\">",
"        9203243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gremeau-Richard C, Woda A, Naves ML, et al, &ldquo;Topical Clonazepam in Stomatodynia: A Randomized Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Pain",
"      </i>",
"      , 2004, 108(1-2):51-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/15109507/pubmed\" id=\"15109507\" target=\"_blank\">",
"        15109507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grushka M, Epstein J, and Mott A, &ldquo;An Open-Label, Dose Escalation Pilot Study of the Effect of Clonazepam in Burning Mouth Syndrome,&rdquo;",
"      <i>",
"       Oral Surg Oral Med Oral Pathol Oral Radiol Endod",
"      </i>",
"      , 1998, 86(5):557-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/9830647/pubmed\" id=\"9830647\" target=\"_blank\">",
"        9830647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanson RA and Menkes JH, &ldquo;A New Anticonvulsant in the Management of Minor Motor Seizures,&rdquo;",
"      <i>",
"       Dev Med Child Neurol",
"      </i>",
"      , 1972, 14(1):3-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/4554096/pubmed\" id=\"4554096\" target=\"_blank\">",
"        4554096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&iacute;nguez Serra MP, Salort Llorca C, Silvestre Donat FJ, &ldquo;Pharmacological Treatment of Burning Mouth Syndrome: A Review and Update,&rdquo;",
"      <i>",
"       Med Oral Patol Oral Cir Bucal",
"      </i>",
"      , 2007, 12(4):E299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/17664916/pubmed\" id=\"17664916\" target=\"_blank\">",
"        17664916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sugai K, &ldquo;Seizures With Clonazepam: Discontinuation and Suggestions for Safe Discontinuation Rates in Children,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1993, 34(6):1089-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/8243361/pubmed\" id=\"8243361\" target=\"_blank\">",
"        8243361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson C, Lang A, Parkes JD, et al, \"A  Double-Blind Trial of Clonazepam in Benign Essential Tremor,\"",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1984, 7(1):83-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/6367975/pubmed\" id=\"6367975\" target=\"_blank\">",
"        6367975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walson PD and Edge JH, &ldquo;Clonazepam Disposition in Pediatric Patients,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1996, 18(1):1-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/8848810/pubmed\" id=\"8848810\" target=\"_blank\">",
"        8848810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zesiewicz TA, Elble R, Louis ED, et al, \"Practice Parameter: Therapies for Essential Tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2005, 64(12):2008-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/15972843/pubmed\" id=\"15972843\" target=\"_blank\">",
"        15972843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zesiewicz TA, Elble R, Louis ED, et al, \"Evidence-Based Guideline Update: Treatment of Essential Tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 77(19):1752-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/45/26328/abstract-text/22013182/pubmed\" id=\"22013182\" target=\"_blank\">",
"        22013182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9284 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-217.117.136.88-59DAAF2E3B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26328=[""].join("\n");
var outline_f25_45_26328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153426\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153387\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153404\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153388\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153389\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795874\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153353\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153338\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153428\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10815684\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153358\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153357\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153423\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153435\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153424\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153362\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153342\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153421\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153347\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153378\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153348\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153366\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153393\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153367\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153365\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153350\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153354\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153368\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153341\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153361\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9284\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9284|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/43/22197?source=related_link\">",
"      Clonazepam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=related_link\">",
"      Clonazepam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_45_26329="Clinical manifestations of systemic sclerosis (scleroderma) lung disease";
var content_f25_45_26329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/45/26329/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26329/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/45/26329/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26329/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26329/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/45/26329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26329/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/45/26329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of pulmonary disease is found in over 80 percent of patients with systemic sclerosis (SSc). Pulmonary involvement is second in frequency only to esophageal involvement as a visceral complication of SSc and has surpassed renal involvement as the most common cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/1\">",
"     1",
"    </a>",
"    ]. Interstitial lung disease (ILD) and pulmonary vascular disease, particularly pulmonary arterial hypertension (PAH), are the most frequent major types of lung involvement. Affected patients have a worse prognosis than patients with SSc who are free of pulmonary involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both ILD and PAH may be detected in SSc patients with no cardiopulmonary symptoms by using a combination of noninvasive tests for screening and invasive studies for confirmation. The ability to detect ILD and PAH at an early presymptomatic stage, coupled with the availability of pharmacologic interventions that may slow the progression of these complications, mandates extensive initial evaluation and periodic monitoring of patients with SSc for pulmonary involvement.",
"   </p>",
"   <p>",
"    The clinical characteristics of SSc-associated lung disease are discussed here. Issues related to evaluation, diagnosis, therapy, and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35382?source=see_link\">",
"     \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=see_link\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF PULMONARY INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main clinical manifestations of SSc lung involvement that may occur together or separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial lung disease &mdash; ILDs are a heterogeneous group of disorders caused by a wide variety of occupational and environmental exposures and connective tissue diseases, including SSc. ILDs may also be idiopathic. Among patients with SSc-associated ILD, the most common pathologic patterns are nonspecific interstitial pneumonitis (NSIP) and usual interstitial pneumonitis (UIP) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. The clinical and pathologic features of ILD are similar in patients with and without SSc. The pathologic features of the idiopathic interstitial pneumonias are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35382?source=see_link\">",
"       \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"       \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary vascular disease &mdash; Pulmonary arterial hypertension (PAH) is the most common manifestation of pulmonary vascular disease in SSc. It is pathologically indistinguishable from idiopathic (primary) pulmonary arterial hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common pulmonary manifestations in SSc include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural disease &mdash; Pleural effusions are uncommon (less than 10 percent) and usually asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aspiration pneumonitis &mdash; Gastroesophageal reflux, present in most patients with SSc, may cause recurrent aspiration of gastric contents [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Recurrent episodes of micro-aspiration may contribute to lung injury in SSc-associated ILD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link&amp;anchor=H7#H7\">",
"       \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\", section on 'Esophageal involvement'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link&amp;anchor=H37#H37\">",
"       \"Treatment of idiopathic pulmonary fibrosis\", section on 'Gastroesophageal reflux and chronic microaspiration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spontaneous pneumothorax &mdash; Spontaneous pneumothorax is a rare complication of SSc lung disease; rupture of a subpleural bleb is the suspected cause [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/10\">",
"       10",
"      </a>",
"      ]. The management of SSc-associated spontaneous pneumothorax is determined by the type and severity of lung disease. Those with little or no lung disease are probably comparable to patients with primary spontaneous pneumothorax, while patients with large subpleural blebs are similar to those with chronic obstructive pulmonary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"       \"Primary spontaneous pneumothorax in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"       \"Secondary spontaneous pneumothorax in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiectasis &mdash; Cylindrical bronchiectasis is a common finding on high resolution computed tomography (HRCT) scanning of the lungs of patients with SSc. In one study of 22 patients, bronchiectasis was present in 59 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/11\">",
"       11",
"      </a>",
"      ]. Clinically apparent bronchiectasis may increase the risk of serious infection and warrants careful evaluation when the use of immunosuppressive drugs is considered [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-associated pneumonitis &mdash; Some drugs used to treat SSc, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , may cause pneumonitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link&amp;anchor=H10#H10\">",
"       \"Approach to the adult with interstitial lung disease: Clinical evaluation\", section on 'Prior medication use and irradiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung cancer &mdash; The risk of lung cancer is increased in SSc patients with diffuse skin involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H24#H24\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Cancer risk'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERSTITIAL LUNG DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms, physical findings, and radiographic characteristics of SSc-associated ILD are similar to other types of ILD. The general diagnostic approach to the patient with ILD is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of ILD in patients with SSc varies based upon population studied and definition of ILD. Interstitial lung disease is found in most patients who have SSc by HRCT and in autopsy series. In a multi-ethnic cohort study of 203 patients with SSc, early development of ILD was associated with African-American ethnicity, higher skin score and serum CPK levels, hypothyroidism, and cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/13\">",
"     13",
"    </a>",
"    ]. Anticentromere antibodies were protective against ILD, as demonstrated previously [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early ILD is frequently asymptomatic. The most common symptoms are fatigue, breathlessness (ie, exertional dyspnea initially), and dry cough. Chest pain is infrequent and hemoptysis is rare; thus, another cause should be sought when the latter occurs.",
"   </p>",
"   <p>",
"    The most characteristic finding of ILD on physical examination is bilateral fine inspiratory crackles (ie, \"Velcro\" rales) at the lung bases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of characteristic autoantibodies supports the diagnosis of systemic sclerosis and may indicate an increased likelihood of specific clinical manifestations, such as ILD. The role and availability of specific laboratory tests in the diagnosis and management of SSc is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain SSc-related autoantibodies have been associated with an increased risk for ILD, including anti-topoisomerase I (also known as anti-Scl-70), anti-U3 ribonucleoprotein (RNP),",
"    <span class=\"nowrap\">",
"     anti-U11/U12",
"    </span>",
"    RNP,",
"    <span class=\"nowrap\">",
"     anti-Th/To,",
"    </span>",
"    and antihistone autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. However, the clinical utility of these observations is uncertain. The sensitivity of these autoantibodies for ILD is low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/2\">",
"     2",
"    </a>",
"    ]; the predictive values of these tests is unclear; and some of these autoantibodies have a low prevalence in SSc (eg,",
"    <span class=\"nowrap\">",
"     anti-U11/U12",
"    </span>",
"    RNP antibodies are only found in 3 percent of patients with SSc) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SSc-associated ILD, are frequently found to have abnormal pulmonary function tests, including those who have mild or absent respiratory symptoms and normal chest radiographs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proportional reduction of the forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) (ie, a normal",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio) suggests a restrictive defect and may be present in patients with ILD. However, early ILD cannot be excluded by normal spirometry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lung volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV) may be decreased in ILD. Patients with SSc who have a near-normal FVC at initial presentation have low risk for progression to severe ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/23\">",
"     23",
"    </a>",
"    ]. However, normal lung volumes cannot be used to exclude early ILD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diffusing capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest detectable functional correlate of lung disease in SSc is a reduction in the single breath diffusion capacity of carbon monoxide (DLCO) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/3\">",
"     3",
"    </a>",
"    ]. This is present in over 70 percent of patients. The decrease in DLCO correlates with the severity of ILD detected by HRCT, and is a predictor of poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Six-minute walk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six-minute walk test (6MWT) assesses both the distance walked (meters) and the degree of oxygen desaturation. It is used as a measure of submaximal exercise performance in a variety of pulmonary diseases (eg, idiopathic pulmonary fibrosis and pulmonary arterial hypertension). However, the value of the 6MWT is more limited in SSc, as it does not discriminate well between patients with lung involvement and those without [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/25\">",
"     25",
"    </a>",
"    ]. This may in part be due to pain from musculoskeletal and peripheral vascular involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific combinations of results with pulmonary function testing may suggest the specific type of lung involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pronounced reduction in DLCO (less than 65 percent predicted) associated with a restrictive pattern on spirometry and decreased lung volumes is strongly suggestive of ILD.",
"     </li>",
"     <li>",
"      A reduction in DLCO accompanied by relatively normal spirometry and lung volumes generally suggests pulmonary vascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased alveolar-arterial oxygen difference during exercise is a sensitive indicator of SSc lung disease, but occurs in both ILD and pulmonary vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are relatively insensitive for the detection of early ILD. The classic radiographic features of established ILD consist of symmetric, reticular opacities. These are usually most pronounced at the lung bases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51163 \" href=\"UTD.htm?21/20/21828\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     HRCT scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thin section (3 mm or less) high resolution computed tomography (HRCT) scanning of the lung has revolutionized the evaluation of ILD. This technique can demonstrate the character and distribution of fine structural abnormalities not visible on chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The HRCT patterns found in SSc-associated ILD mirror the common histopathological patterns of the idiopathic interstitial pneumonias: fibrotic NSIP, UIP, and centrilobular fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with SSc-associated ILD, the most common pathologic pattern, nonspecific interstitial pneumonia (NSIP), is associated with the HRCT finding of ground glass opacities in a peripheral distribution (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70357 \" href=\"UTD.htm?34/35/35381\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72988 \" href=\"UTD.htm?28/2/28709\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/2,30,31\">",
"       2,30,31",
"      </a>",
"      ]. The earliest HRCT change is usually a narrow, often ill-defined, subpleural crescent of increased density in the posterior segments of both lower lobes. As the disease progresses, there is volume loss associated with a reticular appearance and traction bronchiectasis. The honeycomb pattern is rarely seen with NSIP.",
"     </li>",
"     <li>",
"      In the subset of patients with a histologic UIP pattern, the HRCT appearance is usually similar to that of fibrotic NSIP. However, sometimes the HRCT pattern is more consistent with that of UIP with bibasilar reticular opacities, associated with traction bronchiectasis and the development of fine honeycomb air spaces, which ultimately coalesce into large cystic air spaces (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72569 \" href=\"UTD.htm?38/6/39008\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef74479 \" href=\"UTD.htm?1/47/1782\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/2,28,30,32\">",
"       2,28,30,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Centrilobular fibrosis is a rare pattern that is associated with patchy ground glass or consolidative opacities with a central distribution on HRCT scanning. In a series of 28 patients with SSc-ILD, six had centrilobular fibrosis on biopsy. In these patients, centrilobular fibrosis was associated with pathologic evidence of recurrent aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extent of ILD seen on HRCT is negatively correlated with forced vital capacity (FVC), and is a powerful predictor of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/30,33\">",
"     30,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to perform HRCT in the prone as well as supine positions, particularly in patients with subtle findings. This will help eliminate radiographic changes resulting from gravity-induced changes in dependent areas of the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While thoracoscopically guided lung biopsy is seldom warranted in SSc, it may be indicated in the evaluation of patients with lung findings suggestive of other disease processes. This includes patients with HRCT findings inconsistent with SSc-associated lung disease, those in whom granulomatous disease is suspected, and to exclude pulmonary infection, particularly in patients receiving immunosuppressive drugs. Since SSc-associated ILD is predominately subpleural, significant histological changes are more likely to be found in peripheral lung biopsy than from tissue sampling of other locations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequently noted histopathologic finding on lung biopsy in SSc is fibrotic nonspecific interstitial pneumonitis (NSIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/4,24,32,34,35\">",
"     4,24,32,34,35",
"    </a>",
"    ]. Intimal thickening of pulmonary arteries and resulting luminal narrowing is often found in postmortem lung specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=see_link\">",
"     \"Nonspecific interstitial pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SSc-associated ILD typically have elevated numbers of granulocytes in their bronchoalveolar lavage (BAL) fluid, particularly neutrophils and eosinophils, and may sometimes have an increase in lymphocytes and mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. However, the clinical significance of these findings is controversial. BAL still has a role in the evaluation of lung infection in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some centers have used BAL in SSc-associated ILD to assess the degree of alveolitis and predict the response to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/30,38-40\">",
"     30,38-40",
"    </a>",
"    ]. However, the results from a multicenter clinical trial argue against the routine use of BAL to identify active or progressive ILD (ie, alveolitis). In this trial of 158 patients with early SSc-associated ILD, there was no difference in the change in FVC after 12 months when patients with BAL-defined alveolitis were compared to patients who had a normal BAL [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of certain inflammatory cells in BAL has been associated with different radiographic stages of SSc-associated ILD; however, the clinical utility of these observations is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excess lymphocytes may be present despite a normal HRCT appearance.",
"     </li>",
"     <li>",
"      Excess eosinophils are associated with early, less extensive disease.",
"     </li>",
"     <li>",
"      Neutrophils are associated with more extensive disease, possibly due to the presence of bronchiectasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radionuclide clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clearance rate of inhaled radionuclide from the lungs is dependent upon the integrity of the epithelial barrier. Any disorder that disrupts the barrier will result in an increased clearance rate.",
"   </p>",
"   <p>",
"    Radionuclide scanning of the lung using technetium labeled diethylenetriamine pentaacetate (DTPA) is an investigational test that may identify SSc patients with early lung disease and predict the clinical course; it is not available for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/43\">",
"     43",
"    </a>",
"    ]. DTPA clearance may be increased in early SSc, at a time when the chest radiograph and pulmonary function tests are still normal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/29\">",
"     29",
"    </a>",
"    ]. Furthermore, DTPA clearance rate and change in clearance can predict subsequent pulmonary function test abnormalities. DTPA clearance can be affected by cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Investigational assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The levels of KL-6, a glycoprotein found predominantly on type II pneumocytes and alveolar macrophages, are elevated in the serum of patients with SSc-associated ILD and may correlate with the presence of pneumonitis and the radiological fibrosis score in patients with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Serial measurements of serum KL-6 may eventually find a role in the diagnosis and monitoring of ILD in SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar prognostic roles have been proposed for surfactant proteins A and D, which also are elevated in the serum of most patients with SSc-associated lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], and for CCL18, a chemokine that is abundantly expressed by pulmonary macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic factors influence susceptibility to ILD in patients with SSc. As an example, one study found an association between SSc-associated pulmonary fibrosis and the presence of HLA-B*62 and HLA-Cw*0602, whereas PAH was associated with HLA-B*13 and HLA-B*65 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PULMONARY ARTERIAL HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary arterial hypertension (PAH) is a progressive and potentially fatal complication of SSc. It can occur by itself (isolated PAH) or in combination with ILD. PAH is defined as a mean pulmonary artery pressure &gt;25 mmHg at rest or &gt;30 mmHg during exercise as determined by right heart catheterization. In one study, patients with limited cutaneous involvement (lcSSc), mild to moderate PAH, and older age at diagnosis were at an increased risk of developing severe PAH when compared to those with diffuse disease (dcSSc), no echocardiographic PAH, and a younger age of disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of PAH in SSc varies from 7 to 50 percent in different reports, depending upon the methods used for detection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/53-58\">",
"     53-58",
"    </a>",
"    ]. Cardiac catheterization consistently yields lower frequencies than echocardiography, pulmonary function testing, or clinical assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/59\">",
"     59",
"    </a>",
"    ]. In one of the largest studies, 89 of 722 patients with SSc were found to have PAH as measured by right heart catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAH may occur as an isolated pulmonary complication of SSC, or can coexist with and be aggravated by ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/54,58\">",
"     54,58",
"    </a>",
"    ]. It may also be associated with the CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAH remains subclinical until progressive vascular damage results in exertional dyspnea. In a group of 89 patients with SSc who had symptoms (dyspnea, fatigue, or both) but no known PAH, the prevalence of PAH (an estimated systolic pulmonary artery pressure of&gt;35 mmHg by Doppler echocardiography) was 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea on exertion is the most common initial symptom, but early PAH is asymptomatic. Patients with advanced PAH may have chest pain due to right ventricular angina, and near-syncope or syncope on exertion due to reduced cardiac reserve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, advanced PAH may be associated with a prominent A-wave in the jugular venous pulse, a loud pulmonic component of S2, and a right ventricular S4. A murmur of tricuspid regurgitation is common and may be accompanied by a palpable right ventricular lift (ie, heave)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a pulmonary arterial \"tap\". Peripheral edema may be notable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographically, PAH is characterized by an enlarged pulmonary artery and attenuation of the smaller pulmonary vessels (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59416 \" href=\"UTD.htm?24/63/25588\">",
"     image 4",
"    </a>",
"    ). Among patients with SSc-associated ILD, pericardial abnormalities (eg, effusion, thickening) on HRCT may indicate coexisting PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of PAH may be suspected if pulmonary function tests show a significant decrease in DLCO (less than 65 percent of predicted) in the absence of significant spirometry or lung volume abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler echocardiography is most commonly used to screen patients with SSc for the presence of PAH. It generally permits estimation of pulmonary artery pressures when tricuspid regurgitation is present [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The sensitivity and specificity of echocardiography as a screening test are affected by the threshold pressure gradient chosen to separate normal from abnormally elevated pressure. In a prospective study of 137 patients with SSc who underwent cardiac catheterization within three months of noninvasive testing, PAH (defined as a mean pulmonary artery pressure of &ge;30 mmHg), was present in 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/65\">",
"     65",
"    </a>",
"    ]. An estimated echocardiographic tricuspid gradient of &ge;45 mmHg identified PAH with a 47 percent sensitivity, and a 97 percent specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Right heart catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right heart catheterization is the gold standard for identification and evaluation of PAH. While Doppler echocardiography provides an estimate of pulmonary artery pressure, it cannot be relied upon to exclude PAH in high-risk patients because of its limited sensitivity and technical limitations. In addition, the pulmonary artery pressure cannot be estimated in patients who do not have a detectable tricuspid regurgitant jet on Doppler echocardiography. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Echocardiography'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cold challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold-induced vasoconstriction does not appear to significantly contribute to further worsening of established PAH. This was demonstrated in a study of 21 SSc patients with PAH whose hemodynamic responses to ice water immersion of one hand and to a rapid infusion of cold saline during right heart catheterization were measured [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/66\">",
"     66",
"    </a>",
"    ]. No significant change in pulmonary artery pressure was noted following either challenge, arguing against a role for a pulmonary \"Raynaud phenomenon\" in further elevating pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory testing is of no value in detecting SSc-associated PAH. The presence of anticentromere antibodies, which are strongly associated with lcSSc, are not independently predictive value of PAH. The prevalence of elevated levels of antiphospholipid antibodies (aPL) is greater in SSc patients with PAH than in those with normal pulmonary arterial pressures (44 versus 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/67\">",
"     67",
"    </a>",
"    ]. However, an increased prevalence of aPL antibodies has also been noted in patients with non-SSc-associated PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Investigational assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A promising approach to screening for PAH in SSc is measurement of serum levels of brain natriuretic peptide (BNP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    N-terminal pro-brain natriuretic peptide (NT-proBNP). In one study, elevated NT-proBNP levels in SSc patients had a sensitivity and specificity of 90 percent for the presence of PAH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/69\">",
"     69",
"    </a>",
"    ]. This has been confirmed by several studies that have also demonstrated correlation between NT-proBNP levels and tricuspid gradient, mean pulmonary arterial pressure, pulmonary vascular resistance, and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26329/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement occurs in most patients with SSc. The most common forms of pulmonary involvement, interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), can occur in isolation, or they can coexist. Other less common pulmonary complications include pleural effusions, aspiration pneumonia, spontaneous pneumothorax, bronchiectasis, hemoptysis, drug-induced pneumonitis, and lung cancer. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Types of pulmonary involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Manifestations of ILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory symptoms such as cough and exertional dyspnea may not be present until lung damage is irreversible. HRCT performed in both supine and prone positions may reveal ground glass opacities suggestive of alveolar wall inflammation and reticular densities suggestive of fibrotic lung disease even when plain chest radiographs are normal. Reduced lung volumes are a hallmark of ILD and may be detected prior to the appearance of respiratory symptoms. Both ILD and PAH can cause a decreased DLCO. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Interstitial lung disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Manifestations of PAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exertional symptoms such as dyspnea, chest pain, presyncope or syncope may indicate the presence of elevated pulmonary arterial pressures. Physical examination may reveal signs of right ventricular strain and plain radiographs may show an increased size of pulmonary arteries or prominence of the right ventricle. A decrease in DLCO that is out of proportion to the decrease in vital capacity or total lung capacity is suggestive of PAH, particularly if there is little or no radiographic evidence of ILD. Right ventricular systolic pressure can be estimated by Doppler echocardiography if some degree of tricuspid regurgitation is present. While Doppler echocardiography is useful as a screening tool for PAH in patients with SSc, accurate diagnosis and evaluation of PAH requires right-sided cardiac catheterization. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Pulmonary arterial hypertension'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/1\">",
"      Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/2\">",
"      Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008; 134:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/3\">",
"      Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/4\">",
"      Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/5\">",
"      Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol 1998; 37:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/6\">",
"      Highland KB, Heffner JE. Pleural effusion in interstitial lung disease. Curr Opin Pulm Med 2004; 10:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/7\">",
"      Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989; 149:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/8\">",
"      Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/9\">",
"      Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/10\">",
"      Zeuner M, M&uuml;ller-Ladner U, Mohr VD, Lang B. Spontaneous pneumothorax in a patient with systemic sclerosis. Clin Rheumatol 1996; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/11\">",
"      Andonopoulos AP, Yarmenitis S, Georgiou P, et al. Bronchiectasis in systemic sclerosis. A study using high resolution computed tomography. Clin Exp Rheumatol 2001; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/12\">",
"      Lavie F, Rozenberg S, Coutaux A, et al. Bronchiectasis in a patient with CREST syndrome. Joint Bone Spine 2002; 69:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/13\">",
"      McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/14\">",
"      Kane GC, Varga J, Conant EF, et al. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 1996; 90:223.",
"     </a>",
"    </li>",
"    <li>",
"     Alton, E, Turner-Warwick, M. Lung involvement in scleroderma. In: Systemic Sclerosis (Scleroderma), Black, CM, Jayson, MIV (Eds), Wiley, Chichester 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/16\">",
"      Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/17\">",
"      Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/18\">",
"      Sacks DG, Okano Y, Steen VD, et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 1996; 23:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/19\">",
"      Wallace DJ, Lin HC, Shen GQ, Peter JB. Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum 1994; 37:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/20\">",
"      Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/21\">",
"      Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/22\">",
"      Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/23\">",
"      Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/24\">",
"      Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/25\">",
"      Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009; 36:330.",
"     </a>",
"    </li>",
"    <li>",
"     Steen, VD. Systemic sclerosis. In: The Lung in Rheumatic Diseases, , G, Zimmerman, G (Eds), Marcel Dekker, New York 1990. p.279.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/27\">",
"      Schwaiblmair M, Behr J, Fruhmann G. Cardiorespiratory responses to incremental exercise in patients with systemic sclerosis. Chest 1996; 110:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/28\">",
"      Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/29\">",
"      Harrison NK, Glanville AR, Strickland B, et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989; 83:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/30\">",
"      Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/31\">",
"      de Souza RB, Borges CT, Capelozzi VL, et al. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration 2009; 77:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/32\">",
"      Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002; 22 Spec No:S151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/33\">",
"      Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/34\">",
"      Nakamura Y, Chida K, Suda T, et al. Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/35\">",
"      Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/36\">",
"      al-Sabbagh MR, Steen VD, Zee BC, et al. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 1989; 16:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/37\">",
"      Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum 2010; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/38\">",
"      Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990; 141:S169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/39\">",
"      Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/40\">",
"      Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/41\">",
"      Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/42\">",
"      Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994; 150:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/43\">",
"      Wells AU, Hansell DM, Harrison NK, et al. Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J 1993; 6:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/44\">",
"      Mason GR, Uszler JM, Effros RM, Reid E. Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking. Chest 1983; 83:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/45\">",
"      Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995; 108:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/46\">",
"      Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009; 36:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/47\">",
"      Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/48\">",
"      Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000; 162:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/49\">",
"      Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/50\">",
"      Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005; 52:2889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/51\">",
"      Gladman DD, Kung TN, Siannis F, et al. HLA markers for susceptibility and expression in scleroderma. J Rheumatol 2005; 32:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/52\">",
"      Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/53\">",
"      Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/54\">",
"      Schachna L, Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/55\">",
"      Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003; 29:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/56\">",
"      Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/57\">",
"      Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/58\">",
"      Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum 2005; 52:3698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/59\">",
"      Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/60\">",
"      Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977; 86:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/61\">",
"      Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/62\">",
"      Pope JE, Lee P, Baron M, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/63\">",
"      Fischer A, Misumi S, Curran-Everett D, et al. Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease. Chest 2007; 131:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/64\">",
"      Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/65\">",
"      Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/66\">",
"      Mukerjee D, Yap LB, Ong V, et al. The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 2004; 63:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/67\">",
"      Assous N, Allanore Y, Batteux F, et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 2005; 23:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/68\">",
"      Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996; 23:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/69\">",
"      Allanore Y, Borderie D, Meune C, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003; 48:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/70\">",
"      Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/71\">",
"      Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26329/abstract/72\">",
"      Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27:1485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4368 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26329=[""].join("\n");
var outline_f25_45_26329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF PULMONARY INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERSTITIAL LUNG DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lung volumes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diffusing capacity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Six-minute walk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - HRCT scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radionuclide clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Investigational assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PULMONARY ARTERIAL HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Right heart catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cold challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Investigational assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Manifestations of ILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Manifestations of PAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4368|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/20/21828\" title=\"diagnostic image 1\">",
"      Scleroderma lung disease PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/35/35381\" title=\"diagnostic image 2\">",
"      HRCT ground glass in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/6/39008\" title=\"diagnostic image 3\">",
"      HRCT reticular pattern in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/63/25588\" title=\"diagnostic image 4\">",
"      CXR pulmonary hypertension in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4368|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/2/28709\" title=\"picture 1\">",
"      Cellular infiltrate in SD lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/47/1782\" title=\"picture 2\">",
"      Lung biopsy in scleroderma ILD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35382?source=related_link\">",
"      Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_45_26330="Initial treatment of advanced stage diffuse large B cell lymphoma";
var content_f25_45_26330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of advanced stage diffuse large B cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/45/26330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26330/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26330/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/45/26330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26330/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/45/26330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/45/26330/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/45/26330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H735717\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30 percent of patients with NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is an aggressive NHL in which survival without treatment is measured in months (",
"    <a class=\"graphic graphic_table graphicRef59978 \" href=\"UTD.htm?41/26/42412\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of DLBCL is dependent upon the extent of disease. For patients with NHL, disease stage is determined using the Ann Arbor staging system with Cotswold modification, originally developed for Hodgkin lymphoma. This staging system focuses on the number of tumor sites (nodal and extranodal), location, and the presence or absence of systemic (\"B\") symptoms (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 2",
"    </a>",
"    ). For treatment purposes, patients with DLBCL are generally classified as having either limited stage disease or advanced stage disease based upon whether or not the tumor can be contained within one irradiation field:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited stage disease (usually Ann Arbor stage I or II) &mdash; Limited stage DLBCL can be contained within one irradiation field. This population accounts for 30 to 40 percent of patients with DLBCL. Limited stage DLBCL is treated primarily with combined modality therapy consisting of abbreviated systemic chemotherapy (three cycles), the recombinant anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , and involved field radiation therapy. Alternatively, full course (six to eight cycles) systemic chemotherapy plus rituximab without radiation therapy may be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link\">",
"       \"Initial treatment of limited stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advanced stage disease (usually Ann Arbor stage III or IV) &mdash; Advanced stage DLBCL cannot be contained within one irradiation field. This population accounts for 60 to 70 percent of patients with DLBCL. Advanced stage DLBCL is treated primarily with systemic chemotherapy plus the recombinant anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with bulky (&gt;10 cm) stage II disease and patients with stage IIB disease have a less favorable prognosis than those with non-bulky stage II disease without systemic B symptoms. Many clinicians treat such patients in a similar fashion to those with advanced stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link&amp;anchor=H1565172628#H1565172628\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\", section on 'Bulky disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of adults with advanced stage DLBCL is discussed here; diagnosis, staging, prognostic measures, and the treatment of limited stage DLBCL and relapsed disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oncologic emergencies and treatment-related hematologic toxicities are common in the aggressive NHLs. Clinicians must always be alert to their potential presence, and be prepared to deal with them urgently and effectively. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Oncologic emergencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best treat patients with NHL, the initial evaluation must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. General approaches to the diagnostic work-up and staging of non-Hodgkin lymphoma are presented separately (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with DLBCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), hepatitis B, and uric acid. All patients with DLBCL should be encouraged to undergo serologic testing for HIV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy is recommended for all patients.",
"     </li>",
"     <li>",
"      Lumbar puncture is recommended for all patients with testicular, epidural, or sinus involvement. In addition, lumbar puncture could be considered for patients with breast, ovarian or concordant bone marrow involvement, a high International Prognostic Index (IPI) (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 3",
"      </a>",
"      ), or numerous extranodal sites of disease. If lumbar puncture is performed, cerebrospinal fluid should be sent for both cytology and flow cytometry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link&amp;anchor=H1565171727#H1565171727\">",
"       \"Initial treatment of limited stage diffuse large B cell lymphoma\", section on 'CNS involvement'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed for most patients. This evaluation may not be necessary in young patients without a history of cardiac disease who plan to undergo abbreviated anthracycline-based chemotherapy (ie, three cycles of R-CHOP).",
"     </li>",
"     <li>",
"      Men and women with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Given the urgent need for treatment with DLBCL, options for women are limited, but men can often participate in sperm banking. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis should be performed. This study provides critical information on the measurement of disease prior to treatment and aids in staging [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/5\">",
"       5",
"      </a>",
"      ]. When available, we suggest obtaining a combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scan as a measure of disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/6\">",
"       6",
"      </a>",
"      ]. DLBCL is considered a typically FDG-avid tumor such that involved areas should show activity on PET scan. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced stage DLBCL is that which cannot be contained within one irradiation field (usually Ann Arbor stage III or IV disease). This population accounts for 60 to 70 percent of patients with DLBCL.",
"   </p>",
"   <p>",
"    Advanced stage DLBCL is treated primarily with systemic chemotherapy plus the recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . The general treatment principles for advanced stage DLBCL apply to most disease presentations and patient populations. However, involvement of certain organs, particularly when occurring as primary sites of disease, has unique therapeutic implications. In addition, older adults and patients with cardiac disease or HIV infection require special consideration. In addition, there are some special scenarios (eg, testicular lymphoma) in which central nervous system prophylaxis is required. CNS prophylaxis may include high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or intrathecal methotrexate. These are discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H1554322491\">",
"     'Special scenarios'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link&amp;anchor=H1565171255#H1565171255\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\", section on 'Special scenarios'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rituximab containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival without treatment in patients with aggressive NHL, such as DLBCL, can be measured in months. With the advent of combination chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CHOP) or CHOP-like regimens, disease-free survival rates of 35 to 45 percent at four years have been realized&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/7\">",
"     7",
"    </a>",
"    ]. Survival has been further improved with the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to standard CHOP-based therapy (R-CHOP) (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to CHOP-based therapy results in an approximately 10 to 15 percent overall increase in survival beginning at one year from initiation of therapy in patients of all ages with almost no increase in toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Rituximab therapy does impose a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is an overview of the largest prospective, randomized trials that evaluated the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to CHOP-based therapy in previously untreated patients with DLBCL. Different CHOP regimens with and without rituximab have been evaluated, although practically all administered CHOP every 21 days (CHOP-21). These trials have consistently found increased survival with the addition of rituximab. The choice of the optimal CHOP regimen that is combined with rituximab is discussed in the next section. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Choice of chemotherapy regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In three randomized prospective studies consisting of approximately 2000 older patients (&gt;65 years of age) with advanced stage DLBCL, therapy with R-CHOP resulted in significantly higher overall survival at three (approximately 70 versus 57 percent for CHOP alone), five (58 versus 45 percent), and 10 (44 versus 28 percent) years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/11-16\">",
"       11-16",
"      </a>",
"      ]. There was no difference in the rates of severe or serious side effects after CHOP with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In the MabThera International (MInT) Trial, 824 patients younger than 60 years with DLBCL (28 percent stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      and 48 percent with bulky disease) were randomly assigned to treatment with six cycles of CHOP-like chemotherapy administered every 21 days with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/17\">",
"       17",
"      </a>",
"      ]. Bulky and extranodal sites received additional radiotherapy. After a median follow-up of 34 months, patients assigned to R-CHOP had significantly higher rates of three-year event-free (79 versus 59 percent) and overall (93 versus 84 percent) survival. The significant event-free (74 versus 56 percent) survival and overall survival (90 versus 80 percent) benefit was maintained at six years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these studies, it is clear that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -containing CHOP or CHOP-like regimens provide superior survival to the same regimen without rituximab, regardless of the patient's age. As such, for all patients with DLBCL, we recommend the administration of rituximab in addition to conventional chemotherapy rather than chemotherapy alone.",
"   </p>",
"   <p>",
"    In addition to stage of disease, survival with CHOP-based therapy varies with the presence or absence of certain clinical features. The International Prognostic Index (IPI) provides information on patient outcomes with CHOP-based therapy based upon the patient's age, performance status, stage, number of extranodal sites, and LDH level (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 3",
"    </a>",
"    ). For patients treated with R-CHOP, the original IPI classifies patients into four risk categories with three-year overall survival rates of 91, 81, 65, and 59 percent for patients with IPI scores of 0 to 1, 2, 3, or 4 to 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/19\">",
"     19",
"    </a>",
"    ]. A revised International Prognostic Index has also been developed specifically for patients treated with R-CHOP, and appears to be a better predictor of outcome in patients treated with R-CHOP than the standard IPI (",
"    <a class=\"graphic graphic_table graphicRef64554 \" href=\"UTD.htm?0/32/524\">",
"     table 5",
"    </a>",
"    ). Using this revised IPI, four-year overall survival rates for the very good (IPI score of zero), good (score of 1 or 2), and poor (score of 3 or more) risk groups are 94, 79, and 55 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H17219031#H17219031\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'Use of IPI for patients receiving rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice of chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the advent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    containing regimens, CHOP was compared with many other anthracycline-based regimens in prospective, randomized trials. These regimens offered no improvement in remission rate, disease-free survival, or overall survival and were associated with increased toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/7,20-24\">",
"     7,20-24",
"    </a>",
"    ]. Thus, CHOP has been the preferred chemotherapeutic regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11298459\">",
"    <span class=\"h3\">",
"     R-CHOP-21 versus R-CHOP-14",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different CHOP regimens have been evaluated in trials and used in clinical practice. The principal variation among these regimens is the schedule of administration. The most commonly administered regimen has been CHOP-21 (given every 21 days).",
"   </p>",
"   <p>",
"    In an attempt to improve on the results seen with CHOP-21, trials have investigated the use of more dose intense chemotherapy in DLBCL. In such trials, the same total dose of chemotherapy is given over a shorter period of time with growth factor support. The most popular of these more intense regimens is CHOP-14, which is given every 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A paucity of data exists concerning the relative efficacy of CHOP-14 and CHOP-21 with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Conflicting results have been reported in randomized trials performed in the pre-rituximab era that compared CHOP-14 with CHOP-21. One showed a survival benefit with CHOP-14 while others found no difference in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. These trials differed in their patient populations showing improved overall survival in older adults but not in patients with intermediate risk DLBCL.",
"   </p>",
"   <p>",
"    Prospective trials have attempted to compare a dose intense CHOP-like regimen plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to the same regimen given every 21 days plus rituximab.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial used CEOP, a regimen that substitutes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (which are similar anthracyclines). While some clinicians consider CEOP to have equivalent efficacy to CHOP, this equivalency has not been proven. In this report of 217 patients with aggressive lymphoma there was no significant difference between R-CEOP-14 and R-CEOP-21 in terms of complete and overall response rates or overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second trial, reported in abstract form only, randomly assigned patients to treatment with eight cycles of R-CHOP-21 or six cycles of R-CHOP-14 followed by two additional doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/30\">",
"       30",
"      </a>",
"      ]. At a median follow-up of 37 months, there has been no significant difference in overall or failure-free survival rates between the two treatment groups.",
"     </li>",
"     <li>",
"      An interim analysis of another randomized trial of eight cycles of R-CHOP-14 versus eight cycles of R-CHOP-21 in 202 older adults with DLBCL reported similar rates of complete response, event-free survival, and overall survival with the two treatment regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CHOP-14 does not appear to be superior to CHOP-21 when given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and is associated with increased toxicity including an increased risk of pneumocystic jirovecii pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/32\">",
"     32",
"    </a>",
"    ]. For most patients with advanced stage DLBCL, we recommend the use of R-CHOP-21 rather than R-CHOP-14. This is primarily due to our longer clinical experience with this regimen (as described in the previous section), decreased need for growth factor support, and a lack of data showing superiority of one regimen over another in the rituximab era.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11298474\">",
"    <span class=\"h3\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, prior to the advent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -containing regimens, CHOP was compared with many other anthracycline-based regimens in prospective, randomized trials. These regimens offered no improvement in remission rate, disease-free survival, or overall survival and were associated with increased toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/7,20-24\">",
"     7,20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A more intensive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      -based regimen (R-ACVBP) has demonstrated superior disease-free and overall survival to R-CHOP in a single prospective randomized trial when used for a highly select group of young patients with DLBCL [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/33\">",
"       33",
"      </a>",
"      ]. This trial randomly assigned 379 patients (&lt;60 years) with newly diagnosed DLBCL and an age-adjusted IPI of one to either four cycles of R-ACVBP (rituximab,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31123?source=see_link\">",
"       vindesine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , followed by consolidation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      ) or eight cycles of R-CHOP-21. When compared with R-CHOP-21, R-ACVBP resulted in a similar complete remission rate (83 versus 80 percent), and superior three-year event-free (81 versus 67 percent) and overall survival (92 versus 84 percent) rates. R-ACVBP was associated with more hematologic and non-hematologic toxicity.",
"      <br/>",
"      <br/>",
"      Of importance, this regimen incorporates vindesine, an agent that is not available in the US. Until larger randomized trials confirm a benefit from R-ACVBP, we continue to use R-CHOP-21 for most patients with DLBCL. Additional studies are investigating the use of regimens used for the treatment of relapsed or refractory DLBCL (eg, R-EPOCH) for the treatment or newly diagnosed disease.",
"     </li>",
"     <li>",
"      A single arm phase II trial evaluated the use of R-CHOP plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      in 40 patients with previously untreated DLBCL [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/34\">",
"       34",
"      </a>",
"      ]. A partial or better response was seen in 88 percent with 75 percent achieving a complete response (CR) or CR, unconfirmed. At a median follow-up of 51 months, two-year rates of progression-free and overall survival were 64 and 70 percent, respectively. The addition of bortezomib was associated with higher than usual rates of peripheral neuropathy. Of interest, there was no survival difference observed between patients with germinal center B cell like (GCB) or activated B cell like (ABC) gene expression profiles (GEP) suggesting that the inferior outcomes normally seen in patients with ABC DLBCL may be abrogated with the addition of bortezomib.",
"      <br/>",
"      <br/>",
"      As our understanding about different variants of DLBCL increases, we will likely develop specific regimens that target pathways that are abnormal in specific variants. As yet, it is premature to alter treatment based upon the results of GEP analyses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Number of treatment cycles",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    era, the number of treatment cycles of CHOP given to patients with advanced disease has varied over the years from 6 to 12. In current practice, the number of treatment cycles given varies based upon whether the clinician chooses to administer a defined number of cycles independent of response (eg, administer six to eight cycles) or uses a response-based evaluation to determine the number of treatment cycles (eg, administer two cycles after the attainment of a complete response).",
"   </p>",
"   <p>",
"    Of the two options, we use a defined number of treatment cycles of chemotherapy. This is principally because the largest clinical trials that have investigated the use of chemotherapy for advanced DLBCL with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    have used this approach. The response-based evaluation relies upon an interim response as determined by computed tomography (CT) or combined positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT",
"    </span>",
"    imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal defined number of treatment cycles is unclear. No study has directly evaluated the appropriate number of treatment cycles with R-CHOP-21. However, one prospective, randomized trial has directly addressed this question with CHOP-14. The RICOVER-60 trial compared six and eight cycles of CHOP-14, each with and without the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in 1222 patients ages 61 to 80 years with aggressive NHL (80 percent DLBCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/14\">",
"     14",
"    </a>",
"    ]. Survival at three years was the same for those administered six versus eight cycles of R-CHOP-14 (78 and 73 percent).",
"   </p>",
"   <p>",
"    The majority of trials investigating R-CHOP-21 therapy for advanced DLBCL have evaluated eight cycles of R-CHOP-21. The R-CHOP-14 trial described above clearly suggests no benefit of eight cycles over six cycles; whether this can be extrapolated to R-CHOP-21 is not known. Thus, we believe that administration of either six or eight cycles of R-CHOP-21 is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H326784770\">",
"    <span class=\"h2\">",
"     Is there a role for maintenance rituximab?",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the monoclonal anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is a key component to the treatment of DLBCL. Numerous trials have demonstrated improved survival when rituximab therapy is added to standard chemotherapy. While maintenance rituximab has been incorporated into the treatment of other subtypes of lymphoma, maintenance therapy with rituximab does not appear to improve survival among patients who have completed initial therapy with R-CHOP. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Rituximab containing regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The potential role for maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was assessed in a trial of 632 older adults randomly assigned to R-CHOP or CHOP therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/13\">",
"     13",
"    </a>",
"    ]. The 415 patients who attained a complete response were randomly assigned to maintenance rituximab or observation. As in other studies, R-CHOP resulted in a significantly higher failure-free survival rate at three years (53 versus 46 percent) when compared with CHOP. However, maintenance rituximab did not improve failure-free survival rates among patients initially treated with R-CHOP. Survival benefits from rituximab maintenance were initially observed in those treated with CHOP alone followed by maintenance therapy with rituximab alone. However, the overall survival benefit disappeared with longer follow-up suggesting that, unlike induction combination with chemotherapy, rituximab maintenance delays progression but does not increase the cure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Is there a role for transplant?",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose chemotherapy followed by autologous hematopoietic cell rescue (autologous hematopoietic cell transplantation, HCT) is not currently used in the initial treatment of DLBCL. This is principally because HCT is associated with significant morbidity and survival is the same in patients administered chemotherapy with or without HCT. This was best shown in a 2008 meta-analysis that included data from 15 randomized controlled trials with a total of 3079 patients treated for aggressive NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/38\">",
"     38",
"    </a>",
"    ]. Treatment-related mortality, event-free survival, and overall survival were the same whether patients were treated with conventional chemotherapy or high-dose chemotherapy followed by autologous HCT.",
"   </p>",
"   <p>",
"    It is unknown whether patients with high-risk disease may benefit from more intensive therapy at diagnosis. Randomized trials suggest that, even in high-risk disease, HCT at the time of relapse results in similar survival rates when compared with HCT in first complete remission:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intergroup trial (S9704) enrolled 397 patients with high intermediate and high risk IPI scores according to age-adjusted index and randomized treatment to six cycles of CHOP-based therapy (CHOP or R-CHOP) followed by autologous HCT versus eight cycles of CHOP-based therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/39\">",
"       39",
"      </a>",
"      ]. Initial results, available in abstract form only, demonstrated that the addition of autologous HCT resulted in a significantly higher rate of progression-free survival at two years (69 versus 56 percent) but no difference in overall survival at two years (74 versus 71 percent).",
"     </li>",
"     <li>",
"      First-line autologous HCT showed no benefit over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      -based aggressive conventional chemotherapy (CHOP plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      every two weeks) in a similarly designed trial conducted by the German High&ndash;Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial, 162 patients with aggressive B cell lymphoma and a high intermediate or high risk age adjusted IPI score were randomly assigned to R-CHOEP-14 or to dose-escalated sequential high dose therapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-MegaCHOEP) with serial autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/41\">",
"       41",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic and non-hematologic toxicities were more common following R-MegaCHOEP. At a median follow-up of 42 months, when compared with R-MegaCHOEP, R-CHOEP-14 resulted in similar estimated three-year event-free survival (70 versus 61 percent) and overall survival (74 versus 70 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Autologous HCT is still considered for the treatment of relapsed disease and its use in this setting is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'High dose chemotherapy and transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Our approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with advanced DLBCL, we administer six or eight cycles of R-CHOP-21 (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 4",
"    </a>",
"    ). This approach has been associated with two- and five-year overall survival rates of approximately 70 and 60 percent, respectively.",
"   </p>",
"   <p>",
"    Patients who have advanced stage disease are at high risk for developing tumor lysis syndrome with the initiation of treatment. The diagnosis, prevention, and treatment of tumor lysis syndrome are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small percentage of patients receiving their first infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    will have severe infusion-related hypersensitivity reactions. It is standard practice to premedicate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (625 mg orally) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg orally) before each infusion or at the time of the reaction; this practice attenuates but does not prevent these events. We often also give an H2 blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    , 60 minutes prior to the rituximab infusion. With this practice, we rarely see reactions. This complication is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    therapy carries a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    R-CHOP-21 chemotherapy is highly emetogenic and prophylactic antiemetic therapy is indicated. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link&amp;anchor=H127218108#H127218108\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'Regimens with a high risk of delayed emesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1554322491\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general treatment principles for limited and advanced stage DLBCL apply to most disease presentations and patient populations. However, involvement of certain organs, particularly when occurring as primary sites of disease, has unique therapeutic implications. In addition, older adults and patients with cardiac disease or HIV infection require special consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H326785256\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often have concerns over the ability of older adults (ie, over age 60 years) to tolerate intensive chemotherapy and radiation therapy. The management of lymphoma in older adults can be complicated by an increased number of comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/42\">",
"     42",
"    </a>",
"    ]. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the elderly patient, thus permitting the formulation of an appropriate, individualized treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Special considerations for the use of chemotherapy in the elderly population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that most older adults should be initially treated with the same dosing and schedule as younger adults with adjustments made to future cycles according to tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/43,46-48\">",
"     43,46-48",
"    </a>",
"    ]. This is principally because the amount of chemotherapy administered in the initial treatment of DLBCL affects overall survival. However, this observation is confounded by the presence of comorbidities that limit the administration of anthracyclines and may independently adversely affect survival. Nevertheless, in a potentially curable disease such as DLBCL, it is especially important to treat all patients aggressively, even older individuals.",
"   </p>",
"   <p>",
"    The importance of avoiding dose reduction was highlighted in two retrospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective analysis, 115 patients with diffuse large cell lymphoma were treated with anthracycline-based regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/49\">",
"       49",
"      </a>",
"      ]. The amount of drug administered during the first 12 weeks of therapy affected overall survival. The single most important predictor of survival was the administration of at least 75 percent of the recommended dose of adriamycin given in CHOP over the first 12 weeks.",
"     </li>",
"     <li>",
"      A second retrospective review of 210 patients with DLBCL treated with CHOP-21 reported median survivals for patients who received &gt;90 percent, 85 to 90 percent, and &lt;85 percent of scheduled anthracycline of approximately 7, 3, and 1.7 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is a paucity of data regarding the treatment of the very elderly (ie, &gt;80 years old) adult with DLBCL. Initial reports suggest that a subset of these patients may be cured with less intensive chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. It is possible that the addition of rituximab in this setting offsets the potential negative effect of chemotherapy dose reduction, thereby providing acceptable efficacy and decreased toxicity. A multicenter phase II study evaluated six cycles of a reduced dosage CHOP regimen plus rituximab (R-mini-CHOP) in 150 patients age 80 years or older with DLBCL (75 percent stage III or IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/51\">",
"     51",
"    </a>",
"    ]. In this regimen, lower doses were planned for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (400",
"    <span class=\"nowrap\">",
"     mg/m2),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m2),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (1 mg), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    administered every 21 days for six cycles. Rituximab was given at standard dose (375",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    every 21 days. Hematological toxicity was the most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    side effect with neutropenia and thrombocytopenia rates of 39 and 7 percent, respectively.&nbsp;Eleven patients (7 percent) experienced at least one episode of febrile neutropenia. There were 12 deaths related to toxicity. The overall response rate was 74 percent (63 percent complete or unconfirmed complete). At a median follow-up of 20 months, the rates of overall and progression-free survival at two years were 59 and 47 percent, respectively.",
"   </p>",
"   <p>",
"    We suggest treating most older adults (age &gt;60 years) with DLBCL with full dose therapy rather than lower doses. Older adults who are unable to tolerate standard doses of R-CHOP-21 may be considered for a reduced dosage CHOP regimen (ie, R-mini-CHOP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patients with cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although anthracycline-based therapy, such as CHOP, is recommended for patients with DLBCL, patients with underlying cardiac disease may not be able to tolerate the use of an anthracycline since this agent is toxic to cardiac cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/55\">",
"     55",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    or other anthracyclines should not be administered to patients with a baseline ejection fraction below 30 percent. Patients with an ejection fraction greater than 30 percent may require monitoring. Contrary to common belief,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    is not a safe alternative in patients with cardiac disease and produces inferior results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    may permit substantially higher cumulative doses with efficacy equivalent to the free anthracyclines but a lower incidence of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/56\">",
"     56",
"    </a>",
"    ]. The use of anthracyclines in patients with cardiac disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H15#H15\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Approaches for reducing the risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an anthracycline is not an option, non-anthracycline-containing combination chemotherapy programs must be used. When choosing among such regimens, one must keep in mind not only the potential cardiac toxicity but also the intravenous fluid requirements of a regimen. As an example, cisplatin-containing regimens, although active in DLBCL, may require the administration of too much fluid to be easily used for patients with cardiac disease.",
"   </p>",
"   <p>",
"    There is a paucity of data to guide the choice of therapy. There are no randomized trials of chemotherapy for DLBCL that included patients with underlying cardiac disease. A nonrandomized phase II trial investigated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    (CEPP) in 83 patients (mostly &lt;60 years old) with aggressive NHL, 14 of whom had contraindications to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/57\">",
"     57",
"    </a>",
"    ]. The therapy was well tolerated with no cardiac toxicity. The most common side effects were neutropenic fever (12 percent) and severe nausea and vomiting (7 percent). Of the previously untreated patients with DLBCL, complete and partial responses were seen in nine (64 percent) and two (14 percent). Of importance, this study was primarily conducted in younger adults with cardiac disease. Toxicities associated with procarbazine increase with age such that it may be difficult to administer this regimen to patients over the age of 60.",
"   </p>",
"   <p>",
"    There have been no published reports of this regimen in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . However, we advocate the use of rituximab with this regimen since rituximab has dramatically improved results with other regimens and there are no common toxicities between rituximab and CEPP. For patients who are unable to receive an anthracycline, we suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    plus rituximab (R-CEPP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     AIDS-related lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HIV, the diagnosis of NHL is an AIDS-defining malignancy. A significant number of the lymphomas encountered in HIV-infected patients are clinically aggressive (eg, diffuse large B cell lymphoma) or highly aggressive (eg, immunoblastic or small, non-cleaved",
"    <span class=\"nowrap\">",
"     cell/Burkitt's-like",
"    </span>",
"    lymphoma). Treatment of such patients is complicated by their immunocompromised state and also requires specific treatment for their HIV. As such, treatment of these patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bulky disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role for radiation in bulky sites of advanced disease is less certain. It is unclear if patients with advanced disease with bulky lesions are more likely to relapse in the area of previous bulky disease or elsewhere. Local relapse could theoretically be decreased by radiation, but such treatment is unlikely to decrease systemic relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. A retrospective series that included 24 patients with bulky stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    disease reported that patients with advanced disease who had received CHOP without radiation developed relapse in previously bulky sites only 10 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/58\">",
"     58",
"    </a>",
"    ]. The other 90 percent of relapses occurred at distant sites. Another single institution retrospective analysis of 469 patients with newly diagnosed DLBCL, the majority of whom were treated with initial R-CHOP chemotherapy with or without radiation, included 207 patients with bulky disease &gt;5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/59\">",
"     59",
"    </a>",
"    ]. Of the 279 patients with advanced stage disease, 39 were given radiation therapy and 23 of these 39 patients had bulky disease. The small number of patients with advanced stage DLBCL who received RT had superior rates of five-year overall (89 versus 66 percent) and progression-free (76 versus 55 percent) survival when compared with those who did not receive radiation. On matched-pair analysis, bulky disease status did not affect the outcome in relation to the role of radiation therapy.",
"   </p>",
"   <p>",
"    There have been no prospective, randomized trials of adjuvant radiation therapy for bulky advanced stage disease in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    era. Some clinicians advocate radiation to bulky sites after a complete remission is obtained with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In the absence of clear benefit in the rituximab era, we do not advocate radiation therapy after chemotherapy in patients with bulky components to otherwise advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114378738\">",
"    <span class=\"h2\">",
"     DLBCL-Burkitt",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma has been proposed by the WHO as a category to classify those patients that do not truly fit into either category, and accounts for approximately 5 percent of cases previously categorized as DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/63\">",
"     63",
"    </a>",
"    ]. Many cases in this subtype are referred to as &ldquo;double hit&rdquo; lymphomas, which are defined by a chromosomal breakpoint affecting the",
"    <span class=\"nowrap\">",
"     MYC/8q24",
"    </span>",
"    locus in combination with another recurrent breakpoint, mainly a t(14;18)(q32;q21) involving BCL2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/64\">",
"     64",
"    </a>",
"    ]. Patients with &ldquo;double hit&rdquo; lymphomas often present with features predictive of poor outcome including an elevated lactate dehydrogenase level, bone marrow involvement, and central nervous system involvement.",
"   </p>",
"   <p>",
"    Outcomes with R-CHOP-21 are disappointing with a median overall survival of only 2.5 to 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. In addition, the vast majority of patients with DLBCL-Burkitt are older adults (median age 70 years) and are not candidates for highly intensive therapy. There is a paucity of data regarding other treatment options for patients with DLBCL-Burkitt and these patients should be strongly encouraged to participate in clinical trials. Outside of a clinical trial, combination chemotherapy with dose-adjusted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (R-EPOCH) is a reasonable option given its known activity in both Burkitt lymphoma and DLBCL and its general tolerability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some experts suggest the use of aggressive combination chemotherapy regimens commonly used for the treatment of Burkitt lymphoma, such as",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) with IVAC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and intrathecal methotrexate) (",
"    <a class=\"graphic graphic_table graphicRef72511 \" href=\"UTD.htm?35/40/36493\">",
"     table 6",
"    </a>",
"    ), toxicity with",
"    <span class=\"nowrap\">",
"     CODOX-M/IVAC",
"    </span>",
"    is severe and virtually all patients require a prolonged inpatient hospital stay and blood product support. As such, we reserve the use of these intensive regimens for young patients with a good performance status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H326785496\">",
"    <span class=\"h2\">",
"     DLBCL-Hodgkin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are occasional cases of lymphoma presenting in the mediastinum that combine pathologic and clinical features of primary mediastinal B cell lymphoma and Hodgkin lymphoma. Such cases are classified in the WHO system as \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma\". The prognosis and optimal treatment of such cases are uncertain. In general, we use a similar approach to that used for primary mediastinal large B cell lymphoma, which is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment of DLBCL, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). The post-treatment imaging study of choice is the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows for the distinction between active disease and fibrosis.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be obtained six to eight weeks after completion of chemotherapy and 12 weeks after the completion of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging obtained earlier than this is likely to demonstrate increased uptake due to an inflammatory reaction to treatment.",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/70\">",
"     70",
"    </a>",
"    ]. A complete remission has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All post-treatment residual masses are negative on PET scan.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pretreatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the follow-up of patients with lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to obtain a complete response are treated as refractory disease. Treatment of refractory disease is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not advocate the use of PET scans obtained prior to the completion of therapy (ie, interim PET scans) unless there is clinical deterioration necessitating evaluation. This is principally because there are limited data regarding the predictive value of such scans. While some studies have suggested that positive interim PET scans are associated with inferior outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/71\">",
"     71",
"    </a>",
"    ], there appears to be substantial inter-reader variability, even among nuclear medicine experts. As an example, a prospective trial that evaluated the interpretation of 38 interim PET scans reported complete agreement by ECOG and London criteria in 68 and 71 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. Our approach is based upon the following general understandings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of relapses occur during the first two years after completion of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relapses are usually symptomatic and are rarely identified solely on the basis of routine imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If a relapse is picked up a few weeks earlier because of more intense monitoring, it is unlikely to improve outcome.",
"     </li>",
"     <li>",
"      When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/45/26330/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"       \"Radiation-related risks of imaging studies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every three months during the first year, every three to six months during the second year, and every six months starting two years after complete response. At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH.",
"   </p>",
"   <p>",
"    There is no role for routine PET or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in the longitudinal follow-up of asymptomatic patients after response assessment. We do perform CT scans at months 6, 12, 18, 24, 30 or 36, and then yearly until five years after attainment of a complete remission. No more imaging is performed after five years unless an abnormality suggests the possibility of relapse or the patient requests it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Consensus opinion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies, but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. The treatment of relapsed DLBCL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL). It is an aggressive NHL in which survival without treatment is measured in months. Advanced stage DLBCL cannot be contained within one irradiation field. This population accounts for 60 to 70 percent of patients with DLBCL. (See",
"      <a class=\"local\" href=\"#H735717\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to affect treatment options. In addition to a history and physical examination, it is our practice to perform laboratory studies, unilateral bone marrow biopsy, and imaging in all patients. Certain subsets of patients will require further testing of their cerebrospinal fluid and cardiac function. Fertility counseling should be offered to patients in childbearing years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced DLBCL, we recommend treatment with an anthracycline-based combination chemotherapy regimen plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Specifically, we use six to eight cycles of R-CHOP-21 (",
"      <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"       table 4",
"      </a>",
"      ). There is no role for the routine use of maintenance rituximab or high dose chemotherapy with autologous hematopoietic cell rescue in first complete remission. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general treatment principles for limited and advanced stage DLBCL apply to most disease presentations and patient populations. However, involvement of certain organs, particularly when occurring as primary sites of disease, has unique therapeutic implications. In addition, older adults and patients with cardiac disease or HIV infection require special consideration. (See",
"      <a class=\"local\" href=\"#H1554322491\">",
"       'Special scenarios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most older adults (age &gt;60 years) with DLBCL we suggest full dose therapy rather than lower doses (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Older adults who are unable to tolerate standard doses of R-CHOP-21 may be considered for a reduced dosage CHOP regimen (ie, R-mini-CHOP). (See",
"      <a class=\"local\" href=\"#H326785256\">",
"       'Older adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is general agreement that patients with testicular, epidural, or sinus involvement are at increased risk of developing CNS disease. The evidence for an increased risk of CNS relapse is less strong for other scenarios that we still consider high risk, such as patients with breast or ovarian involvement, concordant bone marrow involvement, a high International prognostic index (IPI), or numerous extranodal sites of disease. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      should be obtained six to eight weeks after chemotherapy and 12 weeks after the completion of radiation therapy. Using information gathered from the post-treatment history, physical, and",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan, disease response is determined by the International Workshop Criteria (IWC) (",
"      <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Response evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Surveillance for relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/3\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/5\">",
"      Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008; 111:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/6\">",
"      Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/7\">",
"      Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/8\">",
"      Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/9\">",
"      Pettengell R, Linch D, Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003; 121:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/10\">",
"      Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116:5119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/11\">",
"      Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/12\">",
"      Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/13\">",
"      Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/14\">",
"      Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/15\">",
"      Coiffier, B, Feugier, P, Mounier, N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients (abstract). J Clin Oncol 2007; 25:443s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/16\">",
"      Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/17\">",
"      Pfreundschuh M, Tr&uuml;mper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/18\">",
"      Pfreundschuh M, Kuhnt E, Tr&uuml;mper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/19\">",
"      Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/20\">",
"      Bj&ouml;rkholm M, Magnus B, Andersson T, et al. CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). Eur J Haematol 2008; 80:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/21\">",
"      Gaynor ER, Unger JM, Miller TP, et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. J Clin Oncol 2001; 19:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/22\">",
"      Bartlett NL, Petroni GR, Parker BA, et al. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001; 92:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/23\">",
"      Sparano JA, Weller E, Nazeer T, et al. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood 2002; 100:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/24\">",
"      Burton C, Smith P, Vaughan-Hudson G, et al. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Br J Haematol 2005; 130:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/25\">",
"      Rueda A, Sabin P, Rif&aacute; J, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol Oncol 2008; 26:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/26\">",
"      Pfreundschuh M, Tr&uuml;mper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/27\">",
"      Verdonck LF, Notenboom A, de Jong DD, et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007; 109:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/28\">",
"      Ohmachi K, Tobinai K, Kobayashi Y, et al. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 2011; 22:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/29\">",
"      Economopoulos T, Psyrri A, Dimopoulos MA, et al. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J 2007; 13:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/30\">",
"      Cunningham C, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma (abstract 8000). J Clin Oncol 2011; 29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/31\">",
"      Delarue, R, Tilly, H, Salles, G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B cell lymphoma: results of the interim analysis of the LNH03-6B GELA study (abstract 406). Blood 2009; 114:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/32\">",
"      Kamel S, O'Connor S, Lee N, et al. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/33\">",
"      R&eacute;cher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/34\">",
"      Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29:690.",
"     </a>",
"    </li>",
"    <li>",
"     Safar, V, Dupuis, J, Jardin, F, et al. Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab. Blood 2009; 114:45 (abstr 98). (Available online at file://ash.confex.com/ash/2009/webprogram/Paper21587.html, accessed January 20, 2010).",
"    </li>",
"    <li>",
"     Pregno, P, Chiappella, A, Bell&ograve;, M, et al. Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP. Blood 2009; 114:45 (abstr 99). (Available online at file://ash.confex.com/ash/2009/webprogram/Paper20694.html, accessed January 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/37\">",
"      Morrison, VA, Weller, EAa, Habermann, TM, et al. Maintenance rituximab compared to observation after R-CHOP or CHOP in older patients with diffuse large B-cell lymphoma: An intergroup E4494/C9793 update (abstract). J Clin Oncol 2007; 25:8011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/38\">",
"      Greb A, Bohlius J, Schiefer D, et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev 2008; :CD004024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/39\">",
"      Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP &plusmn; R for eight cycles to CHOP &plusmn; R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL) (abstract 8001). J Clin Oncol 2011; 29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/40\">",
"      Glass B, Ziepert M, Reiser M, et al. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol 2010; 21:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/41\">",
"      Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012; 13:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/42\">",
"      Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (&ge;80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2012; 156:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/43\">",
"      Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/44\">",
"      Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009; 115:4547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/45\">",
"      Fields PA, Linch DC. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 2012; 157:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/46\">",
"      Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22:4302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/47\">",
"      Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients &gt; or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/48\">",
"      Lee KW, Kim DY, Yun T, et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003; 98:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/49\">",
"      Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/50\">",
"      Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008; 87:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/51\">",
"      Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011; 12:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/52\">",
"      Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011; 22:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/53\">",
"      Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma 2012; 53:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/54\">",
"      Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly \"fit\" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma 2012; 53:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/55\">",
"      Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:3159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/56\">",
"      Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010; 21:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/57\">",
"      Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 1990; 76:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/58\">",
"      Shipp MA, Klatt MM, Yeap B, et al. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol 1989; 7:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/59\">",
"      Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010; 28:4170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/60\">",
"      Dorth JA, Prosnitz LR, Broadwater G, et al. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 2012; 84:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/61\">",
"      R&uuml;be C, Nguyen TP, Kl&ouml;ss M, et al. Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann Hematol 2001; 80 Suppl 3:B84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/62\">",
"      Avil&eacute;s A, Fern&aacute;ndezb R, P&eacute;rez F, et al. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 2004; 45:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/63\">",
"      Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009; 23:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/64\">",
"      Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011; 117:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/65\">",
"      Lin P, Dickason TJ, Fayad LE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 2012; 118:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/66\">",
"      Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012; 118:4173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/67\">",
"      Dunleavy K, Pittaluga S, Janik J, et al. Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome (abstract). Blood 2006;108:774A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/68\">",
"      Jermann M, Jost LM, Taverna Ch, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/69\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/70\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/71\">",
"      Dorth JA, Chino JP, Prosnitz LR, et al. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol 2011; 22:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/72\">",
"      Horning SJ, Juweid ME, Sch&ouml;der H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010; 115:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/73\">",
"      Larouche JF, Berger F, Chassagne-Cl&eacute;ment C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 2010; 28:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/74\">",
"      Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/75\">",
"      Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006; 17:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/76\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/77\">",
"      Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology 2009; 251:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/45/26330/abstract/78\">",
"      Berrington de Gonz&aacute;lez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169:2071.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4729 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26330=[""].join("\n");
var outline_f25_45_26330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H735717\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rituximab containing regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11298459\">",
"      - R-CHOP-21 versus R-CHOP-14",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11298474\">",
"      - Other regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Number of treatment cycles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H326784770\">",
"      Is there a role for maintenance rituximab?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Is there a role for transplant?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Our approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1554322491\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H326785256\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patients with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AIDS-related lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bulky disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114378738\">",
"      DLBCL-Burkitt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H326785496\">",
"      DLBCL-Hodgkin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4729\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4729|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/26/42412\" title=\"table 1\">",
"      Classification of NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 2\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 3\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22574\" title=\"table 4\">",
"      R-CHOP21 regimen for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/32/524\" title=\"table 5\">",
"      Revised IPI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/40/36493\" title=\"table 6\">",
"      R-CODOX-M IVAC regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 7\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_45_26331="Dyspnea questionnaire PI";
var content_f25_45_26331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dyspnea questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Please select up to three phrases that best describe your breathing discomfort. If you choose more than one phrase, please also note the phrase that most closely describes the sensation you feel. If none of these phrases applies, please write in your own description of your breathing discomfort.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing is shallow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel an urge to breathe more.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My chest is constricted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing requires effort.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel a hunger for more air.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel out of breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I cannot get enough air.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breath does not go in all the way.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My chest feels tight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing requires work.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel that I am smothering/suffocating.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel that I cannot get a deep breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I feel that I am breathing more.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breath does not go out all the way.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        My breathing is heavy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other descriptions:",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26331=[""].join("\n");
var outline_f25_45_26331=null;
var title_f25_45_26332="Angina meds PI";
var content_f25_45_26332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medicines to treat angina",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of medicine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample US brand names",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Nitrates",
"       </td>",
"       <td>",
"        Nitroglycerin pill for under the tongue",
"       </td>",
"       <td>",
"        Nitrostat&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitroglycerin spray for on or under the tongue",
"       </td>",
"       <td>",
"        Nitrolingual&reg;, NitroMist&trade;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitroglycerin patch",
"       </td>",
"       <td>",
"        Minitran&trade;, Nitro-Dur&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitroglycerin ointment",
"       </td>",
"       <td>",
"        Nitro-Bid&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isosorbide dinitrate",
"       </td>",
"       <td>",
"        Isordil&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isosorbide mononitrate",
"       </td>",
"       <td>",
"        Imdur&reg;, Ismo&reg;, Monoket&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Beta blockers",
"       </td>",
"       <td>",
"        Atenolol",
"       </td>",
"       <td>",
"        Tenormin&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoprolol",
"       </td>",
"       <td>",
"        Lopressor&reg;, Toprol-XL&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acebutolol",
"       </td>",
"       <td>",
"        Sectral&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propranolol",
"       </td>",
"       <td>",
"        Inderal&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labetalol",
"       </td>",
"       <td>",
"        Trandate&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carvedilol",
"       </td>",
"       <td>",
"        Coreg&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Calcium channel blockers",
"       </td>",
"       <td>",
"        Amlodipine",
"       </td>",
"       <td>",
"        Norvasc&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felodipine",
"       </td>",
"       <td>",
"        Plendil&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nifedipine",
"       </td>",
"       <td>",
"        Adalat&reg; CC,",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verapamil",
"       </td>",
"       <td>",
"        Calan&reg;, Verelan&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diltiazem",
"       </td>",
"       <td>",
"        Cardizem&reg;, Cartia&reg;, many others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Ranolazine",
"       </td>",
"       <td>",
"        Ranexa&reg;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Most common medicines to treat angina (except ranolazine and nitroglycerin spray) are usually sold as generic drugs in the US. In many countries outside the US, nitroglycerin is also called glyceryl trinitrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26332=[""].join("\n");
var outline_f25_45_26332=null;
var title_f25_45_26333="Smoking Abstinence Rates";
var content_f25_45_26333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Meta-analysis (2008): Effectiveness and abstinence rates for various medications and medication combinations compared to placebo at 6-months postquit (n = 83 studies)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated odds ratio (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated abstinence rate (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placebo",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Monotherapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varenicline (2 mg/day)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3.1 (2.5-3.8)",
"       </td>",
"       <td>",
"        33.2 (28.9-37.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nicotine nasal spray",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2.3 (1.7-3.0)",
"       </td>",
"       <td>",
"        26.7 (21.5-32.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High-dose nicotine patch (&gt;25 mg) (These included both standard or long-term duration)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2.3 (1.7-3.0)",
"       </td>",
"       <td>",
"        26.5 (21.3-32.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-term nicotine gum (&gt;14 weeks)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2.2 (1.5-3.2)",
"       </td>",
"       <td>",
"        26.1 (19.7-33.6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varenicline (1 mg/day)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2.1 (1.5-3.0)",
"       </td>",
"       <td>",
"        25.4 (19.6-32.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nicotine inhaler",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2.1 (1.5-2.9)",
"       </td>",
"       <td>",
"        24.8 (19.1-31.6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clonidine",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2.1 (1.2-3.7)",
"       </td>",
"       <td>",
"        25.0 (15.7-37.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion SR",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        2.0 (1.8-2.2)",
"       </td>",
"       <td>",
"        24.2 (22.2-26.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nicotine patch (6-14 weeks)",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        1.9 (1.7-2.2)",
"       </td>",
"       <td>",
"        23.4 (21.3-25.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-term nicotine patch (&gt;14 weeks)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1.9 (1.7-2.3)",
"       </td>",
"       <td>",
"        23.7 (21.0-26.6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortriptyline",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1.8 (1.3-2.6)",
"       </td>",
"       <td>",
"        22.5 (16.8-29.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nicotine gum (6-14 weeks)",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.5 (1.2-1.7)",
"       </td>",
"       <td>",
"        19.0 (16.5-21.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Combination therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patch (long-term; &gt;14 weeks) +",
"        <em>",
"         ad lib",
"        </em>",
"        NRT (gum or spray)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3.6 (2.5-5.2)",
"       </td>",
"       <td>",
"        36.5 (28.6-45.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patch + Bupropion SR",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2.5 (1.9-3.4)",
"       </td>",
"       <td>",
"        28.9 (23.5-35.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patch + Nortriptyline",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2.3 (1.3-4.2)",
"       </td>",
"       <td>",
"        27.3 (17.2-40.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patch + Inhaler",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2.2 (1.3- 3.6)",
"       </td>",
"       <td>",
"        25.8 (17.4-36.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patch + Second generation antidepressants (paroxetine, venlafaxine)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2.0 (1.2-3.4)",
"       </td>",
"       <td>",
"        24.3 (16.1-35.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Medications not shown to be effective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selective Serotonin Re-uptake Inhibitors (SSRIs)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1.0 (0.7-1.4)",
"       </td>",
"       <td>",
"        13.7 (10.2-18.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Naltrexone",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.5 (0.2-1.2)",
"       </td>",
"       <td>",
"        7.3 (3.1-16.2)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Go to www.surgeongeneral.gov/tobacco/gdlnrefs.htm for the articles used in this meta-analysis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fiore, MC, Jaen, CR, Baker, TB, et al. Clinical Practice Guideline. Treating Tobacco Use and Dependence: 2008 update. US Department of Health and Human Services, May 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26333=[""].join("\n");
var outline_f25_45_26333=null;
var title_f25_45_26334="Causes genital tract bleeding";
var content_f25_45_26334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of abnormal genital tract bleeding in women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genital tract disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Uterus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Benign growths:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Polyps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Endometrial hyperplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Adenomyosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Leiomyomas (fibroids)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Cancer:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Adenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Infection:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Endometritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anovulatory bleeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Cervix",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Benign growths:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Polyps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Ectropion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Endometriosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Cancer:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Invasive carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Metastatic (uterus, choriocarcinoma)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Infection:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Cervicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Vulva",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Benign growths",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Skin tags",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Sebaceous cysts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Condylomata",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Angiokerataoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Infection:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Sexually transmited diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Vagina",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Benign growths:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Gartner's duct cysts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Polyps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Adenosis (aberrant glandular tissue)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Vaginitis/infection:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Bacterial vaginosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Sexually transmitted diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Atrophic vaginitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Upper genital tract disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fallopian tube cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ovarian cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pelvic inflammatory disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pregnancy complications",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sexual intercourse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sexual abuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Foreign bodies (including IUD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pelvic trauma (eg, motor vehicle accident)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Straddle injuries",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Contraception:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Copper intrauterine device",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Depo-Provera",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hormone replacement therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticoagulants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tamoxifen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticosteroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dilantin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antibiotics (eg, due to toxic epidermal necrolysis or Stevens-Johnson syndrome)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Diseases involving the vulva:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Crohn's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Behcet's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pemphigoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pemphigus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Erosive lichen planus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Coagulation disorders:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            von Willebrand's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thrombocytopenia or platelet dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Acute leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Some factor deficiencies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Advanced liver disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroid disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polycystic ovary syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic liver disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cushing's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hormone secreting adrenal and ovarian tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Emotional or physical stress",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Smoking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Excessive exercise",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Diseases not affecting the genital tract",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urethritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bladder cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemorrhoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vascular tumors and anomalies in the genital tract",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_45_26334=[""].join("\n");
var outline_f25_45_26334=null;
var title_f25_45_26335="Contents: Primary care oncology";
var content_f25_45_26335=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care oncology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care oncology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Brain tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/17/36117\">",
"           Classification of gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/3/25657\">",
"           Clinical presentation and diagnosis of brain tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Breast cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/4/37961\">",
"           Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/40/20106\">",
"           Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/10/20649\">",
"           Breast development and morphology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39386\">",
"           Breast reconstruction in women with breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/49/10009\">",
"           Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32249\">",
"           Genetic testing for hereditary breast and ovarian cancer syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42825\">",
"           Management of the regional lymph nodes in breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/46/19177\">",
"           Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/14\">",
"           Paget disease of the breast",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/7/11385\">",
"           Role of radiation therapy in breast conservation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41754\">",
"           Screening for breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/11/7354\">",
"           Systemic treatment for metastatic breast cancer: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/45/24278\">",
"           Tumor node metastasis (TNM) staging classification for breast cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cancer pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7077\">",
"           Assessment of cancer pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/7/30842\">",
"           Cancer pain management with opioids: Optimizing analgesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9290\">",
"           Cancer pain management with opioids: Prevention and management of side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39066\">",
"           Cancer pain management: Adjuvant analgesics (coanalgesics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/43/43704\">",
"           Cancer pain management: General principles and risk management for patients receiving opioids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4488\">",
"           Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21146\">",
"           Overview of cancer pain syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33924\">",
"           Radiation therapy for the management of painful bone metastases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39894\">",
"           Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39210\">",
"           Prevention and treatment of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32746\">",
"           Approach to the patient with colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2634\">",
"           Association between Helicobacter pylori infection and gastrointestinal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11850\">",
"           Clinical features, diagnosis, and staging of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38762\">",
"           Clinical features, staging, and treatment of anal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17946\">",
"           Clinical manifestations, diagnosis, and staging of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7898\">",
"           Diagnosis and staging of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18938\">",
"           Epidemiology, clinical features, and types of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43881\">",
"           Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16618\">",
"           Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29783\">",
"           Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43063\">",
"           Overview of treatment approaches for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/12/8391\">",
"           Pathogenesis of Barrett's esophagus and its malignant transformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/34/41514\">",
"           Pathology and prognostic determinants of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/9/3224\">",
"           Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6983\">",
"           Screening and prevention of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35337\">",
"           Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35336\">",
"           Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36101\">",
"           Clinical presentation and diagnosis of prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31849\">",
"           Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25978\">",
"           Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17224\">",
"           Epithelial ovarian cancer: Pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/36/16969\">",
"           Initial approach to low-risk clinically localized prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/62/23527\">",
"           Initial staging and evaluation of men with newly diagnosed prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41001\">",
"           Measurement of prostate specific antigen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/31/5624\">",
"           Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/45/9943\">",
"           Posttreatment follow-up for men with testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/52/31562\">",
"           Risk factors for prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34202\">",
"           Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10474\">",
"           Screening for ovarian cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lung cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12298\">",
"           Cigarette smoking and other risk factors for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44537\">",
"           Diagnostic evaluation and management of the solitary pulmonary nodule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16282\">",
"           Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/35/42552\">",
"           Pathobiology and staging of small cell carcinoma of the lung",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10072\">",
"           Women and lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28121\">",
"           Adenocarcinoma of unknown primary site",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/24/42378\">",
"           Cancer prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/34/17960\">",
"           Clinical features and pathogenesis of cancer cachexia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/26/14758\">",
"           Overview of the classification and management of cancers of unknown primary site",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39015\">",
"           Survival estimates in advanced cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/38/3690\">",
"           Various rehabilitation issues in patients treated for cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic cancers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/18/40232\">",
"           Vestibular schwannoma (acoustic neuroma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18073\">",
"           Primary prevention of melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16650\">",
"           Screening and early detection of melanoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Testicular cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41720\">",
"           Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2457\">",
"           Epidemiology of and risk factors for testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24852\">",
"           Risk stratification of metastatic testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/58/38822\">",
"           Serum tumor markers in testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/49/20250\">",
"           Treatment-related toxicity in men with testicular germ cell tumors",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-EAD90E1251-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_45_26335=[""].join("\n");
var outline_f25_45_26335=null;
